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ABSTRACT
The prevalence of nicotine addiction suggests that interactions of neuronal nicotinic 
cholinergic receptors (nAChRs) with illicit substances and multiple neurotransmitter 
systems are involved in mediating the rewarding properties of nicotine, cocaine, and 
morphine. Hence, the overall aim of this thesis was to investigate the role of nAChRs in 
rendering nicotine, a weak primary reinforcer, to be so widely abused.
Interactions between nAChRs and cocaine were investigated at the behavioural and 
receptor density levels, following chronic cocaine treatment and withdrawal. The effects 
of blockade of different nAChR subtypes on the development of cocaine-induced 
behaviours were investigated using dihydro-fi-erythroidine (DhBE; 2.0 mg/kg/inj, i.p.) 
and methyllycaconitine (MLA; 5.0 mg/kg/inj, i.p.). Nicotinic receptor antagonism 
produced very distinct behaviours in C57BL/6 mice, treated for 14 days with a steady 
dose, ‘binge’ administration protocol of cocaine (15.0 mg/kg/inj, i.p.). a4(32* nAChR 
blockade by DhBE prolonged cocaine-induced horizontal locomotor activity, reduced 
vertical activity, and diminished stereotypy sensitization. On the contrary, a l  nicotinic 
receptor antagonism by MLA resulted in the delayed expression of cocaine-induced 
rearing sensitization and induced a unique, intense grooming phenotype in cocaine- 
treated animals. To further understand the mechanisms behind this behavioural 
dissociation, quantitative autoradiography of heteromeric and homomeric nAChRs was 
performed using [^^^Ijepibatidine and [^^^I]a-bungarotoxin, respectively. Following 
‘binge’ cocaine administration, a4p2* nAChR density was increased in the ventral 
tegmental area (VTA) and substantia nigra compacta o f cocaine-treated animals, 
compared to saline controls. Moreover, following 14 days of abstinence from cocaine 
treatment, a l  nAChR density was decreased in the VTA of cocaine withdrawn animals.
Vcompared to controls. These cocaine-induced, subtype- and brain region-specific 
alterations in nAChR density were not observed following 8 days of treatment with 
escalating doses of ‘intermittent’ morphine, nor after the acute and prolonged withdrawal 
of C57BL/6 mice from morphine administration.
An investigation into the mechanism of interactions between nicotinic cholinergic and 
adenosinergic systems was performed using CDl mice with a genetic deletion of the 
adenosine A2A receptor. Following 14 days of nicotine hydrogen salt administration at 24 
mg/kg/day via omotic minipumps, quantitative autoradiography of [^^^I]epibatidine and 
[^^^I]a-bungarotoxin binding sites revealed significant genotype x treatment interaction 
effects on a7 nAChR density. Although chronic nicotine equally increased heteromeric 
nAChR density in wild type and mutant mice, its effects on a7 nAChRs were 
predominantly observed in the brains of wild type, rather than adenosine A2A receptor 
knockout animals.
The mechanisms of nicotine reinforcement were investigated using quantitative 
autoradiography of cytisine-sensitive [^^^I]epibatidine binding sites, following the 
acquisition of nicotine self-administration by drug naïve C57BL/6 mice. Using an 
operant yoked-control protocol of nicotine treatment, increased a4p2* nAChR density 
was observed in the ventral tegmental area and dorsal lateral geniculate nucleus of self- 
administering animals, compared to mice that passively received nicotine.
Overall, the results of the present thesis suggest that alterations in a4p2* and/or a7 
nAChR density occur following chronic treatment with nicotine and illicit substances, 
which are indicative of the interactions that render a weak primary reinforcer as broadly 
abused as nicotine.
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LIST OF ABBREVIATIONS
AC adenylyl cyclase
AcbC nucleus accumbens, core
AcbSh nucleus accumbens, shell
ACh acetylcholine
Amy amygdala
AV anteroventral thalamic nucleus
a-BgTx alpha bungarotoxin
a-CtxMII alpha conotoxin Mil
BLA basolateral amygdaloid nucleus
CAl hippocampus, CAl
CA3 hippocampus, CAB
cAMP 3', 5'-cyclic adenosine monophosphate
Cg cingulate cortex
CHT choline transporter
Cl claustrum
CNS central nervous system
CPP conditioned place preference
CPu caudate putamen
CPuC caudate putamen, caudal part
CPuR caudate putamen, rostral part
CREB cAMP response element binding protein
DA dopamine
DAT dopamine transporter
DEn dorsal endopiriform nucleus
DG dentate gyrus
DhBE dihydro-p-erythroidine
DLG dorsal lateral geniculate nucleus
DM dorsomedial hypothalamic nucleus
DOP delta opioid
ER endoplasmic reticulum
fr fasciculus retroflexus
XVlll
FrA frontal association cortex
GABA y-aminobutyric acid
5 -HT3 5-hydroxytryptamine 3
Hip hippocampus
Hyp hypothalamus
InG intermediate gray layer of the superior colliculus
IP interpeduncular nucleus
i.p. intraperitoneal
i.v. intravenous
KO knockout
KOP kappa opioid
LH lateral hypothalamus
LPMR lateral posterior thalamic nucleus
M l primary motor cortex
M2 secondary motor cortex
MAN medial amygdaloid nucleus
mAChRs muscarinic acetylcholine receptors
18-MC 18-methoxycoronaridine
MCx motor cortex
MG medial geniculate nucleus
MHb medial habenula
MLA methyllycaconitine
MOP mu opioid
mRNA messenger ribonucleic acid
pM micromolar
NAc nucleus accumbens
nAChRs nicotinic acetylcholine receptors
NET norepinephrine transporter
nM nanomolar
NOP nociceptin opioid
ns nigrostriatal bundle
NSB non specific binding
PLCo posteromedial cortical amygdaloid nucleus
XIX
pM picomolar
Po posterior thalamic nuclear group
PrL  prelimbic cortex
S subiculum
s.c. subcutaneous
SERT serotonin transporter
SN substantia nigra
SNc substantia nigra pars compacta
SuG superficial gray layer of the superior colliculus
THC delta9-tetrahydrocannabinol
Tu olfactory tubercle
VI visual cortex
VLG ventral lateral geniculate nucleus
VM ventromedial hypothalamic nucleus
VTA ventral tegmental area
WT wildtype
ZI zona incerta
CHAPTER
ONE
1 GENERAL INTRODUCTION
Cholinergic signalling in the central nervous system (CNS) is mediated by the 
endogenous neurotransmitter acetylcholine (ACh), exerting its effects through two 
distinct classes of receptors: the muscarinic and nicotinic ACh receptors (mAChRs and 
nAChRs, respectively). The latter are multimeric ligand-gated ion channels that have 
been demonstrated to participate in cognitive processes, such as learning, memory, and 
attention, as well as in the perception of pain and the control of movement in normal 
subjects (reviewed in Dani and Bertrand, 2007). Recent advantages in our understanding 
of brain nAChR structure, distribution and subtype diversity, have unmasked the 
contribution of nicotinic cholinergic signalling in several CNS dysftinctions, such as 
epilepsy, schizophrenia, Parkinson’s and Alzheimer’s disease, autism, dementia with 
Lewy bodies, and addiction (reviewed in Albuquerque et al., 2009).
In the beginning of the 1990’s, there was still a great deal of controversy as to whether 
cigarette smoking constituted a form of drug-addiction, or was simply a social habit. A 
large amount of published research has since established that persistent smoking 
behaviour is the result of the reinforcing properties of nicotine, binding in the CNS to its 
corresponding pharmacological targets, the nAChRs. In this respect, nicotine shares with 
other addictive drugs the common property of activating the mesolimbic dopaminergic 
pathway, which originates in the ventral tegmental area and projects towards limbic 
forebrain regions, including the nucleus accumbens (Di Chiara and Imperato, 1988). This 
shared property establishes a neural substrate for the examination of a striking feature of 
nicotine addiction, which is its high co-morbidity with substance abuse disorders. Indeed, 
not only is nicotine addictive, but it has also been implicated as a ‘gateway’ to increased 
substance consumption, since it is often self-administered in combination with several
illicit and licit substances, including the psychostimulants (Weinberger and Sofuoglu, 
2009), the opioids (Pomerleau, 1998), ethanol (Funk et al., 2006), and caffeine (Swanson 
et al., 1994). This positive correlation between smoking and enhanced drug use has 
promped the investigation of the nicotinic cholinergic mechanisms that may contribute to 
the prevalence of poly-drug dependence in cigarette smokers. To this end, the regulation 
of different subtypes o f nAChRs in response to chronic cocaine or morphine treatment 
and withdrawal has been examined in mice by means of quantitative receptor 
autoradiography. To investigate interactions between nicotine and the adenosine system, 
the regulation of different nAChR subtypes following chronic nicotine treatment has been 
examined in mice with a genetic deletion of the adenosine Aia receptor.
The activation of midbrain dopaminergic pathways is a neurobiological commonality that 
is shared by nicotine and other drugs of abuse, potentially accounting for their concurrent 
consumption. Nevertheless, it is still argued that nicotine is only a weak primary 
reinforcer, and that the prevalence of nicotine addiction stems from its ability to enhance 
the potency of other reinforcers, rather than from the drug’s direct rewarding effects 
(reviewed in Chaudhri et al., 2006). To unravel the mechanisms of nicotine 
reinforcement, the regulation of the nicotinic cholinergic and dopaminergic systems 
during the acquisition of nicotine self-administration by drug naïve mice has been studied 
using an operant yoked-control protocol. The latter has been employed to examine 
differences produced by the active or passive nicotine administration, and to determine 
the extent to which nicotine-induced neuroadaptation is the consequence of the drug’s 
direct pharmacological action or the result of the contingency between a subject’s 
response and the delivery of a reinforcer.
1.1 Nicotinic acetylcholine receptors in the CNS
1.1.1 Structure of the nicotinic acetylcholine receptor
Nicotinic acetylcholine receptors (nAChRs) are typical members of the ‘cys-loop’ ligand- 
gated ion channel superfamily, which also includes y-aminobutyric acid (GABAa, 
GAB Ac), glycine, and 5-hydroxytryptamine 3 (5-HTs) serotonin receptors (reviewed in 
Karlin and Akabas, 1995). Based on their major site of expression, nAChRs can be 
subdivided into muscle and neuronal types, the latter of which form hetero- or 
homomeric complexes of related subunits. All members of the nicotinic cholinergic 
family are characterised by a pentameric structure. They comprise five membrane- 
spanning subunits, arranged symmetrically around a central ion channel to form a barrel­
like structure (reviewed in Karlin, 2002). Figure 1.1 shows the topography of a single 
nAChR subunit, which is composed of a long ( -2 1 0  amino acids) N-terminal region, 
four hydrophobic transmembrane helical domains (Mi -  M4), and a shorter C-terminal. 
The N- and C- hydrophilic termini are located on the extracellular region of the 
membrane, and an intracellular loop is formed between the third and fourth 
transmembrane domains. The second membrane-spanning helical segment (M2) from 
each subunit shapes the central channel, which has a diameter of -25 Â at the synaptic 
level and it progressively becomes narrower at the transmembrane level (Unwin et al., 
1988). As the M2 helix contains far more negatively than positively charged amino acids, 
the central pore in the ion channel becomes highly cation selective. Indeed, all nAChRs 
identified so far are permeable to positively charged ions (reviewed in Changeux and 
Edelstein, 1998).
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Figure 1.1 Structure o f the nicotinic acetylcholine receptor subunit
Schematic linear representation of a single nAChR subunit: the N-terminal hydrophilic portion, the transmembrane 
domain, and the small hydrophilic C-terminal domain. Taken from Karlin, (2002).
To date, genes encoding for eight a (a2, a3, a4, a5, a6 , a l, a9, and alO) and three p (p2, 
P3, and p4) mammalian neuronal nicotinic subunits have been cloned (reviewed in 
Nashmi and Lester, 2006). In addition, subunit a 8 has been identified in avian species 
(Schoepfer et al., 1990). Subunits a2 through alO, and P2 through p4 combine to form 
either heteromeric pentameric structures, made up by a or p subunits in an axPy 
stoichiometry, or homomeric (a7)5 and (a9)s nAChRs. Structural data obtained from the 
crystallisation of an acetylcholine-binding protein from the European snail Lymnaea 
stagnalis have greatly improved our understanding of the nicotinic receptor binding sites, 
which lie at the interface between two adjacent subunits at the N-terminal domain 
(Corringer et al., 1995; Prince and Sine, 1996; Brejc et al., 2001). In analogy with 
muscle type nAChRs, and with the exception of subunit a5, all a subunits carry the 
principal agonist binding site, defined by a pair of vicinal cysteines (Wang et al., 1996). 
Subunits P2 and p4 lack the N-terminal cysteine residues and provide the complementary 
binding site, whereas p3 subunits do not contribute to an agonist binding site. Thus, in 
the case of the homomeric nAChRs, it is the vicinity of the a subunits that defines the
acetylcholine (ACh) binding pocket, and five identical binding sites exist per receptor 
molecule. In heteromeric receptors, such as the (u4)2((32)3 receptor, the binding pocket is 
formed between the a4 and its neighbouring |32 subunit. Thus, two ligand binding sites 
exist per receptor molecule, and both ct and (3 subunits contribute to the pharmacology of 
the heteromeric receptor (Luetje and Patrick, 1991; Figure 1.2).
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Figure 1.2 Organisation and structure o f  neuronal nAChRs
(A) and (C); Rotational symmetry of nicotinic subunits and localisation o f the ACh binding sites in transversal sections 
o f homomeric a7 and heteromeric a4p2 nAChR subtypes. Subunits are arranged in an anticlockwise manner along the 
axis. Taken from Gotti and Clementi, (2004). (B): Schematic representation o f the subunits in the heteromeric 
receptor, the location o f the two acetylcholine (ACh) binding sites, and the central ion conducting channel. Adapted by 
Karlin, (2002).
Such wide variety of nicotinic subunit associations gives rise to multiple neuronal 
nAChR subtypes, with distinct physiological, pharmacological and biochemical 
properties.
1.1.2 Localisation o f neuronal nAChRs
1.1.2.1 Distribution and classification o f  nAChR subtypes
In order to describe the topographical distribution of various nAChR subtypes, it is 
necessary to first summarise the main cholinergic pathways in the brain. Nearly every 
region of the CNS receives cholinergic input from five clusters of cholinergic nuclei 
(reviewed in Woolf, 1991). These are briefly described below:
• The Magnocellular basal complex provides the majority of cortical and hippocampal 
cholinergic input.
• The Peduncolopontine-laterodorsal tegmental complex originates from the 
peduncolopontine tegmental nucleus and projects to the thalamic nuclei and the 
midbrain dopamine neurons.
• The Striatum is densely innervated by intrinsic cholinergic neurons that do not project 
beyond the borders of the striatum.
• The Habenulo-interpeduncular system originates from the medial habenula and 
projects to the interpeduncular nucleus via the fasciculus retroflexus. This system 
receives input from the thalamus and is part of a limbic network thought to affect 
visceral and behavioural functions, as well as responses to pain.
• The cholinergic neurons of the Lower brain stem innervate the superior colliculus, 
cerebral nuclei, and cortex.
The diffuse nature of cholinergic neurons throughout the CNS accounts for the broad 
distribution of neuronal nAChRs, which were initially distinguished on a 
pharmacological basis (Clarke et ah, 1985b). High resolution autoradiography, using 
radiolabeled nicotine, acetylcholine and the neuromuscular antagonist a-bungarotoxin (a- 
BgTx), revealed a separation of the a-BgTx binding sites from the nicotine and
acetylcholine binding proteins. It was therefore deduced that more than one neuronal 
nicotinic receptor population exists in the CNS. With the advent of molecular cloning 
techniques, this pharmacological heterogeneity has been confirmed and extended. 
Structurally divergent nicotinic agonists and antagonists, as well as mice lacking the p2 
subunit have been employed to map the composition of distinct nAChR subtypes in 
different brain regions, using autoradiographic, in situ hybridization, and patch-clamp 
techniques (Zoli et al., 1998; see also Section 1.2.3.1). Expanding on a previous 
classification from Alkondon and Albuquerque, (1993), and along with data from 
previous anatomical and electrophysiological studies, four main types of neuronal 
nAChRs have been indentified, which are summarised in Table 1.1.
Receptor
type
Subunit
composition
Predominant localisation in 
CNS
Pharmacology 
(Equilibrium binding & 
electrophysiology)
I a?
Cortex, Limbic area. Hippocampus, 
Hypothalamus, and other 
telencephalic areas
MLA and a-BgTx sensitive 
very fast desensitising 
epibatidine>nicotine>cytisine
II
a4p2 (a5?) Throughout CNS
a-BgTx insensitive 
epibatidine>cytisine=nicotine
(a2?)P2 Interpeduncular nucleus
(a3?)P2
Retina, Superior Colliculus, Lateral 
Geniculate nucleus. Hippocampus
(a6p3?)P2 Catecholaminergic nuclei
III a3p4 (a5?)
Medial Habenula, Interpeduncular 
nucleus, Pineal gland
MLA-insensitive
epibatidine
IV
(a4p4?) Lateral Habenula MLA-insensitive
epibatidine=cytisine>nicotine(a2p4?) Dorsal Interpeduncular nucleus
Table 1.1 Classification o f  neuronal nAChRs
Four classes o f neuronal nAChRs have been distinguished by means o f autoradiographic, in situ hybridization, and patch-clamp 
techniques. The table shows the putative subunit composition o f each class o f receptor, its predominant localisation in the CNS, and its 
characteristic pharmacology. The question mark denotes the nicotinic subunit most likely to participate in the formation o f functional 
nAChRs, from experiments on the anatomy and electrophysiology o f nAChRs. Abbreviations: CNS; central nervous system, a-BgTx; a  
bungarotoxin, MLA; methyllycaconitine. Adapted from Zoli et al., (1998).
9Type I  receptors. Neuronal nAChRs of this class bind a-bungarotoxin (a-BgTx) and 
the competitive antagonist methyllycaconitine (MLA) with high affinity. The pattern 
of labelling by a-BgTx is not altered in p2 subunit knockout animals (p2 -/-), whereas 
in a7 knockout mice a-BgTx binding sites completely disappear (Orr-Urtreger et al., 
1997), indicating that the P2 subunit is not a component of type I receptors. The 
distribution of type I receptors represents the localisation of the a7 homomeric 
nAChRs, which is higher in the hippocampal formation, the hypothalamus, and other 
telencephalic areas (Marks et al., 1986).
Type II  receptors. Containing the p2 subunit (p2*), this class of receptors is a- 
bungarotoxin insensitive, representing the majority of neuronal nAChRs in the mouse 
brain. The most ubiquitously expressed receptor in this group is composed of a4 and 
p2 subunits and it binds nicotinic agonists with nanomolar or subnanomolar affinities. 
This high affinity binding is lost in p2 or a4 subunit knockout animals (Picciotto et al., 
1995; Marubio et al., 1999). a4p2* receptors are highly expressed throughout the 
mammalian CNS, including dopaminergic areas and the striatum. The p2 subunit is 
likely to co-assemble with others, namely the a2, a3, a5 (Vemallis et al., 1993; Wang 
et al., 1996; Zoli et al., 2002), and the p4 (Conroy and Berg, 1995). Despite the fact 
that such combinations have a relatively restricted distribution in the brain, they may 
constitute the main functional subpopulations of nAChRs in the neurons where they 
are expressed. The a3|32* subtype has been demonstrated to be mostly expressed in 
the visual pathway (Gotti et al., 2005), whereas the density of the a6|32* subtype is 
higher in catecholaminergic nuclei, the locus coeruleus, the substantia nigra, the VTA, 
and the striatum (Le Novere et al., 1996; Champtiaux et al., 2003). Overall, type II 
receptors can either constitute simple subtypes, or assemble in more complex forms, 
in axUy p combinations (see Gotti et al., 2006).
1 0
• Type III receptors. They do not contain the p2 subunit and they bind epibatidine with 
high affinity in equilibrium binding studies. The distribution of type III receptors 
represents the localisation of a3p4* nAChRs, which is predominant in the habenulo- 
interpeduncular system, locus coeruleus, cerebellum, area postrema, and the pineal 
gland (Flores et al., 1996; Marks et al., 2002; Hernandez et al., 2004). Type III 
receptors may comprise the a5 subunit, albeit this expression pattern does not change 
their binding properties.
• Type IV  receptors. Containing the P4 subunit in combination with the o2 or a4 
subunit, this class of receptors binds epibatidine and cytisine with equally high 
affinity. They are highly expressed in the lateral habenula and the interpeduncular 
nucleus. Type IV can be distinguished from type III receptors on the basis of their 
faster desensitisation rates in electrophysiological experiments (Zoli et al., 1998).
At this point, it should be mentioned that the exact subunit composition of neuronal 
nAChRs is an ongoing question. In view of the fact that the assembly of individual 
nAChRs depends on the availability of related subunits (Conroy and Berg, 1995; 
Ramirez-Latorre et al., 1996) and the common observation that multiple nicotinic 
receptor channels can be expressed by a single neuron (Alkondon and Albuquerque, 
1993; Connolly et al., 1995), characterising the composition and distribution of multiple 
nAChR subtypes is an extremely demanding task. Nevertheless, a large body of evidence 
suggests that the most common hetero- and homo- oligomeric nAChRs expressed in the 
brain are assembled by a4/p2 and a7 subunits, respectively (Wada et al., 1989; Couturier 
et al., 1990; Chen and Patrick, 1997).
11
1.1.2.2 Presynaptic, postsynaptic and non synaptic location
Confocal and electron microscopy studies have revealed that neuronal nAChRs can be 
distributed not only pre- and post- synaptically, but also at extrasynaptic locations, such 
as the somatodendritic and axonal parts of an individual neuron. In addition, nAChRs 
can be localised intracellularly, where they are often associated with the endoplasmic 
reticulum before translocation to the cell membrane (Jones and Wonnacott, 2004). The 
relative synaptic vs. extrasynaptic distribution of nAChRs on the cell membrane differs 
for distinct nicotinic subtypes. For instance, glutamatergic nerve terminals in the ventral 
tegmental area (VTA) that predominantly express the homomeric a7 nAChR, have 73 % 
of the nicotinic receptor located at presynaptic and preterminal sites, compared with 27 % 
that is situated at extrasynaptic locations (Jones and Wonnacott, 2004). For nigrostriatal 
dopaminergic axon terminals predominantly expressing the p2 subunit, however, nearly 
all P2 containing nAChRs are observed at extrasynaptic sites (Jones et al., 2001). 
Therefore, it seems that distinct nicotinic receptor subtypes are strategically expressed 
along the length of a neuron; depending on their pre-, post-, and non synaptic distribution, 
nAChRs can influence a plethora of synaptic events, generating or altering action 
potentials and modifying membrane excitability (reviewed in McKay et al., 2007). The 
physiological significance of the diverse localisation of nAChRs in neurons is discussed 
in more detail in Section 1.1.4.
1 2
1.1.3 Functional aspects o f  nAChRs
1.1.3.1 Neuronal nAChR transition states
Nicotinic receptors in the CNS can exist in three different fiinctional states: resting (R), 
active (A), and desensitised (D) (reviewed in Galzi and Changeux, 1995). Upon binding 
of ACh the pore-lining helices rotate and the receptor channel extensively changes its 
conformation (Unwin, 2005). The central pore opens to allow conductance of small 
monovalent (Na"^  and K^) and divalent cations (C a ^  down their electrochemical gradient, 
causing the receptor to switch from the resting to an activated state. In this open pore 
state the receptor displays low micromolar (pM) affinity for ACh, whose continued 
presence will eventually lead to receptor desensitisation and ion pore closure. Albeit the 
fact that desensitised nAChRs are refractory to activation, they exhibit 2-4 fold higher 
affinity for ACh (Heidmann and Changeux, 1980). Dissociation of the agonist from its 
binding site will cause the receptor to isomerise to the resting state in the millisecond 
time range (Lester and Dani, 1995). Prolonged exposure to low concentrations of 
agonists, however, can induce a pronounced desensitised state from which recovery 
occurs with slower rates (Sakmann et al., 1980; Lester and Dani, 1995). Desensitisation 
is thus a reversible phenomenon that can occur in stages, with a transient, fast-onset 
desensitised state converting into a more stable, slow-onset desensitised state in the 
persisting presence of an agonist (Wilson and Karlin, 2001). The cycle of activation, 
desensitisation, and recovery is depicted in Figure 1.3. The kinetics for these processes is 
highly dependent on the subunit composition of neuronal nicotinic receptors. Under 
normal physiological conditions, where high concentrations of ACh (~lmM) diffuse in 
the synaptic cleft and acetylcholinesterases hydrolyse the neurotransmitter in 
milliseconds, the homomeric a7 nicotinic receptor displays fast desensitisation and 
recovery kinetics (Castro and Albuquerque, 1993; Anand et al., 1998), whereas
heteromeric nAChRs, such as the a4p2, desensitise slower (Fenster et a l, 1997; Corringer 
et al., 1998). During prolonged periods of sustained exposure to low (~1 pM) agonist 
concentrations, however, a4p2 nAChRs will significantly desensitize, whereas a l 
nAChRs will effectively remain unaffected (Dani et al., 2000; Quick and Lester, 2002; 
Wooltorton et al., 2003). Therefore, desensitisation is an intrinsic property of individual 
nAChR subtypes and it depends on the concentration and length of exposure to agonists. 
Its physiological role becomes extremely important, specifically when considering the 
low levels of nicotine (30-600 nM) that chronically bathe the brains of smokers (Russell 
et al., 1980; Henningfield et al., 1993).
(R) RESTING 
Channel closed
nA ChR a g o n is ts  b in d  w ith 
LOW AFFINITY
&
(A) ACTIVE 
channel open
(D) DESENSITISED
channel closed
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(I) INACTIVE
nAChR a g o n is ts  b in d  w ith  
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Figure 1.3 Transition states o f neuronal nAChRs
Schematic representation of the functional states that nAChRs undergo. The diagram shows the transition from resting 
(R) and desensitised (D) nonconducting states (closed pore), to active (A), conducting conditions (open pore). 
Prolonged exposure to agonists leads the receptor to switch from a desensitised to an inactive state (I), from which the 
recovery rate is very slow. Each transition state is characterised by different receptor-ligand kinetics.
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1.1.3.2 Current rectification
Activated nicotinic receptors pass current freely when a cell is hyperpolarised, providing 
strong inward voltage to drive cations into the channel. This functional feature of the 
neuronal nAChR is distinct from the NMDA subtype of glutamate receptors or other 
voltage-gated ion channels that are normally blocked by external Mg^ "^  at a cell’s resting 
potential. As the transmembrane potential becomes more positive than -40 mV the 
current is reduced, and at very active depolarised postsynaptic membranes nAChRs 
progressively contribute less to signal transmission (Couturier et al., 1990; Mathie et al., 
1990). The whole process is termed current rectification, and it is considered to be a 
molecular mechanism that facilitates the propagation of action potentials towards nerve 
terminals (Haghighi and Cooper, 2000).
1.1.3.3 Neuronal nAChR upregulation
In general, prolonged exposure to agonists induces receptor down-regulation, as a 
consequence of overstimulation (see Creese and Sibley, 1981). In the case of neuronal 
nAChRs, however, the opposite is true; nicotinic receptor density has been shown to 
increase following continued exposure to agonists. This has been well documented for 
nicotine, the principal psychoactive ingredient in tobacco. Postmortem radioligand 
binding studies reveal a dose-dependent increase in [^HJnicotine and [^HJepibatidine 
binding sites in the brains of chronic smokers, compared with non-smokers (Benwell et 
al., 1988; Breese et al., 1997). The observed upregulation displays marked regional 
variability, with many areas of the brain participating and showing different sensitivity to 
nAChR upregulation (Benwell et al., 1988; Perry et al., 1999). The results described 
above have confirmed in humans the findings of numerous rodent studies, which first 
showed that neuronal nAChR upregulate following long term exposure to nicotine. Since
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the discovery that nicotinic binding sites are increased after repeated injections of 
nicotine in rats and following chronic nicotine infusion in mice, the phenomenon of 
nAChR upregulation has been established as the hallmark of chronic nicotine treatment 
(Marks et al., 1983; Schwartz and Kellar, 1983). In both rats and mice, neuronal nAChR 
upregulation is a process that requires hours to weeks to develop, depending on the 
nicotine dose and the duration of treatment (Marks et al., 1985; Rowell and Li, 1997). 
Moreover, subtypes of nAChRs show different sensitivity to upregulation in vivo. 
Following 14 days of nicotine administration to rats, at concentrations that are compatible 
with those observed in the blood of smokers, a4p2* nAChRs seem to be readily 
upregulated in the range of 20-100% over controls, compared with other heteromeric 
subtypes, containing a3, a6 or g4 subunits (Nguyen et al., 2003). In addition, chronic 
infusion of nicotine in the mouse robustly upregulates a4^2*, rather than a l  nAChRs 
(Pauly et al., 1991). Therefore, it seems that the affinity of individual receptor subtypes 
for nicotine greatly contributes to nAChR upregulation, with «4^2* nAChRs being 
affected the most. Evidence from in vitro experiments, however, suggests that chronic 
nicotine has the potential to upregulate several nAChR subtypes in a dose and time 
dependent manner, and that this numerical upregulation occurs with magnitudes and rates 
that depend on the individual subunit composition of each receptor (Ke et al., 1998; 
Warpman et al., 1998; Fenster et al., 1999). Neuronal nAChR upregulation is a non­
permanent, reversible phenomenon. As revealed in rodent and human post-mortem brain 
studies, the upregulation of nAChR binding returns to control levels with a time course 
that depends on the dose and duration of prior nicotine exposure (Marks et al., 1985; 
Breese et al., 1997; Miao et al., 1998).
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Neuronal nAChR upregulation seems to be associated with an increase in receptor 
numbers, without an increase in the mRNA expression of associated subunits. In situ 
hybridisation studies in the mouse revealed no treatment effects on the levels of a4 and 
P2 subunit mRNA, following chronic nicotine infusions at a rate of 4.0mg/kg/hr (Marks 
et al., 1992; Pauly et al., 1996). Following 7 or 10 days of nicotine administration, 
however, an average increase of 42 % or 67 % in nicotine binding sites was observed 
respectively, indicating that the numerical upregulation of nAChRs is independent of 
transcriptional events. Similar results have been obtained in the rat after repeated 
postnatal injections of 0.1 mg/kg of nicotine, twice for 20 days (Miao et al., 1998). In 
vitro, MIO cells that stably express recombinant a4p2 nAChRs exhibit 2.5-fold increases 
in the amount of a4p2 protein, but fail to show increased transcription of a4 or p2 subunit 
mRNA following three days of treatment with 5pM of nicotine (Peng et al., 1994). 
Therefore, it seems that post-transcriptional events, such as decreased surface receptor 
internalisation (Peng et al., 1994) or increased receptor trafficking to the cell surface 
(Harkness and Millar, 2002), increased assembly of subunits from existing pools in the 
endoplasmic reticulum (ER) (Kuryatov et al., 2005) or blockade of nicotinic subunit 
degradation in the ER (Corringer et al., 2006), as well as nicotine-induced conformational 
changes of nAChRs (Vallejo et al., 2005) mediate receptor upregulation.
This unusual phenomenon of agonist-induced receptor upregulation has been the subject 
of intense investigation as to its functional consequences. It has been proposed that 
upregulation reflects receptor desensitisation and loss of nAChR function. Indeed, 
following chronic incubation of oocytes expressing the a4(32 nAChR with nicotine, the 
half maximal concentration necessary to produce desensitisation is the same as that 
needed to induce upregulation of the receptor (Fenster et al., 1999). Moreover, rats
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injected twice daily with nicotine for a period of 10 days, show increased a4p2* nAChR 
density, but decreased nicotine-induced striatal dopamine release, compared with saline 
controls (Jacobs et al., 2002). Accordingly, the increase in a4g2* nAChR binding sites in 
brain regions of mice chronically treated with nicotine highly correlates with a decrease 
in functionality of the receptor in the same brain areas, as measured by ACh-stimulated 
^^Rb  ^ efflux assays (Marks et al., 2004). On the other hand, substantial evidence that 
upregulated nAChRs retain function also exists. Measurement of epibatidine-stimulated 
^^Rb  ^efflux from rat brain slices, suggests that chronic nicotine administration not only 
induces receptor upregulation, but also that these receptors are functional (Nguyen et al., 
2004). Similarly, functional potentiation of human neuronal nAChRs stably expressed in 
cell lines has been demonstrated using patch clamp techniques (Wang et al., 1998; 
Buisson and Bertrand, 2001). The complex relation between nAChR upregulation and 
function can be demonstrated by the fact that, even for a particular receptor subtype, the 
effects of nicotine have been found to differ, depending on brain region (Nguyen et al., 
2004) and cellular specific neural distribution (Nashmi et al., 2007). Therefore, further 
studies are needed to determine the functional consequences of nAChR upregulation, 
since data on the effects of chronic nicotine treatment on receptor function are still 
controversial. It seems probable, however, that the relative subunit association and final 
assembly of an individual nAChR subtype will define its functional response to agonist- 
induced upregulation.
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1.1.4 Physiology o f neuronal nAChRs
1.1.4.1 Presynaptic, postsynaptic and non synaptic nAChRs
In contrast to nAChRs of the neuromuscular junction, which are located post-synaptically 
to mediate fast, excitatory transmission, the general consensus is that nicotinic receptors 
in the CNS are predominantly found at presynaptic locations, where they play a 
modulatory role in neurotransmission (see Role and Berg, 1996). Their activation by 
nicotinic agonists has been implicated in the enhanced release of glutamate (McGehee et 
al., 1995), GAB A (Endo et al., 2005), noradrenaline (Barik and Wonnacott, 2006), 
acetylcholine (Wilkie et al., 1996), dopamine (Whiteaker et al., 1995), and 5- 
hydroxytryptamine (Reuben and Clarke, 2000). Application of nicotinic antagonists, on 
the other hand, decreases neurotransmitter release. The mechanism behind this 
modulation seems to be calcium mediated. Nicotinic receptors allow the passage of a 
small direct calcium efflux, which in turn triggers calcium-induced calcium release from 
intracellular stores (Sharma and Vijayaraghavan, 2003). In addition, activation of 
nAChRs may indirectly promote exocytosis through presynaptic voltage-gated calcium 
channels (Tredway et al., 1999). The overall effect is an elevation of intraterminal 
calcium, which is sufficient to evoke neurotransmitter release (reviewed in Wonnacott,
1997). As neuronal nAChRs exhibit different cation permeability, each receptor subtype 
makes a distinct contribution to the modulation of neurotransmission. Often, the highly 
calcium permeable homomeric a l  receptor is involved, but in other cases different 
nAChR subtypes mediate enhanced neurotransmitter release.
Fast nicotinic transmission has been rarely documented in the CNS. Structural evidence 
suggests that only 7-14 % of acetylcholine release sites make synaptic contacts in the 
mammalian brain (Descarries, 1998). Therefore, due to the low density of nicotinic
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synapses, and because of the diffuse nature of cholinergic neurons in the CNS, the 
detection of fast nicotinic signalling in brain slices has been experimentally difficult. 
Indeed, functional nAChRs have only been recently documented at postsynaptic sites, in 
brain structures that have well-established sources of cholinergic afferents, such as the 
hippocampus and the neocortex. For instance, postsynaptic nicotinic transmission has 
been observed in the rodent hippocampus as a small excitatory input onto GABAergic 
intemeurons (Alkondon et al., 1998; Frazier et al., 1998). Moreover, direct nAChR- 
mediated signalling can be evoked onto both glutamatergic pyramidal and GABAergic 
neurons in the developing visual cortex (Roerig et al., 1997). Given the wide distribution 
of nAChRs throughout the CNS, however, it is likely that nAChR-mediated synaptic 
activity also occurs in brain regions with less well-established cholinergic inputs. This 
has been shown in the supraoptic nucleus of the hypothalamus, and other subcotircal 
areas, including the VTA (Pidoplichko et al., 1997; Hatton and Yang, 2002). Overall, 
however, evidence for a postsynaptic role of nAChRs in mediating synaptic transmission 
is scarce, suggesting that fast nicotinic signalling is not a major excitatory mechanism in 
the CNS.
Beyond their specific pre- and post- synaptic roles at discrete synapses, nAChRs are also 
widely expressed at non synaptic sites on an individual neuron. Pre-terminal nAChRs, 
located before the presynaptic bouton, have been shown to indirectly potentiate GABA 
release by activating voltage-gated ion channels (Lena et al., 1993; Alkondon et al., 1997). 
Axonal, dendritic and somatic nAChRs may also influence synaptic transmission, by 
altering membrane impedance and thereby influencing the spread and efficiency of an 
action potential (see Dani and Bertrand, 2007). It is thus conceivable that nAChRs are
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strategically located along neuronal cells, in order to modulate communication between 
pre-synaptic neurons and their targets in a broader sense.
1.1.4.2 nAChR subunit knockout mice
The wide variety of nicotinic receptor subtypes expressed in the CNS, coupled with the 
lack of subtype-specific ligands, have rendered knockout (KO) mice an extremely 
important tool for investigating the contribution of particular nAChRs to specific 
nicotine-induced behaviours (reviewed in Cordero-Erausquin et al., 2000; Marubio and 
Changeux, 2000). In addition, genetic manipulations of the nicotinic cholinergic system 
have revealed new information not only for the subunit composition of functional 
nAChRs, but also for the role of defined receptors in mediating normal physiological 
function. To date several different nicotinic subunit genes have been silenced, as listed in 
Table 1.2. Of them, only the a3 subunit seems to be necessary for survival, since a3 KO 
mice survive 1-8 weeks postnatal, showing severe autonomic nervous system defects (Xu 
et al., 1999). Deletion of the a4 nAChR subunit diminishes nicotine-induced 
antinociception in the hot-plate and tail-flick tests (Marubio et al., 1999), and produces 
mutant mice that show increased basal levels of anxiety and are less sensitive to the 
locomotor depressant effects of nicotine, compared with their wild type (WT) littermates 
(Ross et al., 2000). The a5 subunit seems to be directly involved in the pathogenesis of 
nicotine-induced seizures (Salas et al., 2003b), and its expression in presynaptic vs. 
extrasynaptic locations differentially contributes to nAChR function (Fischer et al., 2005).
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nAChR
subunit
Cellular/Morphological
Phenotype
Behavioural
Phenotype References
o3
Autonomic nervous system 
defects; megacystis, mydriasis 
and altered A(3h responses in 
SCG neurons
Increased mortality Xu et al., 1999
a4 Loss of high affinity binding
Reduced nicotine-induced 
antinociception; 
Reduced nicotine-induced 
locomotor depression
Marubio et al., 1999 
Ross et al., 2000
a5
Increased agonist-induced 
preterminal vs. somatic nAChR 
activity in SCG neurons
Resistance to nicotine-induced 
seizures
Salas et al., 2003b 
Fischer et al., 2005
a6
Loss of a-Ctx Mil mediated 
inhibition of nicotine-induced 
DA release;
Loss of high-affmity [*^ I^]a-Ctx 
Mil binding sites
Normal spontaneous 
locomotor activity
Champtiaux et al., 2002
a7
Lack of rapidly desensitising 
nicotinic currents in 
hippocampal neurons 
Loss of [^^ I^]a-BgTx binding
Decreased somatic symptoms 
of precipitated nicotine 
withdrawal;
Decrease in long term nicotine 
consumption; Deficits in 
spatial discrimination
Orr-Urtreger et al., 1997
Salas et al., 2007 
Levin et al, 2009
a9 Abnormal efferent innervation of 
hair cells in the cochlea
Loss of suppression of 
cochlear responses Vetter et al, 1999
alO
Abnormal olivocochlear 
morphology and innervation to 
outer hair cells
Loss of suppression of 
cochlear responses
Vetter et al, 2007
P2
Loss of presynaptic nAChR 
activity in GABAergic terminals, 
high affinity nicotine binding, 
and nicotine-induced DA release
Altered learning in aged 
animals, accelerated aging; 
enhanced passive avoidance 
responses; Loss of nicotine 
self-administration; reduced 
antinociception
Picciotto et al, 1995 
Picciotto et al, 1998 
Marubio et al, 1999 
Zoli et al, 1999
p3
Loss of a-Ctx Mil binding 
sites; Small increase in nicotine- 
induced [^H]DA release from 
striatal synaptosomes
Decreased sensorimotor 
gating; Increased locomotor 
activity
Gui et al, 2003
P4 Reduced nicotine-induced 
current in SCG neurons
Altered responses to stress; 
resistance to nicotine-induced 
seizures; Milder symptoms of 
nicotine-withdrawal
Salas et al, 2004 
Salas et al, 2003a 
Kedmi et al, 2004
Table 1.2 Phenotypes o f  nAChR subunit gene knockout mice
Abbreviations used: ACh: acetylcholine; SCG: superior cervical ganglion; DA: dopamine; a-Ctx M il: alpha-conotoxin 
M il; a-BgTx: alpha-bungarotoxin. Adapted from Marubio and Changeux, (2000).
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a6 KO mice do not exhibit any gross neurological or behavioural defects; their generation, 
however, has revealed that a6 instead of a3 subunits combine with the (32 to form 
functional nAChRs that modulate nicotine-induced dopamine release in the mouse brain 
(Champtiaux et al., 2002). Mice lacking the a l  subunit are viable and anatomically 
normal, despite completely lacking a-BgTx binding sites (Orr-Urtreger et al., 1997). In 
the open field test, a l  mutants spent more time in the centre of the open field compared to 
WT animals, which is suggestive of a decreased baseline anxiety level (Paylor et al.,
1998). Subsequent studies, however, have failed to replicate this finding using a battery 
of anxiety-related behavioural tests (Salas et al., 2007). Somatic symptoms of nicotine 
withdrawal are decreased in mice lacking the a l  nicotinic subunit (Salas et al., 2007), 
which has been recently implicated in spatial learning and discrimination, as well as in 
regulating long term nicotine consumption (Levin et al., 2009). The a9 subunit is 
necessary for the development and function of the synaptic connections in cochlear outer 
hair cells (Vetter et al., 1999). alO subunit KO mice exhibit abnormal olivocochlear 
morphology and innervation to outer hair cells, indicating that expression of the alO 
subunit is necessary for normal olivocochlear synaptic activity (Vetter et al., 2007). 
Aged (32 subunit KO mice show degenerative alterations in the cortex and the 
hippocampus, which resemble those observed during physiological aging and 
Alzheimer’s disease in humans. The neurodegeneration is accompanied by significant 
decreases of performance in the Morris maze task, suggesting impaired cognitive 
functioning in aged animals, following deletion of the p2 subunit (Zoli et al., 1999). In 
addition to their role in cognition and neuronal survival, p2 subunits have also been 
implicated in learning and memory, as P2 KO mice fail to show the nicotine-induced 
improvement of performance in the passive avoidance task, which tests for associative 
memory (Picciotto et al., 1995). Moreover, nicotine self-administration and nicotine-
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elicited antinociception are attenuated in the p2 subunit KO mouse, indicating that the 
reinforcing and antinociceptive properties of the drug are exerted via p2* nAChRs 
(Picciotto et al., 1998; Marubio et al., 1999). Deletion of the p3 nAChR subunit increases 
locomotor activity in the open field and decreases prepulse inhibition of the acoustic 
startle response in p3 null mutant mice, compared to WT littermates (Cui et al., 2003). 
p4 nAChR mutant mice exhibit milder signs of mecamylamine-precipitated nicotine 
withdrawal (Salas et al., 2004), are resistant to nicotine-induced seizures (Kedmi et al.,
2004), and differentially respond to stress, depending on the type of anxiety-provoking 
experience (Salas et al., 2003a). In conclusion, the generation of KO mice has greatly 
elucidated the relationship between individual nicotinic subunits, functional nAChR 
subtypes and nAChR-mediated behaviour. Despite the fact that compensatory 
developmental changes can occur in response to the deletion of a particular subunit gene 
(reviewed in Lowenstein and Castro, 2001), a wealth of data has been generated 
regarding the physiology of neuronal nAChRs using homologous recombination 
technologies.
1.1.5 Pharmacology o f neuronal nAChRs
The structural features of the ligand binding site determine the pharmacological profile of 
an individual nAChR subtype. As the ligand binding pocket of distinct nAChRs is 
formed by the assembly of different nicotinic subunits, neuronal nicotinic receptors 
display pharmacological properties that highly depend on their subunit composition. In 
addition, there are ligands that bind to locations other than the agonist binding sites and 
modulate nAChR function (allosteric modulators). Overall, four groups of ligands can be 
distinguished, depending on their location of binding to the nicotinic ion channel (Fig. 
1.4):
24
• Agonists, such as acetylcholine, nicotine and epibatidine occupy the agonist binding 
site and activate the receptor.
• Antagonists, such as dihydro-P-erythroidine (DhBE) and methyllycaconitine (MLA), 
compete with agonists for the nAChR binding site, but do not activate the receptor.
• Allosteric modulators bind to the interface between adjacent subunits, albeit at 
locations different from the agonist binding pocket. Allosteric modulators can either 
potentiate or decrease nAChR channel activity. Examples include the positive 
modulator of receptor function, estradiol (Curtis et al., 2002), and the negative 
allosteric modulator progesterone (Valera et al., 1992).
• Channel blockers, such as mecamylamine, bind within the ion channel pore and 
block ion fluxes.
agonists and non-competitive
competitive i inhibitors and
antagonists ^ modulators
non-com petittve 
channel blockers ' >' cytoskeieton
Figure 1.4 Ligand binding sites on a neuronal nicotinic receptor
A representation o f the different locations that ligands can bind on a nAChR. Depending on the site o f binding, four 
groups of ligands have been distinguished; agonists and antagonists, which compete for the same binding site, allosteric 
modulators, which can occupy multiple binding sites, and non competitive channel blockers, which bind within the 
channel pore. Adapted from Dani, (2001).
Detailed reviews on nicotinic receptor ligands can be found elsewhere (Lloyd and 
Williams, 2000; Romanelli et al., 2007). In this section, the pharmacology of ligands that 
were used in the present set of experiments will be addressed in more detail.
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1.1.5.1 Neuronal nAChR agonists
• (-)-Nicotine [3-(l-methyl-2-pyrrolidinyl)pyridine] is an alkaloid isolated from the 
leafs of the plant Nicotiana tabacum, and it is the prototype nAChR agonist. 
Radioligand and competition binding studies have demonstrated that nicotine binds to 
heteromeric nAChRs with high affinity (in the nM range), but has a much lower 
affinity towards the homomeric a l  nAChR (in the pM range) (Marks et al., 1986; 
Pauly et al., 1989). Its pharmacokinetics has been well established (see Hukkanen et 
al., 2005). In humans, approximately 70 to 80% of nicotine is primarily metabolized 
in the liver to cotinine, mainly by action of the CYP2A6 enzyme. The drug has a 
wide volume of distribution and it readily penetrates the blood brain barrier and the 
placenta. The half life of elimination for plasma nicotine is ~2h in humans, but with 
regular, chronic smoking it slows down to ~20h. Being the main psychoactive 
ingredient in tobacco, nicotine is widely used in behavioural studies.
• Epibatidine [exo-2-(6-chloro-3-pyridyl)-7-azabicyclo-[2.2.1]heptane] is an alkaloid 
compound originally isolated from the skin of the Ecuadorian tree frog, Epipedobates 
tricolor. It binds with high affinity to both heteromeric and homomeric nAChRs, in 
the pM or low nM range, respectively (Gerzanich et al., 1995; Houghtling et al.,
1995). Specifically, epibatidine binds not only to a4p2* nAChRs, which can be 
recognised by nicotine and cytisine, but also to nicotinic receptors containing the a3 
and the P4 subunits (Marks et al., 1998; Whiteaker et al., 2000b). Indeed, 
[^H]epibatidine binding persists in several brain regions of the P2 knockout mouse 
(Zoli et al., 1998). The tritiated ligand binds to a4p2* nAChRs with a Kd o f 8 pM; its 
iodinated analogue [^^^Ijepibatidine, however, displays a slightly lower affinity for 
the same receptor subtype (Kd =50pM) (Davila-Garcia et al., 1997; Whiteaker et al..
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2000b). This reduction in affinity is probably due to the substitution of a for a 
chlorine atom. Nevertheless, the highly specific activity of the iodinated analogue, 
coupled with its high affinity and low non-specific binding, have established 
[^^^IJepibatidine as one of the most potent nAChR ligands. Moreover, its outstanding 
binding characteristics make it a useful tool for the identification of novel receptor 
subtypes. In vivo, epibatidine has been shown to exhibit remarkable non-opioid 
antinociceptive properties (Badio and Daly, 1994; Rupniak et al., 1994). Despite its 
narrow therapeutic window, the compound has generated interest in nAChR as 
potential analgesic targets.
Cytisine [l,2,3,4,5,6-hexahydro-l,5-methano-pyrido[l,2-a][l,5]diazocin-8-one] is an 
alkaloid found in the seeds of Laburnum anagyroides and it binds to a4p2* nAChRs 
with higher affinity than nicotine (Kocyt=0.15 nM, Künic=0.89 nM, Anderson and 
Americ, 1994). As the compound differentially interacts with other nAChRs 
subtypes, it has been used in competition binding experiments with radiolabeled 
epibatidine to distinguish between subpopulations of nicotinic binding sites with high 
(cytisine-sensitive) and low (cytisine-resistant) affinity for cytisine (Marks et al., 
2006). The pharmacology and distribution of [^HJcytisine binding sites highly 
correlates with that of [^Hjnicotine and [^HJacetylcholine, indicating that the ligand 
identifies the same population of heteromeric a4p2* nAChRs (Pabreza et al., 1991). 
Its high affinity and low non-specific binding have made [^HJcytisine a very useful 
ligand for neuronal nAChRs. In in vivo studies cytisine readily penetrates the blood 
brain barrier, and shows a longer half life than nicotine (Sloan et al., 1988), although 
it is less potent than nicotine (Coe et al., 2005).
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• A-85350 [3-((R)-l-azetidin-2-ylmethoxy)pyridine] is a synthetic compound, derived 
after introducing a methyl ether moiety into the nicotine molecule. It has been shown 
to be a potent and selective ligand for the a4p2* nAChR subtype in vitro (K d=10 pM, 
Mukhin et al., 2000). A-85350 has been used in competition binding experiments 
with [^^^IJepibatidine to distinguish between subpopulations of nicotinic binding sites 
with high and low affinity for A-85350; the latter represent the distribution of a3p4 
nAChRs in the habenulointerpeduncular tract (Whiteaker et al., 2002). The iodinated 
ligand readily crosses the blood brain barrier and exhibits low toxicity in mice 
(Vaupel et al., 1998) and Rhesus monkeys (Chefer et al., 1998). Therefore, it has 
been used as a subtype specific ligand for positron emission tomography studies.
1.1.5.2 Neuronal nAChR antagonists
• a-bungarotoxin (a-BgTx) is a long, 75-amino acid peptide that is isolated from 
Bungarus multicinctus, a species of East Asian snake (Lee, 1972). Initially 
recognised for its potency to block postsynaptic, muscle-type nAChRs, a- 
bungarotoxin labels a unique class of neuronal nicotinic receptors, which bind [^^^I]a- 
bungarotoxin with high affinity (K d=0.65-1.7 nM), but [^H]nicotine with lower, 
micromolar affinity (Marks et al., 1986). This population of nAChRs is considered to 
correspond to homomeric a l  receptors, and [^^^I]a-BgTx has been the prototypical 
ligand for studying their distribution and pharmacology (Clarke et al., 1985b).
• Methyllycaconitine (MLA), isolated from the seeds of Delphinium brownii, is a 
natural alkaloid that potently displaces the binding of [^^^I]a-bungarotoxin from rat 
membranes (Ki=4 nM) and exhibits selectivity for a-BgTx, compared to heteromeric 
nAChR binding sites (Ward et al., 1990). MLA has also been shown to be a
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competitive antagonist on other nAChR subtypes, containing a4/p2 (Buisson et a l,
1996), a3/a6 (Mogg et al., 2002), and a3/p4 (Free et al., 2003) subunits, albeit with 
lower affinity. Unlike a-BgTx, MLA discriminates between a l  and muscle nAChRs 
(Ward et al., 1990). The compound displays low blood brain barrier penetration. 
Following its peripheral administration, however, MLA accumulates into brain tissue 
at concentrations that do not produce any overt signs of toxicity and that are 
behaviourally relevant (Turek et al., 1995). [^H]methyllycaconitine has been used as 
an alternative to a-bungarotoxin in equilibrium binding studies, because of its 
faster association kinetics and better signal to noise ratio (Davies et al., 1999).
• Dihydro-p-erythroidine (DhBE) is a plant alkaloid isolated from the seeds of 
Erythina americana. In addition to its curare-like effects, DhBE at nanomolar 
concentrations is a competitive antagonist at heteromeric neuronal nicotinic subtypes 
containing the P2 subunit (Harvey et al., 1996). [^H]DhBE binding sites colocalise 
with high-affmity nicotine binding sites, suggesting that the ligand predominantly 
labels the widely distributed a4p2* nAChRs (Williams and Robinson, 1984). The 
compound penetrates the blood brain barrier and has been shown to antagonise a 
variety of nicotine-induced behaviours thought to be exerted by a4p2* nAChRs, 
including nicotine reward and nicotine-induced enhancement of contextual fear 
conditioning (Corrigall et al., 1994; Davis and Gould, 2006; Kenny and Markou, 
2006).
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1.2 nAChRs in drug addiction
1.2.1 Drug addiction: a chronic disorder of neuronal adaptation
Drug addiction is a state that develops after prolonged exposure to certain 
pharmacological agents, notably the psychostimulants, the opiates, alcohol, nicotine, and 
the cannabinoids (reviewed in Pierce and Kumaresan, 2006). It is characterised by the 
progressive loss of control over drug intake, which ultimately leads to compulsive drug 
use, despite severe medical and social consequences. Moreover, addiction is a chronic 
and recrudescent disorder, defined by the persistence of a high relapse risk, long after an 
individual has stopped taking drugs. Research currently aims to understand the cellular 
and neuronal processes that underlie the transition from occasional drug use to the onset 
of chronic drug addiction. Indeed, while the initial neuronal targets for abused substances 
have been well characterised, little is known about the downstream effects of prolonged 
drug administration, and the long-term adaptations that take place in the CNS in response 
to repeated drug use. These cellular and circuit adaptations manifest with phenomena 
that collectively define addiction, such as dependence, tolerance, sensitisation, 
withdrawal, and relapse. Two major types of neurobiological adaptation are thought to 
account for the characteristic features of compulsive drug use; homeostatic physiological 
adaptations, and synaptic adaptations of the type that mediate associative learning 
mechanisms (reviewed in Berke and Hyman, 2000). Each of these processes has been 
linked to distinct motivational aspects of drug abuse. Homeostatic alterations have been 
held responsible for reinforcing drug taking behaviour by producing tolerance, 
withdrawal, and dependence (reviewed in Koob, 2000). Tolerance can be defined as the 
requirement for increased doses of a drug in order to maintain a stable effect during 
chronic administration. Dependence is an adaptive process that manifests with the onset 
of withdrawal symptoms upon drug cessation. Because of tolerance development, the
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addict increases dosage to maintain the rewarding effects of a drug. During periods of 
abstinence, dependence is expressed with symptoms of withdrawal; in an attempt to 
escape from the negative affective state that accompanies them, drug-intake resumes and 
a vicious circle is established with detrimental results for the health and function of the 
addicted individual. Homeostatic neuroadaptation theories can therefore explain some of 
the cardinal symptoms of compulsive drug use, suggesting that hedonic tolerance and 
affective withdrawal may be the driving forces of addiction. Tolerance, withdrawal and 
dependence are drug- and cell circuit-specific phenomena (reviewed in Nestler and 
Aghajanian, 1997). Their potency and likelihood of occurrence depends highly on the 
type of abused substance and its interactions with specific receptors in relevant cells. For 
instance, heroin produces a powerful physical withdrawal symptom, whereas cocaine 
does not. Tolerance develops to the hedonic properties of heroin, but not to the 
characteristic opiate-induced papillary constriction.
Although informative, the homeostatic adaptation model cannot explain a key aspect of 
compulsive drug use, which is its persistent nature. Addiction is a chronic and relapsing 
disorder that can be reinstated even after prolonged periods of abstinence. Exposure to 
drugs, drug-associated cues, and stress has been linked to the reinstatement of drug- 
taking behaviour, long after withdrawal symptoms have subsided (reviewed in Hyman et 
al., 2006). This suggests that in addition to the avoidance of withdrawal, reward-related 
associative mechanisms contribute to ongoing drug-use. In rat self-administration studies 
for example, drug-seeking can be more efficiently primed by small doses of drugs, rather 
than by withdrawal (Stewart and Wise, 1992). Moreover, drug-seeking in rodents and 
craving in humans can be reliably elicited by exposure to drug-associated cues, when no 
measurable symptoms of withdrawal can be observed (O'Brien et al., 1998; Semenova
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and Markon, 2003). Stress-induced reinstatement involves the activation of reward 
pathways, further suggesting that positive reinforcement rather than withdrawal is 
involved in re-establishing drug-taking behaviour (reviewed in Marinelli and Piazza, 
2002). In addition, patients on morphine for cancer treatment, as well as subjects who 
require benzodiazepines for anxiety disorders, exhibit dependence and withdrawal 
without the compulsion to seek drugs following treatment cessation (Jage, 2005; O'Brien,
2005). Therefore, considerable evidence suggests that in addition to homeostatic 
neuroadaptation, long-term, reward-related learning processes play a crucial role in 
mediating drug addiction. Indeed, for addicted individuals drugs become valued over all 
other goals, including natural rewards, such as food and sex.
1.2.2 The central role o f dopamine
The full pharmacological profile of different classes of abused drugs is mediated by 
several neurotransmitter systems throughout the CNS. Their addictive potential, however, 
seems to stem from their shared property for increasing dopamine release in striatal areas 
(Di Chiara and Imperato, 1988). Therefore, midbrain DAergic pathways are considered 
as the neural substrates that account for compulsive drug use, dependence and late relapse.
1.2.2.1 The Dopaminergic system: localisation, function, receptors 
The dopaminergic system comprises an anatomically and functionally diverse group of 
neurons, localised in the diencephalon, mesencephalon, and the olfactory bulb. 
Mesodiencephalic dopaminergic neurons have been categorised into three main groups 
(Fallon and Moore, 1978; reviewed in Bjorklund and Dunnett, 2007).
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• The nigrostriatal pathway, originating in the substantia nigra pars compacta (SNc), 
extends its axons into the dorsal striatum. This system plays a pivotal role in the 
control of voluntary movement (reviewed in Gerfen, 1992).
• The mesolimbic system is more medial to the nigrostriatal pathway, and arises from 
dopaminergic cells present in the VTA. Mesolimbic fibres mainly project to the 
nucleus accumbens and olfactory bulb, but also innervate the hippocampus, amygdala, 
and the septum.
• The mesocortical pathway also originates in the VTA and projects to the frontal, 
cingulate and perirhinal cortex.
Due to the overlapping nature of their projections, the mesolimbic and mesocortical 
pathways are collectively referred to as the mesocorticolimbic system. This is involved 
in emotion-based behaviour, including motivation and reward (Mogenson et al., 1980).
To date, five subtypes of DA receptors have been indentified, all of which belong to the 
superfamily of G-protein coupled receptors (reviewed in Missale et al., 1998). Dl-like 
receptor subtypes (Dl and D5) are Gs coupled, and their activation stimulates adenylyl 
cyclase (AC), leading to increased 3', 5’-cyclic adenosine monophosphate (cAMP) 
production. On the contrary, D2-like receptors (D2, D3, and D4) are Gi coupled and their 
activation inhibits AC. In addition to AC coupling, both receptor subtypes can interact 
with different signalling pathways; Dl-like receptors couple to the stimulation of 
phosphoinositide metabolism and mobilise intracellular calcium stores (Liu et al., 1992; 
Undie et al., 1994), whereas D2-like receptor activation stimulates inwardly rectifying 
potassium channels (Werner et al., 1996). Dopamine receptors exhibit different patterns 
of neuroanatomical distribution. D l and D2 receptors are widespread compared to other 
DA subtypes, with higher levels observed in the dorsal and ventral striatum, and the
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olfactory tubercle, and lower levels in the hippocampus, neocortex, hypothalamus, and 
thalamus (Weiner et ah, 1991). Presynaptic D2 receptors are expressed by dopaminergic 
neurons in the axon terminal and somatodendritic regions, where they function as 
autoreceptors to regulate dopamine release (Tepper et al., 1987; Tepper et al., 1997). D3 
receptors are localised in the shell of the nucleus accumbens and the islands of Calleja 
(Sokoloff et al., 1990; Bouthenet et al., 1991), whereas D4 are weakly expressed in 
cortical and limbic areas (Svingos et al., 2000; Wedzony et al., 2000). D5 receptor 
mRNA is low in the striatum and neocortex, but higher in the hippocampus, 
hypothalamus and certain thalamic nuclei (Meador-Woodruff et al., 1992; Khan et al., 
2000). Transport of DA from the extracellular space into the presynaptic bouton is 
essential for the termination of DAergic transmission and the maintenance of presynaptic 
storage. This is performed by the dopamine transporter (DAT), a transmembrane, Na"^  
and C r dependent carrier protein (Volz and Schenk, 2005) that is localised in areas of DA 
innervation, including the ventral mesencephalon and the striatum (Ciliax et al., 1995).
1.2.2.2 The Dopaminergic signal
Dopamine neurons exhibit two main patterns of discharge activity, a sustained, single­
spike, irregular mode (tonic signal), and a transient, homogenous burst of action potential 
firing (phasic signal). In both primates and rodents, DAergic neurons switch from tonic 
activity to either a phasic increase or pause of firing rates, in response to the presentation 
or omission of reward and reward-predicting stimuli, respectively (Schultz et al., 1997; 
Hyland et al., 2002). In this way, mesostriatal DA neurons carry information about the 
occurrence of reward-related events to brain regions that are dedicated to processing their 
hedonic value, such the frontal cortex. The tonic vs. phasic patterns of activation at the 
level of the cell body differentially relates to DA release into the terminal projection areas
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of the mesolimbic pathway. Thus, the phasic stimulation of DA cells is believed to 
produce a much higher efflux of extracellular DA compared to tonic firing frequencies 
(Chergui et al., 1994; Garris et al., 1994), thereby effectively conveying the signal of 
reward to corticostriatal areas. Several findings suggest that DA release is a highly 
dynamic rather than a static, fixed-amplitude process. Indeed, the release of extracellular 
DA is accompanied by short-term changes in DA release probability, in such a way that 
DA release in the striatum undergoes a use-dependent depression of release probability at 
rapidly successive pulses (Gragg, 2003; Montague et al., 2004). This type of plasticity in 
DA release probability suggests that DA levels do not depend linearly on the frequency 
of DAergic neuron activity, but that extensive neuromodulation occurs at the terminal 
release sites. Drugs of abuse bypass all the aforementioned physiological processes of 
reward-related signalling by pharmacologically inducing DA release in the striatum, and 
therefore producing a sustained reward signal. The participation of nicotinic cholinergic 
mechanisms on midbrain DAergic neurotransmission will be examined in the following 
section.
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1.2,3 nAChRs and dopaminergic signalling
1.2.3.1 Anatomical foundations
Dopaminergic and cholinergic innervation is denser in the striatum than anywhere else in 
the brain. Moreover, there is a precise overlap in the distribution of the rate limiting 
enzymes for ACh and DA synthesis, suggesting that cholinergic and DAergic fibres are 
closely intertwined in striatal areas (Zhou et al., 2001). In addition, cholinergic 
projections from the mesopontine tegmentum, namely from the pedunculopontine (PPTg) 
and the laterodorsal tegmental nuclei (LDTg), innervate the substantia nigra (SN) and the 
VTA, respectively, providing a source of endogenous acetylcholine that modulates the 
firing of midbrain dopaminergic neurons via nAChRs that are expressed in these areas 
(reviewed in Maskos, 2008). Nicotinic cholinergic mRNA for a4, a5, a6, a3, a7, p2, P3, 
and P4 subunits is widely expressed on the cell bodies of midbrain DA neurons (Azam et 
al., 2002). This potentially gives rise to multiple pentameric nAChR combinations with 
distinct functional properties. The exact subunit composition, stoichiometry and function 
of different nAChRs have been characterised using immunoprécipitation and 
electrophysiology studies, specific ligands, and subunit-specific KO mice. a7 and p4 
subunits are expressed in the SNc and VTA, but are not encountered on striatal DAergic 
terminals (Champtiaux et al., 2003; Quik et al., 2005). All nAChRs that are expressed 
presynaptically on DA terminals in the striatum contain the P2 subunit (Jones et al., 2001; 
Champtiaux et al., 2003). In addition to the p2, a4 and a6 subunits are also abundant in 
the rodent striatum. The a6/a3 selective antagonist a-conotoxin Mil (a-CtxMII) has been 
used to distinguish between two subpopulations of p2-containing nAChRs, those that are 
a-CtxMII sensitive and resistant, respectively (Kulak et al., 1997; Whiteaker et al., 
2000a; Whiteaker et al., 2002). The a-CtxMII sensitive population comprises a6 subunits, 
colocalised with P3, and to a smaller proportion a4 subunits (Le Novere et al., 1996;
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Champtiaux et al., 2003; Gui et al., 2003). The a-CtxMII resistant population is 
composed of a4 subunits, which sometimes associates with the a5 subunit (Zoli et al., 
2002; Champtiaux et al., 2003; Salminen et al., 2004; Salminen et al., 2005). Altogether, 
evidence supports the existence of functional a4p2, a4a5p2, a6a4p2p3, a6p2p3, a6p2, 
a6a4p2 in DA axons of the rodent striatum.
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Figure 1.5 Subtypes o f nAChRs involved in DAergic neurotransm ission
The subunit composition of functional nAChR subtypes expressed by DAergic, GABAergic and glutamatergic neurons 
is shown. The exact contribution o f subunits in brackets remains remains to be elucidated. Adapted from Champtiaux 
et al., (2003).
In addition, nAChRs are expressed presynaptically by GABAergic and glutamatergic 
neurons in both the VTA and NAc, and are therefore capable of modulating DA release 
indirectly, by facilitating inhibitory and excitatory input onto DAergic neurons. 
Specifically, presynaptic a7 nAChRs are located on glutamatergic nerve terminals, and 
a4p2* nAChRs on GABAergic interneurons (Mansvelder and McGehee, 2000; 
Mansvelder et al., 2002). Therefore, the cholinergic modulation of striatal DA release 
seems to involve sophisticated connections between distinct nAChR subtypes, localised 
on several different neurons.
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1.2.3.2 Cholinergic modulation o f  DAergic signalling in the VTA
There is overwhelming evidence that all drugs of abuse activate the mesolimbic 
dopaminergic pathway in order to exert their reinforcing effects (reviewed in Pierce and 
Kumaresan, 2006). Nicotine obtained from tobacco smoke constitutes no exception. The 
responses of DA neurons to endogenous ACh or exogenous nicotine are mediated by 
nAChRs localised on three different cell types; a4p2* nAChRs on the DAergic neuron 
itself, presynaptic a4p2* nAChRs on GABAergic intemeurons, and presynaptic a7 
nAChRs on glutamatergic fibres. In the VTA microcircuitry these nAChR subtypes 
differentially affect DAergic, GABAergic and glutamatergic responses to a concentration 
of nicotine similar to that acquired by smokers, as a result of their inherently distinct 
desensitisation properties (see Section 1.1.3.1). Initially, nicotine rapidly activates high 
affinity, p2 subunit containing receptors on DA and GABA neurons. Indeed, the direct 
depolarisation of DA neurons coincides with an increase of GABAergic synaptic 
transmission (Mansvelder et al., 2002). Desensitisation of p2 subunit containing nAChRs, 
however, results in the decline of inhibitory GABAergic input onto DA neurons. At the 
same time, nicotine activates presynaptic a7 nAChRs that are located on glutamatergic 
nerve terminals. As these receptors are resistant to desensitisation in the range of nicotine 
concentrations experienced by smokers, an increase of glutamate transmission onto DA 
neurons occurs (Pidoplichko et al., 1997). When this enhanced presynaptic glutamate 
release coincides with a sufficient postsynaptic depolarisation of the DA neuron, long 
term potentiation of the excitatory inputs onto the dopaminergic system takes place 
(Mansvelder and McGehee, 2000). These mechanisms explain why a single exposure to 
nicotine causes prolonged increases in striatal DA release in vivo (Imperato et al., 1986; 
Di Chiara and Imperato, 1988).
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1.2.3.3 Cholinergic modulation o f  DAergic signalling in the NAc 
The striatal effects of nicotine on DAergic neurotransmission were until recently 
neglected. The long-held view that nAChRs in the VTA primarily mediate nicotine’s 
addictive potential has been supported by several reports, which indicate that systemic 
nicotine injections or nicotine infiised into the VTA, but not the striatum, sustains 
increased levels of DA in the NAc (Nisell et al., 1994; Ferrari et al., 2002). Moreover, 
blockade of nAChRs in the VTA and not the striatum prevents nicotine self­
administration (Corrigall et al., 1994). Nevertheless, recent insight into nicotine’s mode 
of action reveals that potent cholinergic mechanisms are in place in the striatum, which 
provide an amplification of reward-related signalling in terminal DAergic regions. 
Contrary to microdialysis studies, which show an enhancement of DA release in the 
striatum by nicotine, fast-cyclic voltammetry in mice striatal brain slices reveals that 
desensitising doses of nicotine decrease DA release evoked by tonic stimuli by -80%  
(Zhou et al., 2001). This decrease is also observed after depletion of endogenous ACh 
with vesamicol and following the administration of nicotinic antagonists. In addition, the 
cholinergic modulation of DA release is absent in mutant mice lacking the p2 subunits, 
suggesting that tonic cholinergic activity regulates DA release at the target, via p2- 
containing nAChRs (Zhou et al., 2001). Interestingly, the inhibition of single pulse- 
evoked DA release by nicotine is only observed at low tonic frequencies. Similarly to 
cocaine and amphetamine, nicotine-induced DA release during the phasic activation of 
DAergic neurons has been shown to increase (Rice and Cragg, 2004). This dual effect of 
nicotine - amplification of phasic and suppression of tonic DA release - is explained by 
the dynamic plasticity in DA release probability that occurs at the circuit-level (see 
Section 1.2.2.2). At striatal synapses, short-term depression of DA release takes place, 
diminishing release probability at consecutive pulses (Cragg, 2003). Nicotine, by
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suppressing single pulse-evoked DA release contributes to the relief of short-term 
depression, an effect that is equivalent per successive pulse (Rice and Cragg, 2004). 
Therefore, desensitising doses of nicotine, or a reduction of ACh tone at nAChRs, can 
both enhance reward-related bursts of DA neuron activity and further suppress the DA 
signal that accompanies the omission of rewards. Together, somatodendritic and axonal 
nAChRs serve as a dynamic and diverse cholinergic filter of DA neurotransmission.
Striatal ACh neurons cease action potential firing in response to reward-related events 
(Aosaki et al., 1994; Shimo and Hikosaka, 2001), contrary to mesostriatal DA cells, 
which switch from tonic to burst firing patterns of activity (Bayer and Glimcher, 2005; 
Tobler et ah, 2005). Interestingly, these reward-related neuronal responses coincide 
temporally when recorded in the same tasks, occurring with similar latency and duration 
(Morris et al., 2004). This functional cooperation suggests that nicotinic cholinergic 
mechanisms may play a broader role in mediating reward-related processes. Because 
drugs of abuse reliably increase synaptic DA, it seems highly probable that cholinergic 
modulation via nAChRs may provide an additional neural substrate for the therapeutic 
intervention of drug addiction. In the following section, evidence for the role of nAChRs 
in mediating the abuse potential of different classes of drugs will be reviewed.
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1.3 Interactions between nAChRs and drugs of abuse
1.3.1 nAChRs and cocaine
The prevalence of poly-drug abuse is characteristically depicted in the concurrent 
consumption of nicotine with cocaine. In humans, the extent of smoking has been 
associated both with the probability and the frequency of cocaine abuse (Henningfield et 
al., 1990; Schorling et al., 1994; Konings et al., 1995). Moreover, several studies have 
suggested that the two drugs may facilitate each other’s intake (Budney et al., 1993; 
Higgins et al., 1994; Roll et al., 1996), producing subjective effects that considerably 
overlap (Foltin and Fischman, 1991; Jones et al., 1999). The fact that a single 
administration of nicotine can enhance cue-induced cocaine craving in cocaine-abstinent 
subjects, while mecamylamine can dose-dependently attenuate it, indicates that there are 
direct and persistent psychopharmacological interactions between the two substances 
(Reid et al., 1998; Reid et al., 1999).
1.3.1.1 Cocaine’s mode o f  action
Cocaine exerts its effects on the CNS through its interaction with the dopamine (DAT), 
norepinephrine (NET), and serotonin (SERT) cell membrane transporters (reviewed in 
Carrera et al., 2004). By blocking the carrier proteins, cocaine prevents the reuptake of 
catecholamine neurotransmitters into the presynaptic cleft, and consequently increases 
their synaptic availability, thereby acutely activating DAergic, adrenergic and 
serotonergic receptors. The relative importance o f DAT, NET, and SERT inhibition in 
the reinforcing properties of cocaine has been the subject of intense investigation. 
Evidence suggests that blockade of the DAT, rather than the NET and SERT, is critically 
involved in mediating cocaine’s abuse-related potential (Ritz et al., 1987). Indeed, drugs 
that inhibit noradrenergic or serotonergic reuptake do not prevent cocaine self-
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administration in rodents and non-human primates (De Wit and Wise, 1977; Howell and 
Byrd, 1995). On the contrary, direct DA agonists are self-administered by animals 
trained to self-administer cocaine (Woolverton et al., 1984; Wise et al., 1990; Caine and 
Koob, 1993), and lesions of DAergic nerve terminals in the NAc (Roberts et al., 1977; 
Roberts et al., 1980) or cell bodies in the VTA (Roberts and Koob, 1982) lead to the 
extinction of cocaine self-administration behaviour. Moreover, cocaine is not self­
administered by animals with genetic deletion of the DAT gene (Thomsen et al., 2009), 
or by DAT knockin mice carrying a mutant transporter that is functional, albeit 
insensitive to cocaine inhibition (Chen et al., 2006). These data suggest that DAT 
blockade is necessary for cocaine reward.
As there is currently no available pharmacotherapy for the treatment of cocaine addiction, 
a major goal of the scientific community is to characterise the neuropharmacological 
determinants of the drug’s high abuse potential. Given the role of nAChRs in DAergic 
signalling, manipulation of the nicotinic cholinergic system has the potential to influence 
strategies for cocaine addiction.
1.3.1.2 Neurochemical evidence fo r  interactions between nAChRs and cocaine 
The anatomical foundations for the nicotinic cholinergic influence on DAergic 
neurotransmission have been described in Section 1.2.3.1. Through different molecular 
mechanisms, cocaine and nicotine increase DA release in the NAc, indicating that the 
mesolimbic DAergic pathway is the principal site for interactions between the two drugs 
(Di Chiara and Imperato, 1988; Pontieri et al., 1996). In rats, co-administration of 
nicotine at 0.4 mg/kg with either 10 or 20 mg/kg of cocaine, increases extracellular NAc 
DA levels in an additive or synergistic manner, respectively, suggesting that the degree of
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DA transporter occupancy contributes to the interactions between these drugs (Gerasimov 
et al., 2000). Indeed, by inhibiting DA reuptake through the blockade of dopamine 
transporters, cocaine’s efficacy is determined by the amount of DA that is released and 
available within the synaptic cleft. In the NAc, depletion of endogenous ACh, 
administration of nicotinic antagonists or the genetic deletion of the g2 subunit 
dramatically decreases DA release by -80%, suggesting that endogenous cholinergic 
activity tonically stimulates the mesolimbic DAergic pathway (Zhou et al., 2001). 
Therefore, administration of nAChR antagonists within the NAc is anticipated to 
decrease cocaine-induced DA release, by antagonising the striatal cholinergic tone. 
Indeed, intra-NAc perftision of the broad spectrum nAChR antagonist mecamylamine, or 
co-perfusion of the heteromeric nAChR antagonist DhBE with the homomeric nAChR 
antagonist MLA, attenuates DA increase following an acute i.p. injection of 5 mg/kg 
cocaine in mice (Zanetti et al., 2007). The fact that experimenter- and se lf  administered 
cocaine enhances acetylcholine efflux in various brain regions, including the cerebral 
cortex (Day et al., 1997), hippocampus (Imperato et al., 1992), interpeduncular nucleus 
(Hussain et al., 2008), nucleus accumbens (Mark et al., 1999; Crespo et al., 2006) and 
striatum (Zocchi and Pert, 1994), further suggests that a targeted increase in ACh tone 
may be responsible for significant adaptations of cocaine-induced DAergic 
neurotransmission. In mice that have been repeatedly treated with cocaine, co­
administration of the psychostimulant with nAChR antagonists prevents the development 
of sensitisation to cocaine-induced increases of extracellular DA, strongly implying that 
an enhanced cholinergic tone acting on nAChRs is necessary not only for the acute, but 
also for the long-term effects of cocaine on mesolimbic DAergic signalling (Zanetti et al.,
2006).
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Data on the cholinergic modulation of cocaine reinforcement, however, are as yet 
equivocal. The ablation of cholinergic intemeurons with immunotoxins within the NAc 
has been shown to potentiate cocaine-induced locomotion and conditioned place 
preference, while acetylcholinesterase inhibition suppresses these behaviours, suggesting 
that inhibition rather than activation of the striatal cholinergic neuron is involved in 
cocaine’s stimulant effects (Hikida et al., 2001; Hikida et al., 2003). Similarly, cocaine 
administration has been paralleled with a decrease in ACh turnover in the NAc (Smith et 
al., 2004). Moreover, contrary to their effects within the NAc, the nAChR antagonists 
DhBE and MLA increase cocaine-induced extracellular release of DA when infused 
directly into the VTA (Zanetti et al., 2007). Differences in the experimental conditions 
among these and the aforementioned studies may account for the inconclusive results 
obtained so far as to the cholinergic modulation of cocaine-induced DAergic 
neurotransmission. All the same, given the heterogeneity of nAChR subtypes that are 
expressed by midbrain DAergic neurons, and the dynamic filtering of DAergic 
neurotransmission by nAChRs, no single effect of cocaine on nicotinic cholinergic 
signalling can account for these discrepancies.
1.3.1.3 Behavioural evidence fo r  interactions between nAChRs and cocaine 
Among the paradigms employed to model different aspects of drug reinforcement, the 
self-administration procedure has been favoured as the most direct way of investigating 
the behavioural and neurobiological processes that lead to addiction. In rodents, the 
acquisition of cocaine self-administration can be dose-dependently suppressed by the 
broad nAChR antagonist mecamylamine (Blokhina et al., 2005), and facilitated by pre­
exposure to nicotine (Horger et al., 1992). In rats that have been trained to lever press for 
0.32 mg/kg/infusion of intravenous (i.v.) cocaine, pretreatment with mecamylamine dose-
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dependency reduces cocaine se lf  administration (Levin et al., 2000). Moreover, in the 
presence of mecamylamine, the escalation from moderate to excessive cocaine intake is 
prevented in rats with extended daily access to the psychostimulant (Hansen and Mark,
2007). When the antagonist is removed, drug self-administration is increased, indicating 
that nAChRs prevent the consumption of cocaine under conditions that promote an 
escalation of its intake. Repeated exposure to 0.6 mg/kg of s.c. nicotine prior to the 
initiation of cocaine self administration sessions progressively leads to increased 
responding for 0.1 mg/kg/infusion of i.v. cocaine over the course of 14 days, indicating 
that nicotine can potentiate cocaine’s rewarding effects (Bechtholt and Mark, 2002). 
Following the extinction of self-administration, acute nicotine emits a burst of non­
reinforced responses, indicating that the drug elicits cocaine-seeking behaviour. These 
results suggest that nAChRs are involved in all aspects of cocaine se lf  administration, 
including the acquisition, maintenance, escalation and relapse to this behaviour. In the 
conditioned place preference paradigm (GPP), pharmacological disruption of nicotinic 
neurotransmission with 1 mg/kg of mecamylamine inhibits place preference to 5 mg/kg 
of cocaine, which is the lowest dose that can condition this response in C57BL/6 mice. 
On the contrary, nicotine at 0.2 mg/kg potentiates place preference to a subthreshold dose 
of 3.0 mg/kg of cocaine. The effects of nicotine on cocaine-induced GPP are mediated by 
receptors containing the (32 subunit, since (32 mutant mice fail to condition to 5 mg/kg of 
cocaine (Zachariou et al., 2001). In the drug discrimination paradigm, the discriminative 
stimulus effects of 0.1 mg/kg nicotine fully substitute for those of cocaine, whereas 
cocaine partially substitutes for nicotine, indicating a considerable, yet assymetric overlap 
in the subjective effects of the two drugs (Desai et al., 1999).
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Cocaine has been shown to progressively enhance locomotor activation in rodents during 
its repeated administration. This sensitised response reflects long-term neuroadaptation 
that is considered to contribute to cocaine’s addictive properties. Systemic blockade of 
nAChRs with mecamylamine has been shown to prevent the development of cocaine- 
induced locomotor sensitization. (Schoffelmeer et al., 2002) The same effect can be 
exerted by intra-VTA infusion of the heteromeric, (32 subunit containing nAChR 
antagonist DhBE, but not o f the homomeric nAChR antagonist MLA, suggesting that 
heteromeric receptors within the VTA are involved in the neuroadaptive changes 
underlying cocaine sensitisation (Champtiaux et al., 2006). Repeated administration of 
nicotine, on the other hand, has been shown to cause no sensitisation to the locomotor 
stimulant effects of cocaine in adult rats (Horger et al., 1992) and mice (Itzhak and 
Martin, 1999). Nevertheless, locomotor cross-sensitisation between nicotine and cocaine 
is observed preferentially during periadolescence rather than adulthood, demonstrating 
that this age may be more vulnerable to the risk of cocaine abuse after nicotine exposure 
(Collins and Izenwasser, 2004). Indeed, long-term, low-level adolescent nicotine 
administration produces dose-dependent changes in cocaine-induced motor effects in 
adult mice (Kelley and Rowan, 2004). Altogether, a large body of evidence supports the 
notion that nAChRs are a common denominator for the neurochemical and behavioural 
effects of cocaine.
1.3.2 nAChRs and opioid abuse
There is a large amount of published research that supports interactions between the 
nicotinic cholinergic and opioid systems in humans. Indeed, tobacco smoking can be 
reduced by the MOP receptor antagonist naloxone (Karras and Kane, 1980), 
administration of which dose-dependently induces opioid-like withdrawal symptoms in
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smokers (Krishnan-Sarin et al., 1999). The longer lasting opioid antagonist naltrexone 
has been found to significantly reduce the total number of cigarettes smoked, as well as 
the desire to smoke (King and Meyer, 2000), and it has showed beneficial effects in 
smoking cessation treatment (Covey et al., 1999). Nevertheless, other reports have not 
reached similar conclusions in humans (Nemeth-Coslett and Griffiths, 1986; Sutherland 
et al., 1995; Wong et al., 1999). It is therefore necessary to better identify the 
mechanisms involved in the interaction between nAChRs and the endogenous opioid 
system.
1.3.2.1 The opioid system: Localisation, function, receptors
In the mid-1970s, endogenous peptides with morphine-like activity were isolated: 
methionine and leucine enkephalins were derived from the pig brain (Hughes et al., 1975), 
whereas P-endorphin was isolated from camel pituitary glands (Li and Chung, 1976). 
Another group of peptides, the dynorphins, were subsequently isolated from porcine 
pituitary in the early 1980s (Goldstein et al., 1981). A fourth endogenous opioid agonist 
was reported in 1995 by two groups and named nociceptin/orphanin FQ (Meunier et al., 
1995; Reinscheid et al., 1995). To date, more than 20 endogenous opioid peptides have 
been identified, which are mainly derived from four precursor proteins, pro­
opiomelanocortin, proenkephalin, prodynorphin, and pronociceptin/orphanin FQ 
(reviewed in Vaccarino and Kastin, 2001). Endogenous peptides exert their action by 
acting on specific receptors, namely the MOP, KOP, DOP, and NOP receptors. 
Collectively, opioid peptides and their receptors form the endogenous opioid system. All 
opioid receptors belong to the G-protein coupled family, interacting with pertussis-toxin 
sensitive Gi proteins to inhibit AC, thus reducing intracellular cAMP content. In addition, 
both the a  and the Py subunits of the G protein interact with effector systems to inhibit the
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opening of voltage-gated calcium channels, promote that of inwardly rectifying 
potassium channels and stimulate phospholipase C (reviewed in Waldhoer et al., 2004). 
Quantitative receptor autoradiography and in situ hybridisation have been used to map 
the distribution of opioid receptors in the rodent CNS, which is summarised in Table 1.3.
Receptor Endogenous ligands 
Affinity order
G-
protein
Transduction
Mechanism Distribution
MOP P-end>dynA>met=leu Gi/o
Inhibits adenylyl cyclase 
Activates GIRKs
High in nucleus accumbens, caudate 
putamen, habenula, and thalamus. 
Moderate in amygdala, cortex, superior 
colliculus, hypothalamus
DOP P-end=met=leu>
dynA Gi/o
Inhibits adenylyl cyclase 
Activates GIRKs
High in external plexiform layers o f  
olfactory bulb, caudate putamen. 
Moderate in cortex, basolateral 
amygdala, nucleus accumbens, 
tubercle and hippocampus
KOP dynA »P-end>
leu>met Gi/o
Inhibits adenylyl cyclase 
Activates GIRKs 
Activates PLC
High in claustrum, endopiriform 
nucleus.
Moderate in the nucleus accumbens, 
ventral pallidum, central gray, 
and substantia nigra
NOP N / OF Q » d y n  A Gi/o
Inhibits adenylyl cyclase 
Activates GIRKs 
Activates PLC
High in cortex, amygdala, 
hippocampus, olfactory bulb. 
Moderate in thalamus and 
periaqueductal gray
Table 1.3 Opioid receptors in the m ouse brain
The predominant mechanism o f  coupling and the distribution o f  different classes o f opioid receptors. Quantitative receptor 
autoradiography using [ H]CI-977, [^HJDAMGO, [^HJDELT-I, and [^H] leucyl-nociceptin was performed to label KOP-, 
MOP-, DOP-, and NOP-opioid receptors, respectively (Slowe et al., 1999; Clarke et al., 2001). Abbreviations: GIRKs: G- 
protein-dependent activation o f  inwardly rectifying channels; PLC: phospholipase C.
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1.5.2.2 Neurochemical evidence fo r  interactions between nAChRs and opioids 
Administration of nicotine or opioids has been shown to increase the accumbal release of 
dopamine (DA), an effect that is considered to be critical for the addictive nature of many 
drugs of abuse (Pontieri et a l, 1996). Indeed, the systemic or focal administration of 
either class of substances into the VTA or NAc raises extracellular DA in striatal areas, as 
measured by in vivo microdialysis (Devine et a l, 1993; Hemby et a l, 1995; Ferrari et a l, 
2002; Hirose et a l, 2005). More importantly, chronic oral pretreatment of mice with 
nicotinic solutions enhances morphine-induced DA release in the CPu and the NAc 
(Vihavainen et a l, 2008b), and a single intraperitoneal (i.p.) injection of the selective 
a3p4 nAChR antagonist 18-methoxycoronaridine (18-MC) abolishes the sensitized 
dopamine response in rats that have been repeatedly exposed to morphine (Maisonneuve 
and Click, 1999; Szumlinski et a l, 2000; Taraschenko et a l, 2007a). In addition, lesions 
of striatal cholinergic intemeurons with cholinotoxins eliminate MOP receptor agonist- 
mediated increases in DA release (Dourmap et a l, 1997). Therefore, a large body of 
evidence points to the mesolimbic DA system as the neuronal pathway involved in 
nicotinic-opioid interactions. Midbrain dopaminergic neurons switch from tonic to burst 
patterns of action potential firing in response to rewarding or reward-predicting stimuli, 
and this transition contributes to increased striatal DA release (Schultz, 2007). Recently, 
electrochemical and electrophysiology studies have shown that MOP and DOP receptor 
agonists inhibit tonic DA release indirectly, by suppressing cholinergic intemeuron 
activity within the NAc (Britt and McGehee, 2008). As shown by in vivo microdialysis, 
cholinergic inhibition lowers baseline levels of ACh in the NAc (Rada et a l, 1996), 
which would consequently decrease nAChR activation on DA terminals. The endpoint of 
this cholinergic-mediated decrease in tonic DA release by opioids is an enhanced ratio of 
burst evoked DA levels relative to baseline, and thus an indirect increase in the
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magnitude of the DAergic signal (Britt and McGehee, 2008). Interestingly, nicotine 
similarly acts in the striatum to increase the contrast between tonic and burst-evoked 
dopaminergic signals, by directly desensitising nAChRs on DA nerve terminals (Zhang 
and Sulzer, 2004). This profound mechanistic overlap between nicotine and opioids has 
strong anatomical foundations, as MOP receptors within the shell of the NAc are 
expressed not on dopaminergic, but on cholinergic intemeurons (Svingos et al., 2001). In 
addition, the transition of midbrain DA neurons from tonic to burst firing pattems 
involves the modulation of afferent inputs to the VTA, a structure that highly expresses 
both MOP receptors and nAChRs (Mansour et al., 1995; Picciotto et al., 1998). 
Altogether, substantial evidence suggests that opioids partly exert their effects within the 
reward circuitry indirectly, by modulating DA release through nAChRs.
Following 0.5 mg/kg of subcutaneous nicotine, extracellular DA release in the NAc is 
impaired in preproenkephalin gene KOs compared to WT mice, suggesting that 
endogenous opioids derived from preproenkephalin participate in the modulation of DA 
neurotransmission by nicotine (Berrendero et al., 2005). Indeed, acute and chronic 
nicotine administration increases the release of endogenous opioids (Dhatt et al., 1995; 
Houdi et al., 1998; Isola et al., 2002). Morphine has been shown to excite DA neurons by 
hyperpolarising GABAergic cells in the VTA via MOP receptors (Johnson and North, 
1992). Nicotine-induced increases in the release of endogenous opioids can therefore 
contribute to the disinhibition of DA neurons, and consequently to the reinforcing 
properties of the drug, by activating presynaptic MOP receptors on GABAergic cells. In 
support of this, nicotine-induced conditioned placed preference is not observed in 
preproenkephalin or MOP receptor KO mice, indicating that opioid-dependent 
mechanisms mediate the rewarding effects of nicotine (Berrendero et al., 2002;
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Berrendero et al., 2005). Overall, DAergic transmission within the mesolimbic system 
seems to be a common neurochemical mechanism, both for the cholinergic modulation of 
opioid-induced effects and for the involvement of the opioid system in the reinforcing 
properties of nicotine.
1.3.2.3 Behavioural evidence fo r  interactions between nAChRs and opioids 
Nicotine and morphine have been shown to influence each other’s effects in various 
experimental settings, designed to model the addictive properties of the two drugs. Thus, 
rats that have received 5 daily injections of 0.5 mg/kg of nicotine (Biala and Weglinska, 
2004), and rats that have been pre-exposed to 0.4 mg/kg/day of nicotine for 5 days 
(Shippenberg et al., 1996) show enhanced conditioned place preference (CPP) to 5 mg/kg 
of morphine. Similarly, 7-week oral nicotine pretreatment in mice potentiates morphine- 
induced CPP (Vihavainen et al., 2008a). Furthermore, pretreatment with the broad 
spectrum nicotinic antagonist mecamylamine reverses morphine-induced CPP, while the 
opioid antagonist naloxone diminishes nicotine-induced CPP in mice (Zarrindast et al., 
2003). The participation of different components of the opioid system in the rewarding 
effect of nicotine has been demonstrated by the fact that 8 days of 0.5 mg/kg of s.c. 
nicotine does not induce CPP in MOP-receptor (Berrendero et al., 2002), 
preproenkephalin (Berrendero et al., 2005), and (3-endorphin (Trigo et al., 2009) gene KO 
mice, compared to WT animals. Overall, the interaction between nicotinic receptors and 
the opioid system has been clearly demonstrated in the CPP paradigm of drug abuse. The 
application of the self-administration paradigm, however, has produced mixed results. 
Corrigall and Coen, (1991), failed to show any effect of naltrexone on nicotine-self 
administration in rats. In a study with a positive outcome, the antagonist markedly 
suppressed nicotine-induced increases in responding to a fixed-interval schedule of food
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presentation in mice (Corrigall et al., 1988). In an intravenous morphine self­
administration report, the potent aSp4 nAChR antagonist 18-MC produced a downward 
shift in the entire morphine dose-response curve, indicating that the drug reduced the 
reinforcing efficacy of morphine, without altering is potency (Maisonneuve and Click,
1999). Therefore, further research is required to determine the nature of nAChR-opioid 
receptor interactions in the self-administration paradigm, particularly with respect to 
specific nAChR subtypes that may modulate opioid intake.
Chronic exposure to nicotine or opioids results in the development of physical 
dependence, which manifests with somatic symptoms of withdrawal upon cessation of 
drug-intake (spontaneous withdrawal) or upon the administration of nicotinic and opioid 
antagonists (precipitated withdrawal). Interestingly, the nicotine abstinence syndrome 
closely resembles opioid withdrawal, including responses such as shakes and tremors, 
teeth chattering, writhes, gasps, and chews (Malin et al., 1993; Hildebrand et al., 1997). 
Indeed, mecamylamine at 3.0 mg/kg and naloxone at 1.0 mg/kg precipitate qualitatively 
similar symptoms of nicotine withdrawal in mice that have been exposed to intermittent 
nicotine injections for 7 days (Biala et al., 2005). In rats that have been exposed to 3.2 
mg/kg/day of nicotine for 7 days via osmotic minipumps, a single s.c. injection of 4.5 
mg/kg naloxone precipitates withdrawal, whereas 2  mg/kg of morphine alleviate the 
symptoms of spontaneous nicotine withdrawal (Malin et al., 1993). Moreover, 2 mg/kg 
of naloxone and 1 mg/kg of mecamylamine precipitate a qualitatively similar withdrawal 
symptom in rats that have been pretreated with nicotine via osmotic minipumps at a rate 
of 3.16 mg/kg/day for 8 days (Carboni et al., 2000). The above data imply an important 
role for opioid-dependent mechanisms in nicotine abstinence. Indeed, deletion of the 
MOP receptor (Berrendero et al., 2002) or of the preproenkephalin gene (Berrendero et
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a l, 2005) attenuates the mecamylamine-precipitated somatic expression of the nicotine 
withdrawal syndrome, indicating that an endogenous opioid tone is crucial for the 
manifestation of physical abstinence signs. In addition to the somatic signs, the affective 
aspects of nicotine abstinence may also involve interactions between nAChRs and 
opioids, as the administration of naloxone induces conditioned place aversion in nicotine- 
treated rats (Watkins et al., 2000). Moreover, mecamylamine-induced nicotine- 
withdrawal aversion can be significantly attenuated by morphine pretreatment (Ise et al.,
2000). Similarly to the participation of opioid mechanisms in nicotine-abstinence, 
physical signs of opioid withdrawal can be reversed in morphine-dependent rats. A 
single injection of nicotine 15 min prior to naloxone diminishes the severity of the opioid 
withdrawal syndrome, in a dose-dependent and mecamylamine-reversible manner 
(Zarrindast and Farzin, 1996). Moreover, the repeated, concurrent administration of 
nicotine with morphine dose-dependently abolishes the incidence of withdrawal jumping 
in mice (Haghparast et al., 2008). In conclusion, common neurobiological mechanisms 
seem to subserve nicotine and opioid physical dependence.
1.3.3 nAChRs and adenosine systems
A significant positive correlation for the concurrent consumption of nicotine and caffeine, 
a non selective adenosine Ai and A%A receptor antagonist, has been derived from six 
epidemiological studies, which collectively examined the smoking and coffee drinking 
habits of almost 40,000 people (reviewed in Swanson et al., 1994). The joint use of 
nicotine and caffeine has been further supported by controlled human studies, which 
show that caffeine consumption is larger in smokers compared with non-smokers (Istvan 
and Matarazzo, 1984; Budney et al., 1993; Kozlowski et al., 1993; Rose et al., 1993), and 
that nicotine-intake is enhanced while drinking coffee (Parsons and Neims, 1978;
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Marshall et al., 1980; Emurian et al., 1982; Nellis et al., 1982; Brown and Benowitz, 
1989). Therefore, a number of different reports suggest that interactions exist between 
nAChRs and the adenosine system.
1.3.3.1 The adenosine system: Localisation, function, receptors
Adenosine is a neuromodulator that plays a very important role in basal ganglia function 
(reviewed in Ferre et al., 1997). Its actions are mediated by the adenosine receptors, 
which are part of the G-protein coupled family and classified into Ai, A2A, A2B and A3 
subtypes. Their differential regional distribution in the brain and the heterogeneity of 
receptor coupling reflect adenosine’s diverse neuromodulatory role. Compared to A2B 
and As, Ai and A2A receptors exhibit a much higher affinity for adenosine, and are 
thought to mediate the tonic adenosine tone encountered in most brain regions (see Table 
1.4). Ai receptors are widely distributed throughout the CNS and their stimulation leads 
to inhibition of AC activity via Gi-dependent coupling. In addition, Ai receptor 
activation hyperpolarises the resting potential of the cell membrane, by inhibiting calcium 
channels (MacDonald et al., 1986), and stimulating inwardly rectifying potassium 
channels (Trussell and Jackson, 1985).
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Receptor Adenosine 
Affinity (nM) G-protein Transduction Mechanism Distribution
A i -70 Gi/o
Inhibits adenylyl cyclase 
Activates GIRKs 
Inhibits Ca^ "^  channels 
Activates PLC
Widespread. 
High in hippocampus, 
cerebellum, 
cerebral cortex
A 2A -150 Gs, Golf Activates adenylyl cyclase
Striatum, olfactory 
tubercle, nucleus 
accumbens
A 2B -5100 Gs Activates adenylyl cyclase Activates PLC
Widespread but low 
expression
A 3 -6500 Gi/o Activates PLC Inhibits adenylyl cyclase
Widespread but low 
expression
Table 1.4 Adenosine receptors in the brain
The predominant mechanism of coupling and the distribution of different classes of adenosine receptors. 
Abbreviations: GIRKs: G-protein-dependent activation of inwardly rectifying channels; PLC: phospholipase C. 
Adapted from Dunwiddie and Masino, (2001).
A2A receptors, on the other hand, are Gs-olf coupled and their activation is primarily 
linked to stimulation of the cAMP-PKA cascade (reviewed in Ferre et al., 2007). They 
are highly expressed in the striatum, in brain structures such as the nucleus accumbens, 
which is involved in motivation and reward, as well as in mediating the addictive 
properties of abused drugs. By stimulating postsynaptic Ai and A2A receptors, which are 
colocalised with D l and D2 receptors on GABAergic dynorphinergic and 
enkephalinergic neurons in the striatum, respectively, adenosine exerts an inhibitory tone 
on dopaminergic transmission. This regulatory role stems from antagonistic interactions 
between adenosine Ai/dopamine Dl receptors and adenosine A2A/dopamine D2 receptors 
(reviewed in Franco et al., 2000).
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1.3.3.2 Neurochemical evidence fo r  interactions between nAChRs and adenosine 
The underlying neurochemical mechanism of interactions between nicotinic and 
adenosine receptors is poorly understood. By stimulating neuronal nAChRs, nicotine 
plays an important neuromodulatory role in the CNS and participates in a large number of 
physiological processes (reviewed in Dani and Bertrand, 2007). Several lines of evidence, 
however, have linked the reinforcing and addictive properties of the drug with a 
facilitation of DA neurotransmission in the mesolimbic dopaminergic system (reviewed 
in Picciotto, 1998). Caffeine elicits its stimulant effects through a non-selective 
competitive antagonism at adenosine Ai and A%A receptors (reviewed in Ferre, 2008). 
Despite the large consumption of caffeine-containing beverages worldwide, no consistent 
reports have been obtained as to the drug’s potential of increasing extracellular DA levels 
in the NAc, an elevation that is characteristic o f all abused substances (Di Chiara and 
Imperato, 1988). Consistent with caffeine’s role as a weak primary reinforcer, reports on 
the administration of behaviourally relevant doses of caffeine in rats have either shown 
relatively small significant increases in extracellular DA (Solinas et a l, 2002; Quarta et 
a l, 2004a), or failed to demonstrate caffeine-induced effects on DA levels in the NAc 
(Tanda and Goldberg, 2000; Acquas et a l, 2002). Nevertheless, rats that have been 
exposed to 3 mg/ml of caffeine in their drinking water for three weeks, show enhanced 
extracellular DA levels in the shell of the NAc compared with tap-water drinking animals, 
following s.c. nicotine administration at 0.2 or 0.4 mg/kg (Tanda and Goldberg, 2000). 
Therefore, chronic exposure to caffeine alters the response of the DAergic system to 
nicotine, implying that mesolimbic neurotransmission contributes to the interactions 
between the two drugs. The facilitatory mode of caffeine’s action on nicotine-induced 
DA signalling is most probably the result of antagonism at adenosine A% and A2A 
receptors. Due to the antagonistic nature of interactions between adenosine and
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dopamine receptors, inhibition of Ai and A2A receptors by caffeine would allow a more 
efficient transduction of the DA signal, which may account for the nicotine-induced 
increases in DA release in caffeine pre-exposed animals. In addition to postsynaptic 
interactions, presynaptic adenosine-mediated mechanisms are also involved in the 
regulation of DAergic transmission. Adenosine Ai receptors, for instance, are located 
presynaptically on DAergic synapses, where they inhibit DA release (Borycz et al., 2007). 
Moreover, Ai and A2A receptors are localised presynaptically on glutamatergic nerve 
terminals in the striatum, where they inhibit or induce glutamate release, respectively, 
depending on the extracellular concentration of adenosine (Ciruela et al., 2006). 
Therefore, adenosine antagonists can release the pre- and postsynaptic brakes that the 
neuromodulator exerts on DA signalling, thereby potentiating nicotine’s effects on 
mesolimbic neurotransmission.
The role of the A2A receptor in the neurochemical effects of nicotine has been elucidated 
by the generation of the A2A KO mouse (Ledent et al., 1997). As demonstrated by in vivo 
microdialysis, genetic inactivation of adenosine A2A receptors abolishes nicotine-induced 
increases in NAc DA levels of mutant mice compared to WT animals, suggesting that 
adenosine A2A receptors contribute to the reinforcing properties of nicotine (Castane et al., 
2006). Indeed, conditioned placed preference to 0.5 mg/kg of nicotine is not observed in 
the absence of the A2A receptor (Castane et al., 2006). Adenosine Ai and A2A receptors 
are expressed on striatal cholinergic neurons (Dixon et al., 1996; Preston et al., 2000), 
and functional evidence from synaptosome preparations and electrophysiology suggests 
that their activation exerts opposing actions on ACh release; stimulation of A, decreases, 
whereas activation of A2A receptors increases striatal acetylcholine (Brown et al., 1990; 
Kurokawa et al., 1994; Gubitz et al., 1996; Preston et al., 2000). A2A-mediated ACh
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release in the rat striatum has also been demonstrated in vivo (Kurokawa et ah, 1996), 
suggesting that striatal cholinergic neurotransmission is tonically mediated by adenosine. 
In turn, tonically active cholinergic neurons have been shown to regulate DA release by 
acting at (32 nicotinic subunits on striatal DA axon terminals (Zhou et al., 2001; Rice and 
Cragg, 2004). Depletion of endogenous ACh or silencing of the (32 subunit gene 
decreases evoked DA release by -80%, an effect that can also be evoked by 
mecamylamine, but not the muscarinic antagonist atropine (Zhou et al., 2001). Therefore, 
striatal DA release seems to be under the regulation of ongoing nicotinic cholinergic 
activity. Thus, in animals lacking A2A receptors a corresponding decrease of basal ACh 
tone would most likely relate to decreased basal levels of DA. Indeed, deletion o f the 
A2A gene leads to a hypo-dopaminergic mouse phenotype, with mutant animals showing a 
45% reduction in extracellular DA concentration compared to WT littermates, as shown 
by in vivo microdialysis (Dassesse et al., 2001). A lower basal level of DA following 
deletion of the A2A gene could therefore explain the lack of nicotine-induced DA efflux 
observed in the A2A KO mouse (Castane et al., 2006). Note, however, that contrary to the 
Dassesse et al., (2001) report, lower baseline DA levels were not observed in the A2A KO 
control group in the Castane et al., (2006) study. In view of this discrepancy, one cannot 
exclude that mechanisms other than the direct impact of a decreased cholinergic tone on 
DA signalling, mediate nicotine-induced changes in striatal DA levels of the A2A KO 
mutant. For instance, nicotine has been shown to exert its effects on mesolimbic DAergic 
transmission via presynaptic a l  nAChRs, localized on glutamatergic nerve terminals 
(Mansvelder and McGehee, 2000). Given the colocalisation between adenosine A2A and 
glutamatergic mGluR5 receptors on striatal glutamatergic terminals (Ciruela et al., 2006), 
which has been shown to facilitate glutamate release in a synergistic manner (Rodrigues 
et al., 2005), the possibility exists that the absence of A2A receptors impairs glutamatergic
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neurotransmission, thereby indirectly blunting DA signalling in nicotine-treated A2A KO 
mice. Similarly, antagonistic A2A and D2 receptor interactions on GABAergic 
enkephalinergic neurons, which also express nAChRs of the non-a7 subtype (de Rover et 
al., 2002), are absent in mice lacking the A2A receptor. Therefore, altered GABAergic 
signalling is potentially involved in the diminished nicotine-induced striatal DA release in 
the A2A KO mouse. Altogether, it seems reasonable to suggest that at the level of 
neuronal function adenosine A2A receptors play an essential role in the modulation of 
nicotine-induced DA neurotransmission.
At an intracellular level, chronic nicotine administration in rats at a rate of 6 mg/kg/day 
has been shown to stimulate the adenylyl cyclase (AC) pathway in medium spiny neurons 
(Abreu-Villaca et al., 2003). Importantly, during either spontaneous (Abreu-Villaca et al., 
2003) or mecamylamine-induced (Tzavara et al., 2002) withdrawal, both AC activity and 
cyclic AMP (cAMP) are further increased in nicotine-withdrawn animals. Enhanced AC 
activity results in increased levels of cAMP, which is the precursor of extracellular 
adenosine. These adaptive cellular changes imply functional interactions between 
nicotine and adenosine systems, which might contribute towards the development of 
physical dependence.
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1.3.3.3 Behavioural evidence fo r  interactions between nAChRs and adenosine 
The effects of nicotine and caffeine on locomotion are biphasic. Small doses of caffeine 
stimulate, whereas higher doses depress locomotor activity (reviewed in Daly and 
Fredholm, 1998). In a familiar environment, low doses of nicotine result in locomotor 
activation, whereas acute nicotine treatment in a novel environment rapidly induces 
locomotor depression (reviewed in Picciotto et al., 2000). Interactions between 
adenosine and nicotinic systems have been clearly documented using locomotion as the 
behavioural endpoint. The subcutaneous coadministration of nicotine (0.2 mg/kg) and 
caffeine (8mg/kg) abolishes the depressant locomotor effects of a single nicotine injection 
in rats. Moreover, chronic nicotine at 0.4 mg/kg induces tolerance to the acute 
behavioural depressive effects of the drug, which can be overcome by the 
coadministration of nicotine with caffeine, but not by either drug alone in nicotine- 
tolerant rats (Cohen et al., 1991). In mice, chronic caffeine pretreatment diminishes 
nicotine-induced depression of locomotor activity (Nikodijevic et al., 1993), and nicotine- 
pretreatment at 1.0 or 2.0 mg/kg for 5 days enhances the locomotor stimulant effects of 
5.0 mg/kg caffeine (Celik et al., 2006). Therefore, synergistic interactions between 
caffeine and nicotine have been extensively reported on locomotor activity. In addition, 
although ablation of the A2A receptor gene does not affect acute locomotor responses to 
nicotine, it produces animals with a characteristic hypolocomotor basal phenotype 
(Ledent et al., 1997; Castane et al., 2006), suggesting that adenosine A2A receptors play a 
key role in modulating motor activity.
In paradigms of drug abuse that more directly measure the reinforcing properties of 
psychoactive substances, pre-exposure of rats to caffeine for 7 days at a dose of 150-180 
mg/kg/day accelerates the acquisition of nicotine self-administration. When caffeine is
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excluded from the drinking solution, nose-poking for 0.03 mg/kg/infusion of nicotine 
returns to baseline, whereas adding caffeine to the drinking water of control animals 
increases responding by over 90%, demonstrating that chronic caffeine potentiates the 
reinforcing properties of nicotine (Shoaib et al., 1999). Caffeine’s rewarding effects have 
not been extensively examined using CPP. The drug can induce place conditioning that 
is biphasic in nature, with lower doses (3.0mg/kg) producing place-preference and higher 
(30 mg/kg) place aversion (Brockwell et al., 1991). The relative contribution of Ai and 
A2A receptors in the conditioning effect of caffeine has been examined using subtype- 
selective compounds (Brockwell and Beninger, 1996). The A2A antagonist CGS 15943A 
dose dependently produces CPP, whereas the Ai antagonist CGS 21680 fails to do so, 
underlying the importance of adenosine A2A receptors in establishing place conditioning. 
Importantly, genetic deletion of the A2A receptor attenuates nicotine-induced CPP, which 
identifies A2A as an important factor contributing to the rewarding properties of the drug 
(Castane et al., 2006). In drug-discrimination experiments, chronic caffeine does not 
generalise to a nicotine cue and vice versa, suggesting that there are no similarities in the 
subjective-like effects of the two substances (Modrow et al., 1981; Rosecrans, 1989). 
This lack of cross-generalisation, however, does not preclude that caffeine can acutely 
enhance sensitivity to the subjective effects of nicotine. Indeed, rats chronically exposed 
to 0.25 mg/ml of caffeine in their drinking water discriminate 0.4 mg/kg of nicotine faster 
than tap water-drinking animals (Gasior et al., 2000). This effect is also acutely observed 
to sub-threshold doses of nicotine (0.05 mg/kg) and does not undergo tolerance (Gasior et 
al., 2002). In addition, the discriminative-stimulus effects of nicotine can also be 
potentiated by the A2A antagonist MSX-3 and the Ai antagonist cyclopentyltheophylline, 
suggesting that both adenosine receptors are capable of modulating nicotine 
discrimination (Justinova et al., 2009).
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1.3.4 Interactions between nAChRs and other drugs o f abuse
Psychosocial and neurobiological reasons may account for the high co-morbidity of 
cigarette smoking with substance abuse disorders. For a detailed overview of the 
‘gateway’ mechanisms that link smoking to drug addiction, the reader is referred to 
excellent reviews by Lindsay and Rainey, (1997), and Slotkin, (2002). Briefly, the 
participation of the nicotinic cholinergic system in stimulant abuse is not only restricted 
to cocaine (see Section 1.3.1). The prevalence of cigarette smoking, for instance, is even 
higher in methamphetamine abusers, compared to cocaine addicts and the general 
population (Baker et al., 2004; Brecht et al., 2007; Weinberger and Sofuoglu, 2009). In 
animal models of drug addiction, three weeks of nicotine pretreatment increases, whereas 
mecamylamine attenuates sensitisation of amphetamine-induced locomotor activity 
(Schoffelmeer et al., 2002). Consistent with its behavioural effects, repeated nicotine 
administration enhances DA efflux in the NAc of rats treated with amphetamine (Birrell 
and Balfour, 1998). This suggests that nAChRs are involved in producing persistent 
alterations in the psychomotor and reinforcing effects o f stimulants. Furthermore, 
smoking is robustly correlated not only with stimulant, but also with ethanol consumption. 
Indeed, more than 80% of alcoholics are smokers (DiFranza and Guerrera, 1990), while 
nicotine dependence yields a 2.7 fold increased probability of leading to ethanol addiction 
(Breslau, 1995). Importantly, the two disorders are associated at a genetic level, since 
studies on twins have shown that the genetic factors linked to increased risk for 
alcoholism are similar with those associated for nicotine dependence (Koopmans et al., 
1997). The co-abuse of nicotine and alcohol suggests that common neurobiological 
mechanisms mediate the reinforcing effects of the two drugs.
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2 THESIS AIMS AND HYPOTHESIS
Tobacco use is the single most important preventable risk to human health globally 
(Hatsukami et ah, 2008). Nicotine is only a weak primary reinforcer, but there is 
evidence to suggest that the predominance of nicotine addiction stems from the drug’s 
ability to enhance the potency of other reinforcers, rather than from its direct rewarding 
effects (reviewed in Chaudhri et al., 2006). Indeed, a striking feature of nicotine 
addiction is the prevalence of the drug’s use in combination with licit and illicit 
substances. Tobacco smoking positively correlates with the probability and frequency of 
psychostimulant abuse (Patkar et al., 2002), as well as with the severity of opiate 
dependence (Frosch et al., 2000). In addition, the concurrent consumption of nicotine 
with caffeine places the two substances among the most widely used licit drugs in 
modem societies (reviewed in Fredholm et al., 1999). This high comorbidity raises 
fundamental questions about the extent to which nicotinic cholinergic mechanisms 
contribute to poly-drug abuse. Hence, the overall working hypothesis of the present 
thesis is that alterations in a4(32* and/or a7 nAChR binding occur following chronic 
treatment with nicotine or illicit substances, which are indicative of the interactions that 
render a weak primary reinforcer as broadly abused as nicotine.
• To investigate the influence of distinct subtypes of nAChRs on cocaine related 
behaviour, the effects of chronic a4p2* and a7 nAChR antagonism on cocaine-induced 
locomotor activity, stereotypy and grooming have been studied using dihydro-g- 
erythroidine (DhbE) and methyllycaconitine (MLA), respectively. To establish possible 
neurochemical and neuroanatomical loci for the effects of chronic cocaine administration 
on nAChR regulation, quantitative receptor autoradiography of a4p2* and a7 nAChRs 
has been conducted in brain sections from cocaine-treated C57BL/6 mice.
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Autoradiography of dopaminergic D1 and D2 receptors, as well of the dopamine 
transporters has been conducted in order to identify the impact of specific nAChR 
blockade on the dopaminergic system of cocaine-treated animals. To investigate the 
participation of the nicotinic cholinergic and dopaminergic systems in cocaine 
withdrawal, quantitative receptor autoradiography of a4p2* and a7 nAChRs, and of 
dopaminergic D l, D2 receptors and transporters has been conducted in brains of mice, 
chronically withdrawn from ‘binge’ cocaine treatment.
• To investigate whether morphine administration or the acute and prolonged 
withdrawal from morphine treatment alter the receptor component of the nicotinic 
cholinergic system, quantitative autoradiography of a4p2* and a7 nAChRs has been 
performed in mice treated and withdrawn from an escalating-dose, ‘intermittent’ protocol 
of morphine administration.
• An investigation into the mechanism of interactions between nicotine and 
adenosine has been performed by examining whether genetic deletion of the A2A receptor 
gene leads to compensatory changes in the binding or distribution characteristics of 
nicotinic and dopaminergic receptors. To further characterise the effects of adenosine 
A2A gene deletion on nicotine-induced neuroadaptation, quantitative autoradiography of 
a4p2* and a7 nAChRs, and of dopaminergic D l, D2 receptors and transporters has been 
conducted in CDl wild type and adenosine A2A receptor knockout animals, following 
chronic nicotine treatment.
• The extent to which nicotine-induced neuroadaptation is the consequence of the 
drug’s direct pharmacological action has been examined in C57BL/6 mice, treated with a 
yoked-control paradigm of nicotine-self administration. The consequences of active vs. 
passive nicotine administration on nicotinic cholinergic and dopaminergic regulation
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have been investigated by means of quantitative autoradiography of a4p2* and a7 
nAChRs, and of dopaminergic D l, D2 receptors and transporters.
The ambition of the current work has therefore been to contribute towards unraveling the 
mechanisms of nicotine reinforcement, and to characterise the neurobiological substrates 
that underlie the concurrent consumption of nicotine with illicit and licit drugs.
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3 BEHAVIOURAL AND NEURO CHEMICAL INTERACTIONS BETWEEN
COCAINE AND THE NICOTINIC CHOLINERGIC SYSTEM
3.1 Introduction
The prevalence of poly-drug abuse is characteristically depicted in the concurrent consumption 
of nicotine with cocaine. Cigarette smoking in cocaine abusers is greater compared to the 
general population, and nicotine intake has been associated both with the probability and the 
frequency of cocaine use (Henningfield et al., 1990; Schorling et al., 1994; Breslau, 1995; 
Martinez-Ortega et al., 2006). Moreover, cocaine addiction is linked to an increased incidence of 
psychotic-like behaviours (Tang et al., 2007), with cocaine-dependent individuals reporting both 
stimulant enhancing and calming effects of nicotine consumption (Wiseman and McMillan, 
1998). A prima facie case for these apparently opposing effects of nicotine in cocaine addiction 
is that distinct subtypes of nicotinic acetylcholine receptors (nAChRs) differentially mediate 
cocaine-induced behaviour.
The principal mode of cocaine’s action, responsible for its reinforcing potential and high abuse 
liability, involves activation of the mesolimbic dopaminergic system via blockade of the 
monoamine dopamine transporter (DAT) (Anderson and Pierce, 2005). Nevertheless, it is 
becoming increasingly accepted that cocaine impacts on dopaminergic neurotransmission partly 
via the activation of the nicotinic cholinergic system. The development of cocaine-induced 
locomotor sensitization, for instance, is mediated by nicotinic receptor activation, as pre­
treatment with nicotinic antagonists reduces locomotor activity in cocaine-sensitized rats 
(Schoffelmeer et al., 2002). Moreover, nicotine injections prior to cocaine self-administration 
progressively enhance cocaine intake in rats (Bechtholt and Mark, 2002), whereas treatment with 
nicotinic antagonists diminishes the rewarding effect of cocaine in mice (Zachariou et al., 2001).
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Data from in vivo microdialysis studies point to the mesolimbic dopaminergic system as the site 
for cocaine-nAChR interactions (Gerasimov et al., 2000; Zanetti et al., 2007), suggesting that 
nicotinic cholinergic signalling within dopamine-rich brain regions mediates the effects of 
cocaine.
Neuronal nAChRs are a heterogeneous family of pentameric structures, formed by the assembly 
of five a and (3 subunits (see Section 1.1.1). Of the multiple receptor subtypes that exist, 
heteromeric a4p2* and homomeric a7 nAChRs are abundantly expressed throughout the central 
nervous system (CNS), where they have been shown to differentially mediate the effects of 
nicotine on several CNS functions (Dani and Bertrand, 2007). Although the involvement of the 
nicotine system in cocaine related addictive behaviour has been well documented, the exact 
contribution of distinct nAChR subtypes in the behavioural effects of chronic cocaine is unclear. 
To determine the role of the two major classes of nAChRs in the behavioural effects of chronic 
cocaine, the impact of a4p2* or a7 receptor antagonism on cocaine-induced locomotor activity, 
stereotypy and grooming was studied using a ‘binge’ drug administration protocol, which 
mimics the temporal patterns of cocaine abuse in humans (Koob and Kreek, 2007). To 
determine the neurochemical effects of chronic cocaine treatment and nAChR antagonism on the 
nicotinic and dopaminergic systems, quantitative autoradiography of a4|32* and a l  nAChRs, D l 
and D2 dopaminergic receptors, and of cholinergic and dopamine transporters was carried out. 
Based on the behavioural and neurochemical observations from the ‘binge’ administration 
experiments, the role of a4(32* nAChR upregulation in the stimulant effects of cocaine was 
further investigated following pretreatment with different doses of nicotine. To investigate the 
involvement of the nicotinic cholinergic system in cocaine withdrawal, quantitative 
autoradiography of nAChRs was performed in brain sections of mice, chronically withdrawn 
from ‘binge’ cocaine administration.
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3.2 Materials and Methods
3.2.1 nAChR antagonist dose selection studies
In the current set of experiments, dihydro-B-erythroidine (DhBE, Sigma-Aldrich, UK) and 
methyllycaconitine (MLA, Sigma-Aldrich, UK) were used to block (32* and a l  nicotinic 
subunits, respectively. The doses of nicotinic antagonists were based on literature 
(Damaj et al., 2003; Schoffelmeer et al., 2002), and their potency to antagonize nicotine- 
induced effects was confirmed in preliminary experiments, as detailed in Sections 3.2.1.1 
and 3.2.1.2. For all experiments, 6-8 week old, male C57BL/6 mice (Charles River Ltd., 
Kent, UK), weighing 20-25 g, were used. Animals were housed individually in a 
temperature-controlled room, under a 12 h light/dark schedule. Food and water were 
available ad libitum, except during the experimental sessions. All studies were conducted 
in accordance with protocols approved by the Home Office, UK, and in accordance with 
European Community Council directive 86/609/EEC.
3.2.1.1 Antagonism o f  acute nicotine-induced hypolocomotion by DhfiE
C57BL/6 mice were habituated to the locomotor chambers for 4 days, prior to treatment 
(n=6). On the day of the experiment, animals were pretreated with saline (0.1 ml/kg) or 
DhBE (2.0 mg/kg), 5 min prior to the injection of saline (0.1 ml/kg) or nicotine (1.0 
mg/kg, free-base weight). 5 min after acute nicotine, total locomotor activity was 
measured for 10 minutes. All injections were delivered intraperitoneally.
3.2.1.2 Chronic nicotine pretreatment and MLA-precipitated withdrawal
Chronic nicotine hydrogen salt was delivered to C57BL/6 mice (n=6) using miniosmotic 
pumps (ALZET®2002 model, Charles River, UK), at a dose of 7.8 mg/kg/day (free-base 
weight), at a rate of 0.5 p 1/hour, for a period of 14 days. For minipump implantation.
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animals were anaesthetised with a volatile isofluorane anaesthetic (3.5%-4.5%) (Isoflo, 
Abbott Laboratories Ltd, Kent, UK), which was vaporised in 95% O2 / 5% CO2 gas and 
delivered by a U400 anaesthetic unit (Univentor, Royem Scientific, UK), at a flow rate of 
-450 ml/min. The animals were placed in the anaesthetic chamber for 3-4 min until all 
righting reflex was lost, and were subsequently connected to a mask delivering 
anaesthesia throughout the surgery. A single incision was made along the midline of the 
back, to reveal the subcutaneous layer. Blunt ended scissors were used to open up a 
subcutaneous compartment, where an osmotic minipump was placed parallel to the spine, 
with the flow moderator pointing away from the incision. The incision was closed with 2 
Michelle clips. Upon completion of the surgical procedure mice were allowed to recover 
in a heated recovery chamber until their righting reflex returned, and were transferred to 
their home cage.
After 14 days of nicotine treatment, animals received an acute injection of MLA (5.0 
mg/kg, i.p.) and withdrawal signs were measured for 20 min immediately afterwards in 
an observation chamber. The number o f head shakes, paw tremors, scratches, 
retropulsive movements, body tremor, genital licks and jumps were counted. A global 
withdrawal score was subsequently calculated for each animal, by adding individual signs 
of MLA-precipitated symptoms, as described previously (Berrendero et al., 2002).
3.2.2 Animals and ‘binge* cocaine treatment
6-8 week old, male C57BL/6 mice (Charles River Ltd., Kent, UK), weighing 20-25 g, 
were used in all experiments. Studies were conducted in accordance with protocols 
approved by the Home Office, UK, and in accordance with European Community 
Council directive 86/609/EEC, under housing conditions that have been described in
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Section 3.2.1. Animals were habituated to the testing environment and to handling for a 
period of 7 days, prior to treatment. For the chronic treatment protocol, saline or cocaine 
(Sigma-Aldrich, UK) were delivered alone or were co-administered with nicotinic 
antagonists for a period of 14 days, in a steady dose, ‘binge’ administration paradigm. 
Animals received three daily intraperitoneal (i.p.) injections, one hour apart, with the first 
injection delivered one hour after the beginning of the light phase of the light/dark cycle.
Dailv administration protocol:
Group 1 (n=6): 3 x Saline (0.1 ml/kg/inj)
Group 2 (n=7): 3 x Cocaine (15.0 mg/kg/inj)
Group 3 (n=6): 3 x Saline + DhBE (2.0 mg/kg/inj)
Group 4 (n=7): 3 x Cocaine + DhBE
Group 5 (n=6): 3 x Saline + MLA (5.0 mg/kg/inj)
Group 6 (n=7): 3 x Cocaine + MLA
For the chronic withdrawal study, two groups of animals (n=6) were treated with ‘binge’ 
saline or cocaine (3 x 15 mg/kg/inj for 14 days) and were allowed to withdraw from 
chronic treatment for a period of 14 days. All drugs (salt weights) were dissolved in 
sterile 0.9% saline.
3.2.3 Minipump preparation and nicotine pretreatment experiments 
Osmotic minipumps (ALZET®2002 model, Charles River, UK) were filled with either 
nicotine hydrogen salt in 0.9% sterile saline, or vehicle (0.9% sterile saline; pH=7.4), and 
were implanted to C57BL/6 mice (n=4), as described in Section 3.2.1.2. Nicotine 
hydrogen salt (Sigma-Aldrich, UK) was delivered at 0.2 mg/kg/hr, 0.45 mg/kg/hr, or 0.8
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mg/kg/hr, at a rate of 0.5pl/hour, for a period of 8 days. Doses are reported as the free 
base of nicotine, and were selected as to their ability to upregulate neuronal nAChRs in 
C57BL/6 mice (Marks et al., 2004). A single i.p. injection of cocaine (15.0 mg/kg/inj) + 
DhBE (2.0 mg/kg/inj) was administered to individual groups of mice, 8 days after 
minipump implantation. This time point was chosen based on the temporal pattern with 
which differences emerged among groups o f ‘binge’ treated animals.
3.2.4 Motor activity measurements
Total horizontal activity and total vertical activity (rearing) were measured in 12 motility 
chambers (40cm length x 20 cm wide x 20 cm height; Linton Instrumentation, Norfolk, 
UK). Each cage had two sets of 16 photocells located at right angles to each other, 
projecting horizontal infrared beams 2.5 cm apart and 1 and 6 cm above the cage floor. 
Each daily session began with habituating the animals in the motility chambers for 60 
min (assessment of basal activity). Subsequently, mice received an i.p. injection of saline 
or cocaine (± nAChR antagonists), and were returned immediately to the chambers where 
activity was assessed for 60 min. Animals received a second and third injection 60 min 
and 120 min respectively after the first one. Behavioural activities for each mouse after 
each of the three daily injections of saline or cocaine (± nAChR antagonists) were 
monitored daily for a period of 14 days. Total horizontal and vertical motor activity were 
defined by the measurement of sequential infrared beam breaks, recorded every 5 min, 
beginning immediately after placing the animals in the cage following an injection of 
saline or cocaine (± nAChR antagonists) and continued for a 60 min period.
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3.2.5 Cocaine-induced stereotypy and grooming
Animals were videotaped 20 minutes after each injection, and were later rated for 
stereotypy and grooming by a trained observer, blind as to the animal’s treatment group. 
The time point was chosen based on the half maximal brain concentrations of cocaine, 
following its i.p. administration in C57BL/6 mice (Azar et al., 1998). Observations were 
limited to 40 s for each mouse, to enable all animals to be observed at a similar time point 
following each injection (Schlussman et al., 2005). The rating for stereotypy was based 
on the scale used by Bailey et al., (2007), and consisted of a graded scale of drug-induced 
behaviours: 1) asleep, inactive; 2) alert, ‘comfort’ grooming; 3) increased sniffing 
(occasional light sniffing, often while exploring the cage); 4) intermittent rearing and 
sniffing (two or three rears in a 20s period, with sniffing frequently at the apex of the 
rear); 5) increased locomotion; 6) intense sniffing in one location (rapid sniffing, often 
with head down is the predominant behaviour displayed); 7) continuous pivoting and 
sniffing (no rearing, no locomotion); 8) intermittent rearing and sniffing (intermittent up 
and down rearing behaviour with locomotion); 9) maintained rearing and sniffing (animal 
remains up on hind legs throughout most of the observed period); 10) splayed limbs. 
Each animal received a single score following each injection, which corresponded to the 
specific stereotypic behaviour predominantly observed during the 40 sec observation 
period. Stereotypy was scored every day throughout the duration of the experiment. The 
median score for each mouse on each day was used for later analysis.
For grooming behaviour, a percentage of time spent grooming was calculated for the 
entire observation period for each animal, on each day, throughout the duration of the 
study. The mean percentage of time spent grooming from each group was then used in 
the analysis.
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3.2,6 Quantitative receptor autoradiography
3.2.6.1 Autoradiography o f  dopamine D l and D2, nicotinic cholinergic a4p2"^ and a l  
receptors, and o f  dopaminergic and cholinergic transporters
Animals were killed by cervical dislocation 30 min following the last injection of saline 
or cocaine (± nAChR antagonists) and brains were immediately removed, quickly frozen 
in isopentane and stored at -80°C for subsequent processing. Tissue sectioning was 
carried out at -21°C using a Zeiss Microm HM505E cryostat. 20 pm frozen coronal 
sections were cut at 300 pm intervals, from rostral to caudal levels. Sections were stored 
at -20°C for radioligand binding.
Quantitative autoradiography was performed in order to measure binding to a4p2* and 
a l  nAChRs, the high affinity choline transporter, dopaminergic D l and D2 receptors, and 
the dopamine transporter (DAT). On the day of each experiment, sections were thawed 
and processed according to established protocols (Javitch et al., 1984; Orr-Urtreger et al., 
1997; Whiteaker et al., 2000b; Marks et al., 2002; Lena et al., 2004; Besson et al., 2007), 
with minor modifications. Sections for analysis were derived from six to seven brains 
from each of the six treatment groups (n=6-7). Multiple, adjacent sections from all 
groups were processed together in a paired binding protocol.
For a4p2* nicotinic receptor binding, sections were pre-incubated for 10 min at room 
temperature in Tris-HCl buffer, containing 120 mM NaCl, 5 mM KCl, 2.5 mM CaCL, 
and 1 mM MgCb, pFI 7.4, followed by incubation with 100 pM [^^^Ijepibatidine 
(PerkinElmer, Boston, USA; specific activity 2,200 Ci/mmol) for two hours at room 
temperature. Determination of subtype-specific binding was performed using adjacent 
sections from each brain, in order to measure total [^^^Ijepibatidine binding (no
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rl25ncompeting ligand), and [^^HJepibatidine binding in the presence of 20 nM cytisine 
(Sigma-Aldrich, UK). Competition of [^^^I]epibatidine binding by unlabeled cytisine has 
been used to reveal two subpopulations of nAChRs with high and low affinity for cytisine, 
termed cytisine-sensitive and cytisine-resistant [^^^I]epibatidine binding sites, 
respectively. The epibatidine binding sites with high affinity for cytisine correspond to 
a4p2* nicotinic receptors, and were calculated following the subtraction of cytisine- 
resistant from total epibatidine binding. To determine non-specific binding (NSB), 
further adjacent sections were incubated with epibatidine in the presence of 300 pM 
of (-) nicotine hydrogen tartrate (Sigma-Aldrich, UK). Incubations were terminated by 
two, ten minute washes into ice-cold 50 mM Tris-HCL buffer (pH 7.4), and a rapid rinse 
in ice-cold water.
For the homomeric a l  nAChR, sections were pre-incubated for 30 minutes in 50 mM 
Tris-HCl, containing 1% w/v BSA (pH 7.4, room temperature). Adjacent, non-specific 
binding sections were pre-incubated in the same buffer, containing ImM of nicotine 
bitartrate salt. Sections were then incubated at room temperature with 3nM of [^^^I]a- 
bungarotoxin (GE Healthcare, Little Chalfont, UK; specific activity 250 Ci/mmol; 
PerkinElmer, Boston, USA; specific activity 159 Ci/mmol) for 3 hours. Adjacent 
sections were incubated in the same buffer, in the presence of ImM (-) nicotine hydrogen 
tartrate, to calculate NSB. Incubations were terminated by 3 xIO minute washes into ice 
cold 50 mM Tris buffer (pH 7.4), and a rapid rinse in ice cold water.
For the high affinity choline transporter (CHT), sections were incubated with 8 nM 
[^H]Hemicholinium-3 (PerkinElmer, Boston, USA; specific activity 144.5 Ci/mmol) at 
4°C for 60 min in 50 mM Tris (pH 7.4), containing 300 mM NaCl. After incubation.
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sections were rinsed six times for 1 min each in ice-cold 50 mM Tris (pH 7.4) and briefly 
in distilled water. Non-specific binding was measured in the presence of 100 pM 
unlabeled hemicholinium-3.
For D l and D2 receptor binding, all sections were first pre-incubated for 20 min in 50 
mM Tris-HCl buffer, pH 7.4, containing 120 mM NaCl, 5 mM KCl, 2 mM CaC^ and 1 
mM MgCh, at room temperature. For D l receptors, sections were then incubated for 90 
min in the same buffer, at room temperature, in the presence of 4 nM [^H]SCH23390 
(PerkinElmer, Boston, USA; specific activity 70.3 Ci/mmol) and 1 pM mianserin, in 
order to avoid binding of [^H]SCH23390 to 5-HT2 and 5-HTic receptors. To label D2 
receptors, incubation was carried out for 60 min in the presence of 4 nM [^H]raclopride 
(PerkinElmer, Boston, USA; specific activity 60.1 Ci/mmol), under identical pH and 
temperature conditions. Non-specific binding was determined on adjacent sections in the 
presence of 10 pM of cis-flupenthixol for D l receptors or 10 pM of sulpiride for D2 
receptors. The incubations were terminated by rapid rinses (6x1 min) in ice-cold 50 mM 
Tris-HCl buffer (pH 7.4) followed by a dip into ice-cold distilled water.
For the DAT binding, all slides were pre-incubated for 5 min at 4°C in 50 mM Tris-HCl 
buffer, pH 7.4, containing 300 mM NaCl and 5 mM KCl. The slides were subsequently 
incubated at 4°C for 45 min in the same buffer, containing 4 nM [^Hjmazindol 
(PerkinElmer, Boston, USA; specific activity 20.6 Ci/mmol) and 0.3 pM desipramine, to 
block the binding to norepinephrine uptake sites. Non-specific binding was determined 
in the presence of 10 pM mazindol. After incubation, sections were rinsed twice for 1 
min in ice-cold Tris buffer, and briefly dipped in ice-cold distilled water.
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3.2.6.2 Film exposure and development
Following binding, sections were dried for two hours under a cold stream of air, and they 
were subsequently dried overnight using anhydrous calcium sulphate (BDH Chemicals, 
Poole, UK). Adjacent total and non-specific labelled sections from all animals were laid 
down to Kodak BioMax MR-1 film in parallel. To allow quantification, autoradiographic 
microscales of known radioactive concentration were also apposed to each film. 
[^^^IJepibatidine and [^^^l]a-bungarotoxin bound sections were exposed to film for a 
period of 24 h and 1 week, respectively, along with a set of "^^ C microscale standards, 
which had been cross-calibrated to iodinated standards (Miller and Zahniser, 1987; 
Baskin and Wimpy, 1989). [^Hjradioligand bound sections were exposed to film along 
with microscale calibration standards for a period of 5 weeks for D l receptors and the 
DAT, 6 weeks for D2 receptors, and 25 days for the high affinity choline transporter. 
Kodak BioMax MR-1 films, [^H], [^ ^^ 1], and microscale standards were purchased 
from GE Healthcare Life sciences, Amersham, UK.
For development, films were placed into a tray and were covered with an aqueous 
solution of 50% v/v Kodak D19 developer (Sigma-Aldrich, UK). The reaction was 
stopped after 1 min by placing films in a solution o f distilled water, containing a drop of 
glacial acetic acid for 1 min. Fixation of images was carried out for 3min in Kodak rapid 
fix solution (Sigma-Aldrich, UK). Films were then rinsed under running water for 30 
min and dried overnight in a fume cupboard.
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3.2.6.3 Quantitative analysis
Quantitative analysis of receptor binding was performed by video-based computerised 
densitometry, using an MCID image analyser (Imaging Research, Canada), as previously 
described (Kitchen et al., 1997). Briefly, optical density values quantified from the [^H] 
and microscale standards were entered with their corresponding radioactivity values 
(fmol/mg tissue equivalents) into a calibration table, and the relationship between tissue 
radioactivity and optical density was determined using the MCID software. Appropriate 
adjustments were undertaken to allow for the radioactive decay of both the standards and 
the radioligands. Values of specific receptor binding were derived after subtraction of 
non-specific binding from total binding images.
Where applicable, measurements were taken from both brain hemispheres and thus 
represent a duplicate determination for each brain region examined. Computerised tools 
were used to take measurements from each area. Areas of the cortex, olfactory tubercle, 
and superior colliculus were analysed by sampling with a box tool, and all other areas 
were analysed by freehand drawing. All structures were identified by reference to the 
mouse brain atlas of Franklin and Paxinos, 2001.
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3.2.7 Statistical analysis
Preliminary data from the antagonism of nicotine-induced hypolocomotion by DhBE 
were analysed using one-way ANOVA; Mann-Whitney’s non-parametric test was used 
for the analysis of MLA-precipitated nicotine withdrawal.
For the ‘binge’ treatment protocol, all cocaine-induced behaviours were analysed by two- 
way analysis of variance (ANOVA) for the factors treatment and time, with repeated 
measures for time. Tukey’s Honest Significance (HSD) post hoc test for unequal N 
(Spjotvoll-Stoline test) was applied when appropriate, to compare differences in 
behavioural responses between groups, on individual test days. In addition, one way 
repeated measures ANOVA was used to analyze changes over time within each group. 
Since the expression of behavioural stereotypy was measured with a behavioural rating 
scale, non parametric Mann-Whitney U tests were also used in order to confirm results 
obtained by the ANOVA.
For the nicotine-pretreatment experiments, two-way ANOVA for the factors pretreatment 
(saline vs. nicotine) and treatment (cocaine vs. cocaine+DhBE) was used to compare 
motor activity of pretreated animals, followed by Fischer’s LSD post hoc test.
Two-way ANOVA (for the factors treatment and region) was used for the comparison of 
quantitative measures of a4p2* and a l  nicotinic receptors, choline transporters, 
dopaminergic D l and D2 receptors, and dopamine transporters in brain regions of chronic 
‘binge’ saline and cocaine treated mice. Where ANOVA yielded significant treatment 
effects, and depending on the n number of the treatment groups, Duncan’s multiple 
ranges or Fisher’s LSD post hoc analysis was applied to investigate differences in 
radioligand binding between groups in individual regions.
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3.3 Results
3.3.1 Preliminary studies
3.3.1.1 DhfiE dose selection
The dose of DhBE used to block P2 subunit-containing nAChRs was based on its potency 
to antagonize nicotine-induced hypolocomotion. Acute nicotine treatment failed to 
induce locomotor depression in the presence of 2.0 mg/kg DhBE. Moreover, DhBE at 2.0 
mg/kg did not affect baseline locomotor activity (Fig. 3.1). Therefore, this dose was used 
to block P2 subunits in subsequent experiments.
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Figure 3.1 Antagonism of nicotine-induced hypolocomotion by DhRE
For selecting the dose of DhBE that antagonizes p2 subunit-mediated behaviour, animals were treated with saline or 
DhBE, 5 min prior to the injection of saline or nicotine (1.0 mg/kg, i.p.). 5 min after acute nicotine, total locomotor 
activity was measured for 10 minutes. Data are presented as the mean±SEM of 6 animals per group. *P<0.05 vs. all 
other groups, Bonferroni’s post hoc test.
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3.3.1.2 MLA dose selection
The dose of MLA used to block a7 nAChRs was based on its potency to precipitate somatic 
signs of withdrawal in C57BL/6 mice that had been chronically exposed to nicotine via 
osmotic minipumps (Damaj et ah, 2003; Salas et al., 2007). As shown in Figure 3.2, MLA at 
5.0 mg/kg produced somatic signs of withdrawal in nicotine treated animals, and therefore 
this dose was used to block a7 receptors in subsequent experiments.
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Figure 3.2 M LA-precipitated nicotine withdraw al
Individual (A) and total (B) somatic signs precipitated by an acute injection of MLA (5.0 mg/kg, i.p.), following chronic 
infusion of nicotine or saline. Data are presented as the mean±SEM of 6 animals per group. **P<0.01 vs. saline 
pretreatment, Mann-Whitney’s non-parametric test.
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3.3.2 Effect o f chronic nACHR blockade on cocaine-induced horizontal activity 
Horizontal locomotor activity was measured daily for each animal, after each of the three 
injections, throughout the duration of the chronic, ‘binge’ protocol. Mice treated with 
cocaine (± nAChR antagonists) showed greater horizontal activity compared to their 
respective saline controls on all days of treatment (Fig. 3.3). By day 4, repeated drug 
administration produced an increase in the horizontal activity of all cocaine-treated 
groups compared to day 1, indicating the presence of behavioural sensitization to the 
stimulating effects of cocaine (day 4 vs. day 1; cocaine group: P<0.001, cocaine+MLA 
group: P<0.05, cocaine+DhbE group: P<0.001; HSD post hoc test for unequal N).
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Figure 3.3 E ffect o f  nicotinic acetylcholine receptor blockade on cocaine-induced horizontal activity
Animals were injected with cocaine (15.0 mg/kg/inj), cocaine+DhpE (2.0 mg/kg/inj), or cocaine+MLA (5.0 mg/kg/inj) 
three times daily, and the horizontal activity of each group was calculated after each injection and summed over three 
hours. Data are presented as the mean ± SEM of 6 to 7 animals per group, throughout the duration of the chronic 
‘binge’ administration paradigm. Two-way repeated measures ANOVA showed significant main effects of treatment 
[F(5,33) =14.3, P<0.0001] and day [F(12,396)=8.5, P<0.0001], and significant treatment x day interaction effects 
[F(60,396)=2.8, P<0.0001]. One way repeated measures ANOVA was used to analyze changes over time within each 
group. For coeaine+DhBE treated mice, significant increases in cocaine-induced horizontal activity were observed on 
days 3-9 compared to day 1 (days 3-9 vs. day 1; eocaine+DhBE group: P<0.01, HSD post hoc test for unequal N). 
Coeaine+DhBE treated animals showed increased total activity compared to cocaine+MLA mice on days 8 and 9.
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The duration and magnitude of this response was modified by the addition of nicotinic 
antagonists. Cocaine and cocaine+MLA treated animals quickly returned to day 1 levels 
of total activity (day 5 vs. day 1, P>0.05), whereas co-administration of cocaine with the 
P2 subunit antagonist DhGE prolonged the effects of the psychostimulant on total activity 
up to day 9 (day 9 vs. day 1, P<0.01). Between groups comparison showed a significant 
enhancement in cocaine-induced horizontal activity in cocaine+DhGE treated mice 
compared to cocaine+MLA treated animals (P<0.05). Post hoc comparison revealed that 
the largest differences in motor stimulation between the two groups were observed on 
days 8 and 9 (P<0.05). Following day 4, cocaine-induced motor activity in DhGE-treated 
animals was markedly enhanced during each hourly session, predominantly within the 
first 30 minutes after drug administration (Fig. 3.4). The effects of binge treatment for all 
treatment groups are shown in Figure 3.4 on days 1 ,4 ,8  and 13, throughout the daily 3h 
observation period. Within each individual group, no differences in cocaine-induced 
activity were observed among the three Ih observation sessions following drug treatment. 
Horizontal activity after the first drug administration was similar to that observed after 
the second or third treatment, on each daily session. Two-way repeated measures 
ANOVA confirmed significant main effects of treatment and day on total horizontal 
activity, with significant treatment x day interaction effects.
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3.3.3 Effect o f chronic nAChR blockade on cocaine-induced vertical activity 
Total vertical activity (rearing) of C57BL/6 mice was measured for 60 min after each of the 
three hourly injections, for a total daily period of 180 min. Two-way repeated measures 
ANOVA showed significant main effects of treatment, and no significant day or treatment x 
day interaction effects (Fig. 3.5). Mice treated with cocaine (± nAChR antagonists) showed 
greater vertical activity compared to their respective saline controls on all treatment days. 
The co-administration of cocaine with the a4p2* antagonist DhBE diminished cocaine- 
induced vertical activity. Animals in the cocaine+DhBE group showed decreased rearing 
behaviour compared to cocaine-treated animals on days 3, 4, and 7-12 (P<0.05, HSD post 
hoc test for unequal N), and compared to cocaine+MLA treated mice on days 10-13 (P<0.01,
HSD post hoc test for unequal N).
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Figure 3.5 Effect o f  nicotinic acetylcholine receptor blockade on cocaine-induced rearing
Animals were injeeted three times daily with coeaine (15.0 mg/kg/inj), coeaine+DhpE (2.0 mg/kg/inj), or cocaine+MLA (5.0 
mg/kg/inj), and the vertical activity of each group was calculated after each injection and summed over three hours. Data are 
presented as the mean ± SEM of 6 to 7 animals per group. Two-way repeated measures ANOVA was performed for the factors 
treatment and day, showing significant treatment effects [F(5,33)=22.2, P<0.001], and no significant day [F(12,396)-0.8, P>0.05] 
or treatment x day [F(60,396)=l.l, P>0.05] interaction effects. Mice treated with coeaine+DhPE showed decreased rearing 
activity compared to cocaine-treated animals on days 3, 4, and 7-12. Co-administration of cocaine with MLA resulted in the 
delayed expression of coeaine-indueed rearing (One-way ANOVA).
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One-way repeated measures ANOVA revealed that cocaine-induced rearing was not 
sensitized neither in cocaine, nor in cocaine+DhBE treated animals. Co-administration of 
cocaine with MLA, however, resulted in the delayed expression of cocaine-induced 
rearing sensitization, with animals in this group showing enhanced rearing during the last 
three days of treatment, compared to day 1.
3.3.4 Effect o f chronic nAChR blockade on cocaine-induced grooming and stereotypy 
For grooming activity, a percentage of time spent engaged in this behaviour was 
calculated for the entire observation period for each animal, on each day, throughout the 
duration of the study. It should be noted that assessing the effects of nAChR blockade on 
cocaine-induced grooming was not an original aim of the present study. Instead, 
grooming behaviour was analysed because of an intense and previously uncharacterised 
phenotype following the co-administration of cocaine with the a7 nAChR antagonist 
MLA. Behaviour in cocaine+MLA treated mice was constantly interrupted by bursts of 
grooming, with animals in this group spending as much as 50% of the entire observation 
period engaged in grooming activity from day 5 onwards (Fig. 3.6A). A negative 
correlation between the increased time spent grooming and the locomotor activity of 
cocaine+MLA treated animals was derived, indicating the competing nature of the 
measured behaviours (Fig. 3.6B).
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Figure 3.6 Effect o f  nicotinic acetylcholine receptor blockade on cocaine-induced groom ing (A) and correlation  
between groom ing and locom otor behaviour in cocaine+M LA treated anim als (B)
An intense grooming phenotype developed in mice ‘binge’-treated with cocaine (15.0 mg/kg/inj) and the a7 
nAChR antagonist MLA (5.0 mg/kg/inj). To analyse this behaviour, a percentage o f  time spent grooming was 
calculated for each animal out o f  the entire observation period, daily, throughout the duration o f  the study. (A) Co­
administration o f  cocaine+MLA significantly increased time spent grooming, compared to saline+MLA and 
cocaine on days 8-11. Two-way repeated measures ANOVA showed significant main effects o f  treatment 
[F(5,33)=3.0, P<0.05], with no significant day [F(13,429)=1.5, P>0.05] or treatment x day [F(65,429)=0.9, P>0.05] 
interaction effects. Values are shown as the mean ±  SEM o f 6 to 7 animals per group. (B) A  negative correlation 
between locomotor and grooming activities was derived in cocaine+MLA treated mice, indicating the competing 
nature o f  the two behaviours. Each data point represents the mean locomotor activity o f  cocaine+MLA treated 
animals plotted against their corresponding time-spent grooming on individual test days. These data were collected 
by H. L. Keyworth, in collaboration with the author.
Grooming activity was intense and interrupted, progressed randomly rather than 
sequentially, and left the fur of mice substantially worse than that of animals in other 
groups. As a result, the evaluation of cocaine-induced stereotypy in cocaine+MLA 
mice was not included in the analysis. Two-way repeated measures ANOVA showed 
significant main effects of treatment on grooming behaviour, with no significant day 
or treatment x day interaction effects. Post hoc analysis confirmed that co­
administration of cocaine+MLA significantly increased time spent grooming, 
compared to administration of saline+MLA and cocaine on days 8-11 (P<0.05, HSD 
test for unequal N).
Stereotypy was scored for 40 seconds, 20 min after each of the three hourly injections 
and the median score was calculated daily for each animal. Two-way repeated 
measures ANOVA showed significant main effects of treatment, day, and significant 
treatment x day interaction effects (Fig. 3.7). Administration of cocaine resulted in 
the expression of behavioural stereotypy. The magnitude of this effect differed 
between cocaine-treated groups. Animals receiving cocaine+DhBE showed 
diminished stereotypy on days 2, 3, 4 , 7 ,  11 and 13 compared to cocaine-treated 
animals (P<0.05, HSD post hoc test for unequal N). Stereotypy sensitization was 
observed only in the cocaine group from day 3 onwards (day 3 vs. day 1, P<0.01, 
HSD post hoc test for unequal N), and it was maintained for the duration of this study 
(days 4-14 vs. day 1, P<0.001 HSD post hoc test for unequal N). In contrast, cocaine- 
induced stereotypy sensitization was attenuated by the administration of the nicotinic 
antagonist DhBE.
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Figure 3.7 E ffect o f  nicotinic acetylcholine receptor blockade on cocaine-induced stereotypy
The stereotypy score assigned to each animal was its median stereotypy score, which was calculated from each of the three daily 
injections of saline or cocaine (±Dhl3E). Data are presented as the mean±SEM of 6-7 animals per group. Two-way repeated 
measures ANOVA showed significant main effects of treatment [F(3,22)=355.9, P<0.001], day [F(13,286)=4.5, P<0.001], and 
significant treatment x day interaction effects [F(39,286)-2.4, P<0.001] on cocaine-induced stereotypy. Sensitization was only 
observed in the cocaine group, was maintained for the duration of the experiment, and it was attenuated by the administration of 
DhBE (One-way ANOVA). These data were collected by H. L. Keyworth, in collaboration with the author.
Overall, blockade of different nAChR populations produced distinct behaviours in 
chronically cocaine-treated animals.
3.3.5 Quantitative autoradiography o f a4p2* and a l  nACHRs, and o f the high affinity 
choline transporter, following chronic, steady dose, b^inge* cocaine treatment 
Animals were killed by cervical dislocation 30 min following the last injection of saline 
or cocaine (± nAChR antagonists) on day 14 of the study, and brains were immediately 
removed and subsequently processed for quantitative autoradiography. The density of
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total, cytisine-sensitive, and cytisine-resistant [^^^I]epibatidine binding sites in brain 
regions of saline or cocaine treated mice is detailed for all areas analysed in Tables 3.1, 
3.2, and 3.3, respectively. Non specific binding was indistinguishable from film 
background.
R e g io n
T o ta l 1 ]e p ib a tid in e  b in d in g  (fm o l/m g  t i s s u e  e q u iv a le n t)
S a lin e C o c a in e S a lin e + D h p E C o c a in e + D h p E Saline+ M L A C o cain e+ M L A
Olfactory tu b erc le 8.0 ± 0.7 7.6 ± 1.0 8.2 ± 0.7 10.7 ± 0.6 8.9 ± 0.7 7.2 ± 1.0
Prelim bic co rtex 8.2 ± 0.9 6.8 ± 1.0 7.6 ± 0.7 8.3 ± 0.8 6.8 ± 0.5 8.4 ± 0.6
C ingulate co rtex 8.1 ± 1.0 7.8 ± 0.7 9.4 ± 0.7 10.0 ± 0.8 8.0 ± 0.6 8.1 ± 0.5
N ucleus a c c u m b e n s
Core 7.9 ± 0.9 7.8 ± 0.8 9.1 ± 1 .0 9.7 ± 0.9 8.4 ± 0.9 7.3 ± 0.6
Shell 7.8 ± 1.0 7.5 ± 0.8 8.2 ± 0.7 9.1 ± 0.4 8.3 ± 0.9 7.0 ± 0.8
C au d ate  pu tam en 9.7 ± 1.1 10.0 ± 0.8 11.1 ±1 .1 11.9 ± 0.9 10.6 ± 1 .0 9.6 ± 0.7
Prim ary m oto r co rtex 8.5 ± 0.7 7.9 ± 0.8 10.1 ± 0 .7 10.6 ± 0.8 8.3 ± 0.6 8.5 ± 0.5
S e co n d ary  m oto r co rtex 8.4 ± 0.7 7.6 ± 0.6 9.9 ± 0.7 10.6 ± 0.9 8.7 ± 0.8 8.4 ± 0.5
H ippocam pus 3.2 ± 0.5 3.6 ± 0.5 3.5 ± 0.5 3.5 ± 0.4 2.9 ± 0.5 3.4 ± 0.3
Subiculum 16.2 ± 1.8 18.2 ± 1.7 17.6 ± 2.6 16.7 ± 1.5 15.1 ±1.1 15.6 ± 1.3
A nteroventral thalam ic n u c leu s 20.6 ± 1.0 25.3 ± 1.8 21.8 ± 1 .9 23.2 ± 2.3 20.8 ± 2.3 20.7 ± 2.9
P o s te rio r thalam ic n u c lea r g ro u p 15.3 ± 1.3 15.9 ± 1.1 18.6 ± 1 .5 18.8 ± 1.7 18.2 ± 2 .0 17.6 ± 2.6
Lateral p o s te rio r  thalam ic n u c leu s 16.2 ± 1.4 16.6 ± 0.9 19.6 ± 1 .7 19.2 ± 1.4 19.1 ± 1 .5 18.0 ± 2.4
Medial gen icu la te  n u c leu s 14.9 ± 1.9 18.5 ± 1.6 22.0 ± 4.1* 21.4 ± 2.2* 16.1 ± 1 .5 17.7 ± 1.5
V entral lateral g en icu la te  n u c leu s 21.8 ± 2.3 22.3 ± 1.8 24.4 ± 2.4 26.6 ± 2.3 24.0 ± 3.1 23.6 ± 2.8
D orsal lateral gen icu la te  n u c leu s 22.7 ± 2.2 23.1 ± 1.6 26.8 ± 2.5 27.2 ± 2.2 26.1 ± 2.8 24.9 ± 3.0
V isual C ortex 8.4 ± 0.8 8.1 ± 0.4 9.6 ± 0.8 10.0 ± 0.6 8.8 ± 0.6 8.7 ± 0.9
Superficial g ray  layer o f th e
20.0 ± 2.4 22.7 ± 1.9 26.3 ± 4.9* 28.8 ± 2.8** ’^su p e rio r  colliculus 20.6 ± 2.3 22.1 ± 1.7
V entral tegm en ta l a re a 13.0 ± 1.0 18.4 ± 1.6 20.4 ± 2.4** 21.3 ± 2.0** 16.1 ± 1 .6 17.8 ± 1.3
S u b s tan tia  nigra, p a rs  co m p acta 14.7 ± 1.1 20.2 ± 1.5 22.0 ± 2.9** 21.2 ± 1.7* 17.4 ± 1 .3 19.9 ± 1.3
Table 3.1 Q uantitative autoradiography o f  heterom eric nAChRs, following ‘binge’ treatm ent o f  cocaine ±  
nA ChR antagonists
Animals were treated using a ‘binge’ administration protocol, receiving three daily injeetions of saline or eoeaine (± nAChR 
antagonists), one hour apart, for a period of 14 days. Values of speeifie [’^ ^I]epibatidine binding represent mean ± SEM 
fmol/mg of tissue equivalent in brain regions of 6-7 animals per group, and were caleulated after the subtraetion of non-specific 
from total [’^^I]epibatidine binding. Two-way ANOVA was performed for the factors treatment and region. Analysis showed 
significant main effects of treatment [F(5,657)=11.2, P<0.001] and region [F(19,657)=106.9, P<0.001], with no significant 
treatment x region interaction effects [F(95,657)=0.6, P>0.05] on total ['^^I]epibatidine binding density. Within-region 
differences were examined using Duncan’s post hoc test. *P<0.05 vs. saline and saline+MLA, **P<0.01 vs. saline, ^P<0.05 vs. 
coeaine and coeaine+MLA.
The chronic, ‘binge’ administration of steady doses of cocaine resulted in significant, 
region-specific increases of cytisine-sensitive [^^^IJepibatidine binding sites in the SNc 
and VTA of cocaine-treated animals, compared to saline controls (Table 3.2). On the
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contrary, no differences in total or cytisine-sensitive [^^^I]epibatidine binding density 
were detected between saline+DhBE vs. cocaine+DhBE, and between saline+MLA vs. 
cocaine+MLA treated animals, in any of the brain areas examined.
R egion
C y tis in e -se n s itiv e  f  ^ ® l]epibatidine b in d in g  (fm ol/m g t is s u e  eq u iv a len t)
Saline Cocaine Saline+DhpE Cocaine+DhpE Saline+MLA Cocaine+MLA
Olfactory tubercle 6.9 ± 0.5 6.4 ± 0.8 6.8 ± 0.5 9.4 ± 0.7 7.8 ± 0.8 6.3 ± 0.9
Prelimbic cortex 8.1 ± 0.9 6.6 ± 0.8 7.4 ± 0.6 8.0 ± 0.8 6.6 ± 0.5 8.2 ± 0.6
Cingulate cortex 
Nucleus accum bens
7.7 ± 0.9 7.5 ± 0.7 9.1 ± 0.7 9.7 ± 0.9 7.8 ± 0.6 7.9 ± 0.4
Core 6.2 ± 0.6 5.9 ± 0.5 7.4 ± 0 .9 7.8 ± 0.4 6.8 ±0.7 5.9 ± 0.5
Shell 6.1 ± 0.7 5.7 ± 0.5 6.5 ± 0.5 7.4 ± 0.3 6.8 ± 0.6 5.7 ± 0.6
C audate putam en 8.1 + 0.9 8.3 ± 0.7 9.5 ±1 .0 10.1 ± 0.9 9.0 ± 0.9 8.3 ± 0.5
Primary m otor cortex 8.2 ± 0.6 7.6 ± 0.7 9.8 ± 0.7 10.2 ± 0.8 8.0 ± 0.6 8.2 ± 0.5
Secondary  m otor cortex 8.2 ± 0.7 7.4 ± 0.6 9.6 ± 0.7 10.3 ± 0.9 8.3 ± 0.9 8.2 ± 0.5
Hippocam pus 3.0 ± 0.4 3.3 ± 0.4 3.4 ± 0.5 3.2 ± 0.4 2.7 ± 0.4 3.2 ± 0.3
Subiculum 1 3 .4 + 1 .7 14.7 ± 1.8 14.6 ± 2.2 13.3 ± 1.2 12.1 ±1.0 12.5 ± 1.4
Anteroventral thalamic nucleus 17.1 ± 1.1 22.0 ± 1.8 18.4 ±1 .8 19.8 ± 2.1 17.2 ±2.2 18.4 ± 2.6
Posterior thalam ic nuclear group 13.4 ± 1 .2 13.7 ± 1.1 16.2 ± 1 .5 16.4 ± 1.6 16.2 ±1.9 15.4 ± 2.6
Lateral posterior thalamic nucleus 13.7 ± 1.2 13.3 ± 1.0 16.5 ± 1 .4 15.7 ± 1.5 15.9 ±1 .5 14.8 ± 2.5
Medial geniculate nucleus 12.8 ± 1 .7 16.6 ± 1.6 18.5 ±3.1* 18.9 ± 2.2* 14.0 ±1 .5 15.4 ± 1.5
Ventral lateral geniculate nucleus 12.1 ± 1.5 11.0 ± 1.4 13.6 ±2.1 15.4 ± 1.8 12.9 ±2.1 13.0 ± 2.5
Dorsal lateral geniculate nucleus 14.0 ± 1.4 12.5 ± 1.4 16.3 ±2 .0 16.5 ± 4 .5 15.6 ±2 .0 14.8 ± 2.8
Visual Cortex 8.1 ± 0.7 7.7 ± 0.3 9.2 ± 0.7 9.6 ± 0.5 8.5 ± 0.6 8.4 ± 0.9
Superficial gray layer of the 
superio r colliculus
8.0 ± 2.0 12.1 ± 1.8 18.7 ±3.7** 16.8 ± 2.8** 10.4 ±3.5** 12.8 ± 1.4*
Ventral tegm ental area 9.7 ± 1.0 14.9 ± 1.4* 15.8 ±2.3* 16.9 ± 2.0* 12.5 ±1.6 14.1 ± 1.5
Substantia  nigra, pars com pacta 12.0 ± 1 .0 17.4 ± 1.6* 18.6 ±3.0* 18.0 ±1.8* 14.7 ±1.3 17.6 ± 1.5*
Table 3.2 Quantitative autoradiography of u4p2* nAChRs, following ‘binge’ treatment of cocaine ± nAChR 
antagonists
Values of cytisine-sensitive ['^^I]epibatidine binding represent mean ± SEM fmol/mg of tissue equivalent in brain regions 
of 6 to 7 animals per group. Specific cytisine-resistant binding was subtracted from total ['^^I]epibatidine binding in order 
to quantify the density of a4p2* receptors. Two-way ANOVA showed significant main effects of treatment 
[F(5,657)=10.3, P<0.001] and region [F(19,657)=51.1, P<0.001], with no significant treatment x region interaction effects 
[F(95,657)=0.8, P>0.05] on cytisine-sensitive ['^ I^Jepibatidine binding density. Within-region differences were examined 
using Duncan’s post hoc XqsX. *P<0.05, **P<0.01 v s . saline, ^P<0.05,^P<0.01 vs. saline+DhBE.
The chronic co-administration of the a4p2* antagonist DhBE with either saline or cocaine 
increased cytisine-sensitive [^^^I]epibatidine binding in most regions examined, compared 
to saline treatment. The increase reached significance in the VTA, substantia nigra 
compacta (SNc), medial geniculate nucleus (MG), and superficial gray layer of the
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superior colliculus (SuG) of DhBE-treated animals, compared to saline controls 
(Duncan’s multiple ranges post hoc). For total and cytisine-sensitive [^^^IJepibatidine 
binding, two-way ANOVA confirmed significant main effects of treatment and region, 
with no significant treatment x region interaction effects on nAChR density.
No differences in the density of cytisine-resistant [^^^IJepibatidine binding sites were 
observed among groups, following 14 days o f ‘binge’ cocaine administration (Table 3.3).
R eg io n
C y tis in e - re s is ta n t [^^^l]epibatidine b in d in g  (fm ol/m g t is s u e  eq u iv a len t)
S a lin e C o c a in e Saline+ D hpE C o cain e+ D h p E Saline+M LA C ocaine+M LA
Olfactory tubercle 1.1 ± 0.3 1.2 ± 0.3 1.4 ± 0 .2 1.2 ± 0.3 1.0 ± 0 .4 1.0 ± 0.2
Nucleus accum bens 
Core 1.7 ± 0.4 1.9 ± 0.3 1.7 ±0 .3 1.9 ± 0.3 1.6 ±0 .3 1.5 ± 0 .3
Shell 1.6 ± 0.4 1.7 ± 0.3 1.7 ± 0 .3 1.7 ± 0.3 1.5 ±0 .3 1.3 ± 0.3
C audate putam en 1.7 ± 0 .4 1.7 ± 0.3 1.6 ± 0 .3 1.8 ± 0.3 1.6 ±0 .3 1.3 ± 0 .3
Subiculum 2.9 ± 0.5 3.5 ± 0.2 3.1 ± 0 .5 3.4 ± 0.5 3.0 ± 0.3 3.1 ± 0.3
A nteroventral thalam ic nucleus 3.5 ± 0.3 3.3 ± 0.3 3.4 ± 0.4 3.4 ± 0.5 3.6 ± 0.5 2.2 ± 0.6
Posterio r thalam ic nuclear group 1.9 ± 0.4 2.2 ± 0.2 2.3 ± 0.2 2.3 ± 0.4 1.9 ±0 .3 2.1 ± 0.2
Lateral posterio r thalam ic nucleus 2.5 ± 0.4 3.3 ± 0.4 3.1 ± 0.4 3.5 ± 0.6 3.1 ± 0.5 3.3 ± 0.5
Medial geniculate nucleus 2.1 ± 0.3 1.8 ± 0.4 3.5 ± 1 .5 2.5 ± 0.2 2.0 ± 0.4 2.3 ± 0.4
Ventral lateral geniculate nucleus 9.7 ± 1.1 11.3 ± 0.9 10.8 ± 0.7 11.2 ± 1.6 11.1 ±1 .2 10.6 ± 0.9
Dorsal lateral geniculate nucleus 8.8 ± 1.1 10.5 ± 0.8 10.6 ± 0.7 10.7 ± 1.4 10.5 ±1 .0 10.2 ± 0.8
Superficial gray layer of the 
su perio r colliculus 12.0 ± 1.2 10.6 ± 2.6 7.6 ± 1 .7 12.0 ± 2.4 10.3 ±2 .0 9.4 ± 1.7
Ventral tegm ental area 3.3 ± 0.6 3.5 ± 0.6 4.6 ± 0.5 4.4 ± 0.2 3.5 ± 0.4 3.7 ± 0.4
S ubstan tia  nigra, pars com pacta 2.7 ± 0.5 2.8 ± 0.4 3.3 ± 0.4 3.2 ± 0.3 2.7 ± 0.6 2.3 ± 0.5
Table 3 3  Quantitative autoradiography of cytisine-resistant nAChR density, following ‘binge’ treatment of 
cocaine ± nAChR antagonists
Values of cytisine-resistant ['^ I^Jepibatidine binding represent mean ± SEM fmol/mg of tissue equivalent in brain regions of 6 to 
7 animals per group. Two-way ANOVA showed no significant treatment effects [F(5,462)=1.4, P>0.05], and no significant 
treatment x region interaction effects [F(65,462)=0.5, P>0.05] on cytisine-resistant [*^ I^]epibatidine binding sites.
Figure 3.8 shows representative autoradiograms of total and cytisine-resistant 
[^^^IJepibatidine binding (A), and of [^^^I]a-bungarotoxin nAChR binding (B), in coronal 
brain sections from animals of each of the six treatment groups.
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Figure 3.8 Representative autoradiogram s o f heteromeric (A) and a l  nAChR binding (B), following  
chronic ‘binge’ cocaine
C57BL/6 mice were treated with a steady dose, ‘binge’ administration protoeol for a period of 14 days. 30 min following the last 
injeetion of saline or cocaine (± nAChR antagonists) animals were killed using the Schedule 1 method of euthanasia, and their 
brains were immediately removed and frozen into isopentane for quantitative autoradiography. (A) The panels show coronal 
brain sections cut at the level of the ventral tegmental area (bregma -3.16 mm). To label a4p2* receptors, adjacent sections were 
incubated for 2 hrs with 100 pM of ['“^ Ijepibatidine alone or in the presence of 20 nM cytisine and 300 pM (-) nicotine hydrogen 
tartrate, to calculate non-specific binding (NSB). Sections were apposed to Kodak BioMax MR-1 film for a period of 24 hours. 
(B) The panels show coronal brain sections cut at the level of the hippocampus (bregma -1.70 mm). To label a l  nAChRs, 
adjacent sections were incubated for 3 hrs with 3 nM ['^^I]a-bungarotoxin, alone or in the presence of 1 mM (-) nicotine 
hydrogen tartrate, to calculate non-specific binding (NSB). Sections were apposed to film for 7 days.
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For a l  nAChRs, the density of specific [^^^I]a-bungarotoxin binding in brain regions of 
saline and cocaine treated mice is detailed for all areas analysed in Table 3.4. Two-way 
ANOVA showed significant region effects, with no significant treatment or treatment x 
region interaction effects.
R eg io n
[^^^ l]a-b u n g arcto x in  b in d in g  (fm ol/m g  t i s s u e  e q u iv a le n t)
Saline C ocaine Saiine+DhpE Cocaine+DhpE Saline+MLA Cocaine+MLA
Frontal asso c ia tio n  cortex 20.4 ± 6.9 19.6 ± 6.3 19.7 ± 4 .2 23.5 ± 4.5 12.6 ± 2 .8 17.4 ± 1.9
Cinguiate cortex 25.3 ± 5.6 21.4 ± 7.9 21.2 ± 2.9 25.5 ± 4.6 15.5 ±3.1 20.4 ± 4.4
C audate putam en 33.1 ± 8.5 31.2 ± 7.3 29.1 ± 4.2 37.6 ± 5.3 23.7 ± 5.1 29.2 ± 5.3
Endopiriform nucleus, dorsal 41.5 ± 6.9 46.0 ± 6.5 38.6 ± 8.7 49.6 ± 9.6 36.0 ± 9.0 36.4 ± 7.3
Primary m otor cortex 30.6 ± 5.4 35.1 ± 7.0 26.4 ± 2.7 38.8 ± 3.6 19.6 ± 1 .8 24.1 ± 4.5
Claustrum 40.6 ± 10.1 40.5 ± 5.9 28.1 ± 7.5 38.3 ± 5.5 30.9 ± 6.7 21.2 ± 3.6
Posterio r thalam ic nuclear group 28.6 ± 1 1 .6 28.7 ± 7.0 23.3 ± 3.3 24.9 ± 4.8 20.9 ± 5.0 25.7 ± 5.1
H ippocam pus, CA1 30.3 ± 4.9 32.3 ± 5.4 27.6 ± 8.3 33.7 ± 4.3 32.0 ± 8.5 25.8 ± 3.7
H ippocam pus, CA3 34.6 ± 6.2 37.1 ± 5.1 33.2 ± 6.8 41.0 ± 6.3 34.8 ± 8.2 33.8 ± 5.8
Dentate gyrus 22.5 ± 6.1 32.5 ± 7.2 29.8 ± 2.9 28.0 ± 4.6 26.9 ± 6.0 24.6 ± 3.2
Basolateral am ygdaloid nucleus 36.0 ± 8.7 34.6 ± 3.6 28.1 ± 6.6 35.7 ± 6.3 32.1 ± 6.5 34.9 ± 5.5
Posterom edial cortical am ygdaloid 
nucleus 100.1 ± 23.1 67.6 ± 12.0 70.9 ± 12.0 90.9 ± 18.8 84.0 ± 14.6 69.7 ± 6.4
Medial am ygdaloid nucleus 49.2 ± 9.7 41.3 ± 2.2 45.5 ± 9.5 46.2 ± 5.5 49.7 ± 13 .0 52.9 ± 6.6
Dorsom edial hypothalam ic nucleus 33.9 ± 9.7 29.3 ± 2.5 28.5 ± 3.5 38.3 ± 6.5 35.5 ± 11 .8 39.5 ± 4.9
Ventrom edial hypothalam ic nucleus 30.5 ± 6.6 43.1 ± 6.2 43.7 ± 3.8 39.9 ± 6.6 46.1 ± 13 .5 42.6 ± 4.3
Lateral hypothalam us 28.0 ± 4.4 19.4 ± 4.1 22.3 ± 2.8 20.5 ± 2.9 27.5 ± 4.6 25.3 ± 4.0
Z ona incerta 41.9 ± 8.6 35.2 ± 9.3 35.9 ± 10.1 30.3 ± 4.8 29.9 ± 7.8 41.2 ± 7.3
Ventral lateral geniculate  nucleus 54.0 ± 8.9 32.3 ± 4.9 52.9 ± 6.8 42.7 ± 6.5 53.9 ± 12 .4 53.6 ± 7.9
Superficial gray layer of th e  
su perio r colliculus 86.7 ± 12.8 89.9 ± 12.1 94.3 ± 10.8 94.3 ± 13.2 91.7 ± 16 .2 91.2 ± 13.7
Ventral tegm ental area 40.8 ± 4.7 41.8 ± 5.8 49.8 ± 3.2 50.7 ± 9.9 49.7 ± 6.5 46.4 ± 7.0
S u b stan tia  nigra 21.2 ± 6.1 37.5 ± 6.7 24.1 ± 4.1 31.7 ± 5.5 19.8 ± 4 .0 25.8 ± 5.3
Table 3.4 Quantitative autoradiography of a l  nAChRs following ‘binge’ treatment of coeaine ± nAChR 
antagonists
Animals were treated using a steady dose, ‘binge’ administration protocol, receiving three daily injeetions of either saline or 
eoeaine (± nAChR antagonists), one hour apart, for a period of 14 days. Autoradiographic data of a l  nAChR binding are 
presented as the mean specific binding of [^a-bungarotoxin ± SEM in brain regions of 6-7 animals per group. No significant 
treatment [F(5,689)=l.l, P>0.05] or treatment x region interaetion effects [F(100,689)=0.5, P>0.05] were observed.
Figure 3.9 shows representative autoradiograms of total and non specific 
[^HJhemicholinium binding at the level of the nucleus accumbens, in coronal brain 
sections from animals of each of the six treatment groups.
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Figure 3.9 Representative autoradiogram s o f  fH ]hem icholinium  binding following chronic ‘binge’ cocaine (± 
nAChR antagonists) adm inistration
On day 14, 30 min following the last injection of saline or cocaine (± nAChR antagonists), animals were killed by cervical 
dislocation and their brains were immediately removed and frozen into isopentane for subsequent processing using 
quantitative autoradiography. To label choline transporters, adjacent sections were incubated at 4 °C for 60 min with 8 nM 
of f  Hjhemicholinium alone or in the presence of 100 pM unlabeled hemicholinium, to calculate non-specific binding (NSB). 
The panels show coronal brain sections cut at the level of the nucleus accumbens (bregma 1.10 mm). Sections were apposed 
to Kodak BioMax MR-1 film for a period of 25 days. The colour bar indicates a pseudo-colour interpretation of black and 
white image density, calibrated in fmol/mg of tissue equivalent.
There was an overall decrease of choline transporter (CHT) density across all regions 
examined in cocaine+MLA animals, compared to cocaine+DhBE treated mice (P<0.05, 
Duncan’s multiple ranges post hoc). Individual post hoc comparison showed no 
significant quantitative differences between the two groups, in any of the regions 
analysed. The density of specific [^H]hemicholinium binding in brain regions of saline 
and cocaine treated mice is detailed for all areas analysed in Table 3.5. For the high
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affinity CHT, two-way ANOVA revealed significant main effects of treatment and region, 
with no significant treatment x region interaction effects.
pH]hem icholinium  binding (fmol/mg tis su e  equivalent)
Saline Cocaine Saline+DhpE Cocaine+DhpE Saiine+MLA Cocaine+MLA
Olfactory tubercle 
Nucleus accumbens
41.5 ± 5.6 35.9 ± 4.4 42.0 ± 7.1 44.4 ± 4.0 26.9 ± 8.3 31.0 ±4.9
Core 23.4 + 3.7 17.5 ± 2.8 20.3 ± 3.4 21.0 ± 3.0 15.5 ±4.2 14.9 ± 3.4
Shell 
Caudate putamen
27.8 ± 3.1 22.8 + 4.1 27.7 ± 3.9 28.2 ± 3.8 17.5 ±5.4 20.8 ± 4.2
Rostral part 42.4 ± 7.7 31.1 ± 4.0 35.0 ± 4.7 38.4 ± 3.7 28.9 ± 8.1 25.6 ± 4.3
Caudal part 44.0 ± 7.2 41.3 ± 5.5 48.8 ± 8.8 37.7 ± 4.4 27.0 ± 5.6 31.9 ± 5.8
Basolateral amygdaloid nucleus 36.3 ± 5.8 31.5 ± 5.5 25.7 ± 3.0 35.7 + 3.4 28.7 ±4.3 25.9 ± 2.9
Island of Calleja, major island 39.1 ± 5.6 44.6 + 4.8 43.1 ± 2.3 48.1 ± 6.5 36.1 ± 14.3 27.7 ± 6.5
Anteroventral thalamic nucleus 46.8 ± 9.1 29.6 ± 3.9 31.1 +6..6 49.4 ± 8.1 28.2 ±7.7 28.7 ± 7.8
Interpeduncular nucleus 152.1 ± 25.5 137.0 ± 13.4 112.2 ± 9.6 131.9 ± 12.2 151.2 ±38.3 128.0 ± 15.4
Table 3.5 Q uantitative autoradiography o f  eholine transporters, following ‘binge’ treatm ent o f  coeaine ±  nAChR  
antagonists
Animals were injected with cocaine (15.0 mg/kg/inj), cocaine+DhpE (2.0 mg/kg/inj), or cocaine+MLA (5.0 mg/kg/inj) 
three times daily, for a period of 14 days. 30 min after the last injection, mice were killed and their brains removed and 
processed for quantitative receptor autoradiography. Data for the binding of choline transporters are shown as the mean 
specific binding of [^HJhemicholinium ± SEM in brain regions of 6 to7 animals per group. Two-way ANOVA was 
conducted for the factors treatment and region, showing significant treatment [F(5,287)=3.2, P<0.01] and region 
[F(8,287)=101.7, P<0.001] effects, and no significant treatment x region interaction [F(40,287)=0.6, P>0.5]. Analysis 
revealed an overall decrease in the density of high affinity choline transporters across all regions in cocaine+MLA 
animals, compared to cocaine+DhBE treated mice (P<0.05, Duncan’s multiple ranges post hoc).
3.3,6 Effects o f nicotine pretreatment on cocaine-induced locomotor stimulation
In view of the region-specific upregulation of cytisine-sensitive nAChRs by ‘binge’ 
cocaine, it was hypothesized that the behavioural phenotype displayed by cocaine+DhBE 
treated animals was due to blockade of a4p2* nAChR upregulation in the SNc and VTA. 
Figure 3.10 A&B shows acute locomotor activity of mice, pretreated with different doses 
of nicotine, which have been shown to induce maximal, half-maximal, or sub-maximal 
upregulation of nAChRs in the mouse brain (Marks et al., 1991; Marks et al., 2004). 
Nicotine at 0.8 mg/kg/hr significantly enhanced locomotor activity in cocaine+DhBE 
treated mice, compared with saline pretreatment and with nicotine at 0.45 mg/kg/hr or 0.2
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mg/kg/hr. At the nicotine dose of 0.2 mg/kg/hr, antagonism of a4p2* nAChRs reduced 
cocaine-induced locomotion (P<0.05). This effect was abolished with higher doses of 
nicotine pretreatment. The disinhibitory effect of a4p2* nAChR antagonism on cocaine- 
induced locomotion was clearly evident when motor activity of cocaine-treated mice was 
expressed as percentage change from baseline activity of saline-pretreated animals (Fig. 
3.1GB). Differences in cocaine-induced motor stimulation between groups emerged as a 
fraction of nicotine dose. Pre exposure to nicotine at doses that marginally upregulate 
a4p2* nAChRs similarly enhanced cocaine-induced motor activity in cocaine-treated 
animals. Nicotine doses that half-maximally or maximally upregulate nAChRs increased 
locomotor stimulation in cocaine+DhBE treated mice accordingly. A positive correlation 
between nicotine pretreatment dose and cocaine+DhBE-induced motor stimulation was 
derived. In mice treated with cocaine alone, an inverted U-shaped curve was observed 
for the effects of nicotine pretreatment on acute motor activity. No locomotor cross­
sensitization was observed between cocaine and nicotine, at any of the nicotine 
pretreatment doses employed. Two-way ANOVA confirmed significant effects of 
nicotine pretreatment and significant pretreatment x treatment interaction effects on acute 
cocaine-induced motor stimulation.
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Figure 3.10 Effect o f  nicotine pretreatm ent on cocaine-induced m otor activity
C57BL/6 mice were treated for a period of 8 days with 0.8, 0.45 or 0.2 mg/kg/day of nicotine using miniosmotic pumps, 
in order to induce maximal, half-maximal or sub-maximal a4p2* nAChR upregulation, respectively. On day 8, a single 
injection of cocaine (15.0 mg/kg) or cocaine+DhBE (2.0 mg/kg) was administered, and cocaine-induced motor activity 
was subsequently assessed for 1 hr. Beam break counts were collected in 5 minute bins and summed over 1 hr. No 
change in baseline locomotor activity was observed among groups, at any dose of nicotine pretreatment. (A): Antagonism 
of o4p2* nAChRs reduced cocaine-induced motor activity, following pretreatment with 0.2 mg/kg/hr of nicotine for 8 
days. This effect was abolished at higher doses of nicotine pre-exposure. Data are presented as the mean ± SEM of 4 
animals per group. Two-way ANOVA showed significant effects of nicotine pretreatment on cocaine-induced locomotor 
activity [F(3,24)=4.9, P<0.01], and significant pretreatment x treatment interaction effects [F(3,12)=3.1, P<0.05]. 
**P<0.01 vs. cocaine+DhBE in all treatment groups, *P<0.05 vs. cocaine 0.2 mg/kg/hr, Fischer’s LSD post hoc test. (B): 
Cocaine-induced locomotor stimulation, expressed as percentage change from mean baseline activity of saline-pretreated 
animals. At doses of nicotine that have been shown to produce maximal, half-maximal, or sub-maximal o4p2* nAChR 
upregulation, the disinhibitory effects of DhBE on cocaine-induced motor stimulation were significantly correlated with 
nicotine dose (R=0.93, P<0.03, two-tailed value). Moreover, at these doses of nicotine-pretreatment a bell shaped 
relationship between nicotine and cocaine-induced motor stimulation was derived.
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3.3.7 Quantitative autoradiography o f D1 and D2 receptors, and o f the dopamine 
transporter, following chronic, steady dose, ^binge’ treatment
The density of specific [^HJraclopride binding in brain regions of saline and cocaine 
treated mice is detailed for all areas analysed in Table 3.6. Figure 3.11 shows 
representative autoradiograms of total and non specific [^HJraclopride binding at the level 
of the nucleus accumbens (bregma 1.10 mm), in coronal brain sections from animals of 
each of the six treatment groups. An increase in D2 receptor density was observed in the 
rostral part of the caudate putamen of cocaine+DhBE mice, compared to saline treated 
animals (P<0.05, Duncan’s multiple ranges post hoc). In the same region, the increase of 
[^HJraclopride binding in cocaine+DhBE compared to cocaine+MLA animals was close 
to significance (P=0.06).
R egion
[^H ]raclopride b in d in g  (fm ol/m g t is s u e  e q u iv a len t)
Saline Cocaine Saline+DhpE Cocaine+DhpE Saline+MLA Cocaine+MLA
Olfactory tubercle 45.4 ± 3.0 52.3 ± 4.0 48.4 ± 6.3 57.1 ± 2.8 48.9 ± 3.5 54.6 ± 2.9
Nucleus accum bens
Core 38.2 ± 3.4 42.5 ± 3.4 38.1 ± 6.2 41.1 ± 5.6 40.7 ± 6.9 41.6 ± 3.5
Shell 33.9 ± 2.3 39.5 ± 3.4 35.1 ± 5.8 36.8 ± 5.6 35.7 ± 6.4 38.4 ± 3.8
Caudate putam en
Rostral part 62.6 ± 3.3 67.2 ± 4.0 67.7 ± 3.9 76 ± 2.9* 65.8 ± 5.6 66.6 ± 2.8
Caudal part 60.2 ± 4.2 64.3 ± 5.0 68.2 ± 3.5 71.4 ± 5.8 68.6 ± 5.7 62.9 ± 4.1
Ventral tegm ental area 15.6 ± 2.2 15.9 ± 3.3 16.4 ± 1.7 18.8 ± 1.7 15.0 ± 1.4 15.7 ± 1.5
Substantia  nigra, pars com pacta 15.5 ± 1.4 19.7 + 2.7 17.5 ± 2.0 18.5 ± 1.9 15.2 ± 1.9 14.9 ± 2.0
Table 3.6 Quantitative autoradiography of D2 receptors, following ‘binge’ treatment of cocaine ± nAChR 
antagonists
On day 14 of the steady dose ‘binge’ treatment protoeol, animals were killed by cervical dislocation and their brains were 
immediately removed and frozen into isopentane for subsequent processing using quantitative autoradiography. Values of D2 
receptor binding represent the mean specific binding of [^HJraelopride ± SEM in brain regions of 6 to7 animals per group. 
Two-way ANOVA was conducted for the factors treatment and region, showing significant treatment [F(5,229)= 2.4, P<0.01] 
and region [F(6,229)=178.3, P<0.001] effects, and no significant treatment x region interaetion [F(30,229)=0.4, P>0.05]. 
Within-region differences were examined using Duncan’s post hoc test, *P<0.05 vs. saline.
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Figure 3.11 Representative autoradiograms of pHjracIopride binding following chronic ‘binge’ cocaine
To label D2 receptors, adjacent sections were incubated for 60 min with 4 nM [^Hjraclopride alone or in the presence 
of 10 pM of sulpiride, to calculate non-specific binding (NSB). Sections were apposed to Kodak BioMax MR-1 film 
for a period of 6 weeks. The colour bar indicates a pseudo-colour interpretation of black and white image density, 
calibrated in fmol/mg of tissue equivalent.
For D1 receptors, the density of specific [^H]SCH-23390 binding in brain regions of 
saline and cocaine treated mice is detailed for all areas analysed in Table 3.7. Two-way 
ANOVA showed no significant main effects of treatment and no significant treatment x 
region interaction effects.
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R egion
[®H]SCH-23390 b ind ing  (fm ol/m g t is s u e  equ iva ien t)
Saline Cocaine Saline+DhpE Cocaine+DhpE Saline+MLA Cocaine+MLA
Olfactory tubercle 
Nucleus accum bens
288.3 ± 14.4 347.5 ± 23.6 335.9 ±21.0 330.2 ± 21.1 342.0 ± 13.5 329.6 ± 14.9
Core 278.0 ± 17.4 278.7 ± 16.4 244.8 ±21.0 273.3 ± 39.5 281.9 ±20.6 236.7 ± 14.4
Shell 267.6 ± 18.8 269.8 ± 12.1 243.8 ± 16.3 267.8 ± 35.3 280.8 ±21.1 232.0 ± 15.4
Claustrum 64.4 ± 6.8 67.1 ± 5.5 70.0 ± 9.1 69.2 ± 5.5 61.0 ±3.3 65.9 ± 3.0
Endopiriform nucleus, dorsal 76.9 ± 3.3 83.2 ± 3.2 80.7 ± 3.2 79.6 ± 5.0 82.6 ± 3.9 81.6 ± 3.1
Nigrostriatal bundle 
Caudate putamen
53.4 ± 8.7 63.7 + 6.0 49.3 ± 4.0 55.9 ± 8.0 52.9 ± 8.4 52.4 ± 5.0
Rostral part 402.1 ± 15.2 404.0 ± 16.8 408.9 ± 10.4 390.9 ± 28.3 410.1 ± 9.0 394.1 ± 13.0
Caudal part 331.0 ± 19.1 343.6 ± 21.0 347.9 ± 17.1 339.5 ± 23.8 334.6 ± 9.9 308.8 ± 23.5
Amygdala 46.7 ± 3.2 48.7 ± 2.3 47.2 ± 1.0 48.4 ± 2.3 50.1 ± 2.8 45.9 ± 2.1
Hippocampus 21.5 ± 2.6 28.1 ± 1.7 21.8 ± 1.9 20.8 ± 1.1 22.7 ± 2.4 23.8 ± 2.7
Hypothalamus 20.3 ± 2.1 22.5 ± 1.4 19.5 ± 0.9 20.5 ± 1.1 20.3 ± 2.0 20.5 ± 2.2
Ventral tegmental area 36.2 ± 3.5 39.4 ± 2.3 40.2 ± 2.9 35.8 ± 3.6 34.8 ± 4.9 46.5 ± 6.1
Substantia nigra, pars com pacta 162.3 ± 4.8 187.6 ± 4.3 183.0 ± 5.1 184.3 ± 8.3 170.0 ± 2.6 176.2 ± 2.8
Table 3.7 Quantitative autoradiography of D1 receptors, following ‘binge’ treatment of cocaine ± nAChR 
antagonists
C57BL/6 mice were treated with a steady dose, ‘binge’ administration protocol for a period of 14 days. 30 min following 
the last injection of saline or cocaine (± nAChR antagonists), animals were killed using the Schedule 1 method of 
euthanasia, and their brains were immediately removed and frozen into isopentane for quantitative autoradiography. Data 
for D1 receptor binding are presented as the mean specific binding of [^HjSCH-23390 ± SEM in brain regions of 6-7 
animals per group. Two-way ANOVA revealed a significant effect of region [F(12,408)=422.2, P<0.001], and no 
significant treatment [F(5,408)=1.6, P>0.05] or treatment x region interaetion effect [F(60,408)=0.6, P>0.05].
The density of specific [^H]mazindol binding in brain regions of saline and cocaine (± 
nAChR antagonists) treated mice is detailed for all areas analysed in Table 3.8. Chronic, 
‘binge’ cocaine administration increased DA transporter binding in the rostral part of the 
caudate putamen of cocaine+DhBE animals, compared to saline treated mice (P<0.05, 
Duncan’s multiple ranges post hoc). Two-way ANOVA showed significant main effects 
of treatment and region on [^H]mazindol binding sites, with no significant treatment x 
region interaction effects. Figure 3.12 shows representative autoradiograms of total and 
non specific [^H]mazindol binding at the level of the nucleus accumbens, in coronal brain 
sections from animals of each of the six treatment groups.
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R eg io n
[^H ]m azlndol b in d in g  (fm ol/m g t i s s u e  e q u iv a le n t)
S a lin e C o c a in e S a lin e+ D h p E C o c a in e+ D h p E Saline+M LA C ocaine+M L A
Olfactory tubercle 120.9 ± 19.3 216.0 ± 35.2 153.7 ± 20.0 234.3 ± 51.6 209.4 ±46.0 206.2 ± 67.5
Nucleus accum bens
Core 148.6 ± 32.8 220.5 ± 41.9 183.4 ± 32.3 282.3 ± 47.9 232.6 ±48.0 221.9 ± 59.0
Shell 91.8 ± 24.9 159.6 ± 29.6 122.9 ± 24.3 186.2 ± 35.3 191.9 ±46.6 171.0 ± 47.6
Caudate putamen
Rostral part 206.3 ± 43.7 328.6 ± 47.6 274.3 ± 53.4 382.8 ± 49.3* 335.4 ± 58.2 350.1 ± 75.6
Caudal part 216.1 ± 44.0 285.1 ± 43.4 276.4 ± 63.7 224.5 ± 32.9 286.0 ± 62.2 332.0 ± 58.1
Ventral tegmental area 174.1 ± 25.5 212.2 ± 44.8 126.7 ± 17.3 217.1 ± 30.9 136.4 ±33.8 169.6 ± 46.8
Substantia nlqra, pars
compacta 131.2 ± 22.8 186.1 ±40.5 127.4 ± 11.5 177.5 ± 35.8 126.6 ±29.9 159.4 ± 42.1
Table 3.8 Quantitative autoradiography of dopamine transporters, following ‘binge’ treatment of cocaine ± 
nAChR antagonists
Animals were injected with cocaine (15.0 mg/kg/inj), cocaine+DhpE (2.0 mg/kg/inj), or cocaine+MLA (5.0 mg/kg/inj) three 
times daily, for a period of 14 days. 30 min following the last injection, mice were killed and their brains removed and 
processed for quantitative receptor autoradiography. Values for the dopamine transporters represent the mean specific binding 
of f  Hjmazindol ± SEM in brain regions of 6 to 7 animals per group. Two-way ANOVA revealed a significant main effect of 
treatment [F(5,224)=3.9, P<0.01] and region [F(6,224)=l 1.3, P<0.001], and no significant treatment x region interaction effect 
[F(30,224)=0.4, P>0.05]. Duncan’s post hoc test was used to investigate differences in radioligand binding between groups in 
individual regions, *P<0.05 vs. saline.
fmol/mg Saline Cocaine NSB Saline Cocaine NSB
fmol/mg Saline+DhpE
i
Cocaine+DhpE Salme+DhPE Cocame+DhpE
fmol/mg Saline+MLA 
!
Cocaine+MLA Saline+MLA Cocaine+MLA NSB
Figure 3.12 Representative autoradiograms of fHjmazindoi binding following chronic ‘binge’ cocaine
To label dopamine transporters, adjacent sections were incubated for 45 min at 4 °C with 4 nM [^Hjmazindol alone or in the presence 
of 10 pM of unlabeled mazindol, to calculate non specific binding. Sections were apposed to Kodak BioMax MR-1 film for a period 
of 5 weeks. The colour bar indicates a pseudo-colour interpretation of black and white image density, calibrated in fmol/mg of tissue 
equivalent. Representative images are shown at the level o f the caudate putamen (bregma 1.10 mm) and the ventral tegmental area 
(bregma -3.16 mm).
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3.3.8 Quantitative autoradiography o f a4p2* and a l  neuronal nAChRs, following 
prolonged withdrawal from steady dose, ^binge’ cocaine treatment 
To investigate whether withdrawal from chronic cocaine alters the receptor component of 
the nicotinic cholinergic system, two groups of C57BL/6 mice were treated with cocaine 
or saline under a steady dose, ‘binge’ administration protocol for a period 14 days. 
Animals were subsequently withdrawn from cocaine or saline for 14 days. Quantitative 
autoradiography of heteromeric nAChRs revealed no differences in total (Fig. 3.13) and 
cytisine-sensitive (Fig. 3.14) epibatidine binding between saline and cocaine treated 
animals, following prolonged abstinence from ‘binge’ drug administration.
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Figure 3.13 Q uantitative autoradiography o f  heterom erie nA ChR binding following withdrawal from  chronie 
‘binge’ cocaine
C57BL/6 mice were ‘binge’ treated with saline or coeaine (3 x 15.0 mg/kg/inj daily) for a period of 14 days. They were subsequently 
allowed to withdraw from treatment for a period of 14 days, before being used for quantitative autoradiography studies. Values of 
nAChR binding represent the mean speeifie binding of ['^^Ijepibatidine ± SEM in brain regions of 6 animals per group. Two-way 
ANOVA showed no signifieant treatment [F(l,192)=0.0, P>0.05] or treatment x region interaction effects [F(19,192)=0.0, P>0.05]. 
Abbreviations: PrL: Prelimbic Cortex, Ml: Primary Motor Cortex; M2: Secondary Motor Cortex; AcbC: Nucleus Accumbens, Core; 
AcbSh: Nucleus Accumbens, Shell; CPu: Caudate Putamen; Tu: Olfaetory Tubercle; Cg: Cingulate Cortex; AV: Anteroventral Thalamic 
Nucleus; LPMR: Lateral Posterior Thalamic Nucleus; Po: Posterior Thalamic Nuclear Group; DLG: Dorsal Lateral Geniculate Nucleus; 
VLG: Ventral Lateral Geniculate Nucleus; MG: Medial Geniculate Nucleus; SuG: Superficial Gray Layer of the Superior Colliculus; 
VTA: Ventral Tegmental Area; SNc: Substantia Nigra, pars Compacta; VI: Visual Cortex; Hip: Hippocampus; S: Subiculum.
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Figure 3.14 Q uantitative autoradiography o f cytisine-sensitive (A) and cytisine-resistant (B) [*“ l]epibatid ine  
binding following withdrawal from chronic ‘binge’ cocaine
Values represent the mean specific epibatidine binding ± SEM in brain regions of 6 animals per group. Two-way 
ANOVA showed no signifieant treatment [F(l,195)=0.0, P>0.05] or treatment x region interaction effects 
[F(19,195)=0.3, P>0.05] on the density of a4p2* nAChRs. Similarly, no treatment [F(l,135)=1.2, P>0.05] or treatment 
X region interaction [F(13,135)=0.4, P>0.05] effects were observed on cytisine-resistant nAChR populations. 
Abbreviations: PrL: Prelimbic Cortex, Ml: Primary Motor Cortex; M2: Secondary Motor Cortex; AcbC: Nucleus 
Aceumbens, Core; AcbSh: Nucleus Accumbens, Shell; CPu: Caudate Putamen; Tu: Olfactory Tubercle; Cg: Cingulate 
Cortex; AV: Anteroventral Thalamic Nucleus; LPMR: Lateral Posterior Thalamic Nucleus; Po: Posterior Thalamic 
Nuclear Group; DLG: Dorsal Lateral Geniculate Nucleus; VLG: Ventral Lateral Geniculate Nueleus; MG: Medial 
Geniculate Nucleus; SuG: Superfieial Gray Layer of the Superior Colliculus; VTA: Ventral Tegmental Area; SNc: 
Substantia Nigra, pars Compacta; VI: Visual Cortex; Hip: Hippocampus; S: Subiculum.
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Prolonged withdrawal from ‘binge’ cocaine treatment resulted in a decrease of 
[^^^IJbungarotoxin binding across all regions examined (Fig. 3.15). Significantly lower levels 
of a l  nAChR density were observed in the VTA of cocaine-withdrawn animals, compared to 
saline controls. Representative autoradiograms of a l  nAChR binding are shown in Figure 
3.16.
□  Saline 
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Figure 3.15 Quantitative autoradiography of a l  nAChR binding following withdrawal from chronie ‘binge’ 
cocaine
C57BL/6 mice were ‘binge’ treated with saline or cocaine (3 x 15.0 mg/kg/inj daily) for 14 days, and were subsequently allowed 
to withdraw from treatment for a period of 14 days, before being used for quantitative autoradiography studies. Values of a l  
nAChR binding represent the mean specific binding of [*^ l^]a-bungarotoxin ± SEM in brain regions of 6 animals per group. Two- 
way ANOVA showed significant treatment [F(l,190)=8.5, P<0.01] and region [F(19,190)=15.7, P<0.001] effects, and no 
treatment x region interaction effects [F( 19,190)^0.3, P>0.05]. Levels of a? nAChR density were significantly lower in the VTA 
of cocaine-treated animals, compared to saline-treated mice (*P<0.05 vs. saline, LSD post hoc). In addition, ['^ 1^]a-bungarotoxin 
binding was reduced by 56% in the SN of animals receiving chronic ‘binge’ cocaine. Abbreviations: FrA: Frontal Association 
Cortex; Cg: Cingulate Cortex; CPu: Caudate Putamen; DEn: Dorsal Endopiriform Nucleus; Ml: Primary Motor Cortex; Cl: 
Claustrum; Po: Posterior Thalamic Nuclear Group; CAl: Hippocampus, CAl; CA3: Hippocampus, CA3; DG: Dentate Gyrus; 
BLA: Basolateral Amygdaloid Nucleus; PLCo: Posteromedial Cortical Amygdaloid Nucleus; MAN: Medial Amygdaloid 
Nucleus; DM: Dorsomedial Hypothalamic Nucleus; VM Ventromedial Hypothalamic Nucleus; LH: Lateral Hypothalamus; Zl: 
Zona Incerta; SuG: Superficial Gray Layer of the Superior Colliculus; VTA: Ventral Tegmental Area; SN: Substantia Nigra.
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Figure 3.16 Representative autoradiogram s o f [‘^®I]a-bungarotoxin binding following withdrawal from chronic 
‘binge’ cocaine
Following 14 days of withdrawal from ‘binge’ cocaine treatment, animals were killed by cervical dislocation and their 
brains were removed for quantitative autoradiography studies. To label a7 nAChRs, adjacent sections were incubated for 3 
hrs at room temperature with 3 nM [’^^I]a-bungarotoxin alone or in the presence of ImM of nicotine salt to calculate non 
specific binding. Sections were apposed to Kodak BioMax MR-1 film for a period of 7 days. The bar shows black and 
white image density calibrated in fmol/mg of tissue equivalent. Abbreviations: NSB: Non Specific Binding.
3.3.9 Quantitative autoradiography of D1 and D2 receptors, and o f the dopamine 
transporter, following prolonged withdrawal from steady dose, ^binge' cocaine 
treatment
The density of specific [^H]SCH-23390 binding in brain regions of saline and cocaine 
withdrawn mice is detailed for all areas analysed in Figure 3.17. No treatment effect was 
observed on D1 receptor density, following 14 days of withdrawal from ‘binge’ cocaine.
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Figure 3.17 Q uantitative autoradiography o f  D1 receptor binding following withdrawal from chronic ‘binge’ 
cocaine
C57BL/6 mice were ‘binge’ treated with saline or cocaine (3 x 15.0 mg/kg/inj daily) for 14 days, and were subsequently allowed 
to withdraw from treatment for a period of 14 days, before being used for quantitative autoradiography studies. Values of D1 
receptor binding represent the mean specific binding of [^HJSCH-23390 ± SEM in brain regions of 6 animals per group. Two- 
way ANOVA showed no signifieant treatment [F(l,128)=0.0, P>0.05] and treatment x region interaction [F(12,128)=0.5, 
P>0.05] effects. Abbreviations: AcbC: Nucleus Aecumbens, Core; AcbSh: Nucleus Accumbens, Shell; Tu: Olfactory Tubercle; 
CPuR: Caudate Putamen, Rostral part; CPuC: Caudate Putamen, Caudal part; SN: Substantia Nigra; VTA: Ventral Tegmental 
Area; Cl: Claustrum; DEn: Dorsal Endopiriform Nucleus; ns: Nigrostriatal Bundle; Amy: Amygdala; Hip: Hippocampus; Hyp: 
Hypothalamus.
A significant interaction between the effects of treatment and region on D2 receptor 
density was observed following prolonged withdrawal from ‘binge’ treatment. However, 
withdrawal from chronic cocaine had no effect on D2 receptor binding. Figure 3.18 
shows specific [^HJraclopride density in brain regions of saline and cocaine withdrawn 
animals.
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Figure 3.18 Quantitative autoradiography o f D2 receptor binding following withdrawal from chronic ‘binge’ 
cocaine
Following 14 days of withdrawal from ‘binge’ cocaine treatment, animals were killed by cervical dislocation and their 
brains were removed for quantitative autoradiography studies. Values of D2 receptor binding represent the mean 
specific binding of [^HJraclopride ± SEM in brain regions of 6 animals per group. Two-way ANOVA showed no 
significant effect of treatment on D2 receptor density [F(l,68)=l.l, P>0.05], and a significant treatment x region 
interaction effect [F(6,128)==99.6, P<0.05]. Abbreviations: AcbC: Nucleus Accumbens, Core; AcbSh: Nucleus 
Accumbens, Shell; Tu: Olfactory Tubercle; CPuR: Caudate Putamen, Rostral part; CPuC: Caudate Putamen, Caudal 
part; SNc: Substantia Nigra, pars compacta; VTA: Ventral Tegmental Area.
The density of specific [^H]mazindol binding in brain regions of saline and cocaine 
withdrawn mice is detailed for all areas analysed in Figure 3.19. No treatment effect was 
observed on dopamine transporter density, following 14 days of withdrawal from ‘binge’ 
cocaine.
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Figure 3.19 Quantitative autoradiography of dopamine transporter binding following withdrawal from chronic 
‘binge’ cocaine
Following 14 days of withdrawal from ‘binge’ cocaine treatment, animals were killed by cervical dislocation and their brains 
were removed for quantitative autoradiography studies. Values of dopamine transporter binding represent the mean specific 
binding of f  HJmazindol ± SEM in brain regions of 6 animals per group. Two-way ANOVA showed no significant effect of 
treatment [F(l,68)=0.8, P>0.05], and no significant treatment x region interaction effect [F(6,68)=0.1, P>0.05]. Abbreviations: 
Tu: Olfactory Tubercle; AcbC: Nucleus Accumbens, Core; AcbSh: Nucleus Accumbens, Shell; SNc: Substantia Nigra, pars 
compacta; VTA: Ventral Tegmental Area; CPuR: Caudate Putamen, Rostral part; CPuC: Caudate Putamen, Caudal part.
3.4 Discussion
In the current set of experiments, the effects of a4p2* nAChR blockade on cocaine- 
induced behaviour were clearly distinguishable from those of a7 nAChR antagonism. 
‘Binge’ administration of the psychostimulant with DhBE prolonged the locomotor 
activating effect of cocaine and diminished stereotypy sensitisation, whereas co 
administration of the drug with MLA precipitated grooming. Hence, subtype-specific 
nicotinic antagonism can shift the effects of a widely abused substance towards two
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markedly different directions, suggesting that each nicotinic subtype makes a distinct 
contribution to cocaine-induced behaviour.
Consistent with studies that have applied a similar protocol of steady-dose, ‘binge’ drug 
administration, chronic cocaine resulted in the expression of stereotypy sensitisation, and 
produced sensitisation and then tolerance to its locomotor activating effects (Schlussman 
et al., 2003; Schlussman et al., 2005; Bailey et al., 2008). These behavioural responses 
were accompanied by increases in cytisine-sensitive [^^^I]epibatidine binding within the 
VTA and SNc of cocaine-treated mice, suggesting that chronic cocaine region- 
specifically regulates a4p2* nAChRs. Cholinergic projections from the mesopontine 
tegmentum innervate the SN and the VTA, providing a source of endogenous 
acetylcholine that tonically activates nAChRs (Maskos, 2008). Furthermore, self­
administered and passively received cocaine enhances acetylcholine release in the VTA, 
implicating the neurotransmitter and its cholinergic afférents to the VTA in the 
reinforcing effects of the psychostimulant (You et al., 2008). Therefore, increased 
acetylcholine release after chronic cocaine may account for the enhanced cytisine- 
sensitive [^^^Ijepibatidine binding in ‘binge’ treated mice. Indeed, a4p2* nAChRs are 
readily upregulated compared to other nAChR subtypes (Pauly et al., 1991; Nguyen et al., 
2003), and have been shown to increase after chronic exposure to several nicotinic 
agonists, including the structural analogues of acetylcholine, methylcarbamylcholine and 
N, N-dimethylcarbmylcholine (Warpman et al., 1998; Whiteaker et al., 1998).
Chronic a4p2* nAChR antagonism abolished cocaine-induced stereotypy sensitisation 
and prolonged the locomotor activating effects of the psychostimulant. The ability of
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DhBE to attenuate sensitisation is in agreement with previous reports, which show that 
administration of antagonists at heteromeric nAChRs blocks cocaine-induced 
sensitisation, whether behaviour is measured as locomotor activity or stereotypy 
(Schoffelmeer et al., 2002; Champtiaux et al., 2006). Psychomotor stimulants have been 
consistently shown to induce motor activation and stereotyped behaviour by acting 
predominantly on the mesolimbic and nigrostriatal dopaminergic (DAergic) systems, 
respectively (Kelly and Iversen, 1976; Ljungberg and Ungerstedt, 1985; Amalric and 
Koob, 1993; Aliane et al., 2009). Moreover, heteromeric a4p2* nAChRs are 
conveniently placed on excitatory and inhibitory neurons within the VTA and the SNc 
(Klink et al., 2001; Zoli et al., 2002), to inhibit and stimulate DAergic neurotransmission, 
respectively, upon the administration of cocaine (Zanetti et al., 2007) or nicotinic agonists 
(Lichtensteiger et al., 1982; Clarke et al., 1985a; Sorenson et al., 1998; Tapper et al., 
2004; Nashmi et al., 2007). Since it is shown here that ‘binge’ cocaine region- 
specifically increases a4p2* receptors after its chronic administration, the emergence of a 
protracted locomotor activity response in place of stereotypy in cocaine+DhBE mice may 
reflect the consequences of blocking a4p2* nAChRs at a certain level of cocaine-induced 
upregulation.
To further investigate the physiological significance of a4p2* nAChR upregulation in 
cocaine-related behaviour, C57BL/6 mice were pretreated with nicotine at doses that are 
known to induce maximal, half-maximal, or sub-maximal upregulation of cytisine- 
sensitive epibatidine binding in the mouse brain (Marks et al., 1991; Marks et al., 2004), 
and a single injection of cocaine or cocaine+DhBE was subsequently administered. 
Notwithstanding that the effects of nicotine on cocaine-induced locomotion are age and
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sex dependent (Collins and Izenwasser, 2004), the results of this experiment confirm the 
lack of motor cross-sensitisation between the two substances, extending the findings of 
previous reports across a range of nicotine pretreatment doses (Schenk et ah, 1991; 
Birrell and Balfour, 1998; Itzhak and Martin, 1999; Desai and Terry, 2003). Importantly 
for the present discussion, the pharmacological blockade of a4p2* nAChRs at increasing 
doses of nicotine pretreatment unmasks a crucial role for nicotinic receptor upregulation 
in the motor stimulant effect of acute cocaine. The inverted U-shaped relationship 
between the effects of nicotine-pretreatment and cocaine-induced motor stimulation 
suggests a negative correlation between a4p2* nAChR upregulation and cocaine-induced 
activity. In support of this, the antagonism of a4p2* nAChRs at increasing doses of 
nicotine pretreatment was significantly and linearly linked to acute motor stimulation. 
Therefore, the chronic ‘binge’ and acute cocaine administration data strongly imply that 
the upregulation of a4p2* nAChRs is a behaviourally relevant neurobiological 
commonality that is important for the cholinergic modulation of cocaine-induced effects. 
Indeed, a progressive, region-specific upregulation of nAChRs by chronic cocaine may 
explain why nAChR antagonists are only effective at preventing sensitisation or the 
escalation of cocaine self-administration when repeatedly co-administered with the 
psychostimulant, and not upon their acute administration following chronic cocaine 
treatment (Corrigall et al., 1994; Schoffelmeer et al., 2002; Champtiaux et al., 2006; 
Zanetti et al., 2006; Hansen and Mark, 2007). Moreover, it is shown here that under 
conditions of diminished a4p2* receptor availability, the relative potency of cocaine to 
stimulate locomotion is enhanced by increasing doses of nicotine, without a change in the 
absolute maximal effect of the psychostimulant on motor activity.
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Co-administration of cocaine with MLA resulted in a unique behavioural modification. 
Excessive grooming emerged exclusively following a7 nAChR antagonism, and it was 
evident in the increased time cocaine+MLA treated mice spent engaged in this behaviour. 
Animals in this group were observed to groom to the extent of hair removal, indicating 
the intense nature of their phenotype. The fact that grooming was displayed in a novel, 
habituated context (i.e. activity chambers) might also reflect its severity, since novel 
environments have been suggested to suppress grooming (Berridge et al., 2005). 
Moreover, cocaine+MLA treated mice frequently disrupted their locomotor activity to 
groom, confirming the persisting nature of this behaviour. This type of excessive activity 
is far from what is termed normal, ‘comfort’ grooming (Berridge et al., 1987). Instead, it 
is reminiscent of animal models of stress-induced or compulsive disorders, in which 
paradoxical patterns of grooming are observed (Greer and Capecchi, 2002; Berridge et al., 
2005; Kalueff and Tuohimaa, 2005). Interestingly, stress and obsessive compulsion have 
both been associated with the chronic abuse of cocaine in the clinical setting (Crum and 
Anthony, 1993; Kranzler et al., 1994; S inha et al., 2006).
Evidence suggests that activation of the nigrostriatal system mediates the generation of 
grooming patterns (Berridge and Whishaw, 1992; Aldridge and Berridge, 1998) and that 
enhancement of DAergic nigrostriatal neurotransmission boosts grooming behaviour 
(Campbell et al., 1999; Berridge and Aldridge, 2000). In the present study, no 
differences in dopamine receptor and transporter binding were observed between 
cocaine-treated groups, which is in accordance with studies that have employed the same 
protocol of steady-dose, ‘binge’ administration (Unterwald et al., 1994; Bailey et al., 
2008). Although this does not preclude alterations in receptor function (Bailey et al..
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2008), the decrease in [^H]hemicholinium binding in cocaine+MLA mice, compared to 
cocaine+DhBE treated animals, suggests that the grooming phenotype relates to 
perturbations of cholinergic neurotransmission following a7, but not a4p2* nAChR 
antagonism. Selective labelling of the high affinity choline transporters by 
[^HJhemicholinium is considered to depict in vivo cholinergic neuron activity (Ribeiro et 
al., 2006). The expression and functional capacity of choline transporters are reduced in 
the dopamine transporter knockdown (DAT-KD) mouse, suggesting that a 
hyperdopaminergic system deregulates cholinergic neurotransmission (Parikh et al., 
2006). Of note, DAT-KD mice groom more than wild-type animals, exhibiting abnormal 
patterns of grooming behaviour (Greer and Capecchi, 2002; Berridge et al., 2005). In 
addition, ablation of striatal cholinergic neurons leads to compensatory upregulation of 
a4 nAChR subunits in the SN (Kitabatake et al., 2003). In analogy with all of the 
aforementioned studies, ‘binge’ administration of a dopamine transporter antagonist with 
MLA precipitated an intense grooming phenotype, reduced [^H]hemicholinium binding 
sites, and increased density of a4p2* receptors in the SNc of cocaine+MLA treated 
animals, compared to saline alone. Therefore, the protective role of a7 nAChRs against 
cocaine-induced behavioural disorders may arise by sustaining a balance between 
cholinergic and dopaminergic neurotransmission during repeated exposure to cocaine. 
Antagonistic interactions between cholinergic and dopaminergic systems are often 
described in the literature (Hikida et al., 2001; Hikida et al., 2003). In support of an 
important role for a7 nAChRs in mediating them, intra-accumbal or intra-VTA 
administration of MLA has been shown to significantly enhance cocaine-induced 
dopamine release (Zanetti et al., 2007).
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Following 14 days of withdrawal from ‘binge’ cocaine treatment, the enhanced cytisine- 
sensitive [^^^IJepibatidine binding in the VTA and SNc of cocaine-treated animals 
returned to baseline levels. This observation is in agreement with findings of previous 
studies in rodents and humans, which have established that the numerical upregulation of 
P2 subunit-containing nAChRs is a reversible phenomenon (Marks et al., 1985; Collins et 
al., 1990; Breese et al., 1997). Indeed, heteromeric nAChR binding levels have been 
shown to return to control values within 7 to 10 days after the cessation of nicotine 
administration in mice (Marks et al., 1985). The present results thus demonstrate that 
cocaine regulates the a4p2* component of the nicotinic cholinergic system in a similar 
way to nicotine, both during its chronic administration, and upon subsequent 
psychostimulant withdrawal. This suggests that the neurochemical mechanisms 
mediating the effects of nicotine and cocaine in the SNc and the VTA share common 
features, at least with regards to the impact of the two substances on a4p2* nAChR 
density.
Drug-induced decreases of nAChR binding have only occasionally been reported in the 
literature, since both agonists and antagonists at nicotinic receptors have been 
consistently shown to induce receptor upregulation (see Section 1.1.3.3). Moreover, as 
mentioned before, nAChR upregulation does not occur permanently; it persists with a 
time course that depends on the dose and duration of prior nicotine exposure. [^^^I]a- 
bungarotoxin binding sites, in particular, have been shown to return to contol levels 
within 2 to 4 days following termination of nicotine treatment (Miner and Collins, 1989; 
Collins et al., 1990). In this respect, the observation that a7 nicotinic receptors are 
significantly reduced in the VTA of animals chronically withdrawn from cocaine, albeit
116
novel and intriguing is difficult to interpret. Decreased a7 nAChR binding has been 
implicated in the pathohysiology of various neuropsychiatrie disorders, including 
schizophrenia (Mathew et al., 2007), Parkinson’s (Burghaus et al., 2003) and Alzheimer’s 
(Wevers et al., 1999) disease. Interestingly, prolonged cocaine abuse is characterised by 
severe mood disturbances, ranging from depression and anxiety into the etreme of 
paranoia (Cadet and Bolla, 1996; Lejoyeux et al., 2000). In the current study, blockade 
of a7 receptors during ‘binge’ cocaine treatment induced an intense grooming behaviour, 
which is reminiscent of animal models of compulsive or stress-induced syndromes. One 
can therefore speculate that withdrawal from chronic cocaine unmasks a permanent 
neuroadaptation in the regulation of a7 nAChRs, which relates to the observed grooming 
phenotype and that is solely characteristic of this drug class. Importantly, the observation 
that a7 nAChRs decrease following prolonged withdrawal from cocaine confirms that the 
nicotinic cholinergic system is part of the neurochemical circuitry that is affected by 
chronic cocaine administration.
From a neurobiological perpective, the decrease in [^^^I]a-bungarotoxin binding sites in 
the VTA of cocaine withdrawn animals may simply reflect some compensatory response 
to the increased a4p2* nAChR density, which was observed in the same brain region 
following chronic ‘binge’ administration of cocaine. It has been shown that chronic 
nicotine cell-specifically desensitises p2* nAChRs in the mouse VTA, but also triggers 
an a7 mediated mechanism that counteracts this inactivation (Besson et al., 2007). To the 
extent that cocaine and nicotine share common neurobiological processes, the observed 
reduction in the density of a7 nAChRs may constitute the long term expression of this 
compensatory process in the VTA of cocaine withdrawn mice. Although a7 nAChRs do
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not upregulate in response to chronic ‘binge’ cocaine, one cannot preclude that the 
psychostimulant mobilises and permanently depletes a large reserve pool of nicotinic 
receptors in the VTA, a neuroadaptation that is expressed after the cessation of chronic 
drug administration. Indeed, while quantitative autoradiography measures nAChRs 
present in the cytosol and on cell membranes, the majority of a7 nAChRs in the rodent 
VTA has been shown to reside in the cytoplasm (Jones and Wonnacott, 2004). Therefore, 
although the absolute numbers of a7 nAChRs within a cell may not change, perhaps the 
numbers of receptors with functional, synaptic roles in the VTA is actually increased 
after prolonged cocaine use, and decreases upon cocaine withdrawal. It is thus possible 
that the reduction in [^^^I]a-bungarotoxin binding sites of cocaine withdrawn animals 
represents drug-induced, permanent alterations in the functional balance between p2* and 
a7 nAChR in the VTA.
No changes in the density of D1 and D2 dopaminergic receptors and transporters were 
observed following prolonged withdrawal from ‘binge’ cocaine administration. This is 
consistent with several other reports, which have applied a similar protocol of intermittent 
cocaine administration to examine alterations in the regulation of the dopaminergic 
system during cocaine abstinence (King et al., 1994; Maggos et al., 1998). Nevertheless, 
it has been demonstrated that receptor density does not necessarily relate to receptor 
function, and it would therefore be interesting to examine dopaminergic receptor 
coupling in response to chronic cocaine administration and withdrawal (Bailey et al., 
2004b; Bailey et al., 2008).
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In conclusion, nicotinic receptor subunit antagonism caused a progressive, subtype 
specific dissociation of cocaine-induced behaviours, following the chronic, ‘binge’ 
administration of the psychostimulant. Genetic evidence has linked a risk allele for 
nicotine dependence with a protective role in cocaine addiction (Grucza et al., 2008). 
The present results also imply a protective role for nicotine in cocaine-induced behaviour, 
and further suggest a subunit-specific involvement of the nicotinic cholinergic system in 
the behavioural effects of chronic cocaine. Upregulation of a4p2* nAChRs mediates the 
stimulatory and stereotypic effects of the psychostimulant, whereas a7 nAChRs are 
protective against an intense phenotype that is reminiscent of cocaine-related behavioural 
disorders. An important implication of the present report is that the co-abuse of nicotine 
with cocaine can both enhance stimulation and protect against cocaine-induced 
behavioural abnormalities, depending on the availability of distinct nAChR subtypes. 
The face-validity of this assumption is supported by surveys in cocaine dependent 
individuals, who report both stimulant-enhancing and calming effects of cigarette 
smoking (Wiseman and McMillan, 1998). The clear-cut behavioural dissociation that 
arises from the antagonism of different nAChR subunits after chronic cocaine 
administration suggests that manipulation of the nicotinic cholinergic system has the 
potential to influence treatment strategies for cocaine dependence, and implicates a tailor- 
made pharmacological approach for the alleviation of cocaine abuse symptomatology.
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4 QUANTITATIVE AUTORADIOGRAPHY OF HETEROMERIC AND 
HOMOMERIC NEURONAL nAChR SUBTYPES IN C57BL/6 MICE, 
FOLLOWING CHRONIC MORPHINE TREATMENT AND WITHDRAWAL
4.1 Introduction
Opiate drugs have a long medical history in the treatment of pain, but their clinical use is 
limited by severe side effects, including respiratory depression, constipation, and 
vomiting (reviewed in Raehal and Bohn, 2005). In addition, opiates are highly addictive, 
and their abuse-related potential renders them a leading cause of death, morbidity, and 
productivity loss in society (reviewed in Gruber et al., 2007). Morphine is the 
prototypical opioid that is isolated from the plant extracts of opium poppy, and its 
analgesic and addictive properties are mainly exerted through MOP receptors in the CNS 
(reviewed in Kieffer, 1999). While the role of dopamine in mediating the reinforcing 
effects of morphine is well established, the involvement of other neurotransmitter 
systems has been less investigated. Recently, several studies have suggested that the 
nicotinic cholinergic system influences morphine-induced behaviour and neurochemistry 
(see Section 1.3.2). Thus, morphine-induced conditioned place prereference (GPP) is 
enhanced following pretreatment with nicotine in both rats (Shippenberg et al., 1996; 
Biala and Weglinska, 2004) and mice (Vihavainen et al., 2008a), whereas morphine’s 
locomotor activity in mice is potentiated after nicotine administration (Biala and 
Weglinska, 2004; Vihavainen et al., 2006). In morphine-treated animals, nicotine has 
been shown to attenuate naloxone-induced conditioned place aversion (Araki et al., 2004) 
and withdrawal jumping (Zarrindast and Farzin, 1996; Haghparast et al., 2008), 
suggesting that nAChRs are involved not only in morphine reward, but also in the
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negative affective and somatic states that characterise morphine abstinence. Furthermore, 
infusion of the potent aSp4 nAChR antagonist 18-methoxycoronaridine (18-MC) into 
brain rich cholinergic nuclei, such as the medial habenula and the interpeduncular nucleus, 
reduces morphine self-administration and attenuates sensitisation of morphine-induced 
dopamine release (Click et al., 2002; Click et al., 2006; Taraschenko et al., 2007a). 
Therefore, an increasing body of evidence indicates that nAChRs can modulate the 
effects of morphine administration.
Neuronal nAChRs constitute a heterogeneous family of pentameric ligand-gated ion 
channels, with unique pharmacological properties and distinct topographical distribution 
(see Section 1.1.2). Based on the evidence for interactions between morphine and the 
nicotinic cholinergic system, it was hypothesized that the effects of morphine treatment 
and withdrawal could be depicted at the neurochemical level, as changes in the density of 
different nicotinic receptor subtypes. To this end, quantitative autoradiography of 
heteromeric and homomeric nAChRs was performed in brain sections of morphine- 
treated mice. To investigate the involvement of the nicotinic cholinergic system in 
morphine withdrawal, quantitative autoradiography of nAChRs was performed in brain 
sections of mice that were acutely and chronically withdrawn from morphine 
administration. For the purposes of this study, an escalating, ‘intermittent’ protocol of 
morphine treatment was applied, which resembles human patterns of opiate abuse (Kreek 
et al., 2002).
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4.2 Materials and Methods
4.2.1 Animals and drug treatment
Male C57BL/6 mice (B&K Universal Ltd, Hull, UK), weighing 20-25 g were used. 
Animals were housed individually in a temperature-controlled room, under a 12 h 
light/dark schedule. Food and water were available ad libitum. All studies were 
conducted according to protocols approved by the Home Office, UK, and in accordance 
with European Community Council directive 86/609/EEC. Animals were habituated to 
handling for a period of 7 days, prior to treatment. Following acclimatization, 
subcutaneous (s.c.) injections of either saline or morphine were administered to C57BL/6 
mice in an ‘intermittent’ escalating dose paradigm, in order to mimic the pattern of opiate 
self-administration in human abusers (Kreek et al., 2002). Animals were separated into 
five groups:
Group 1 (n=6): Saline for 7 days, followed by Saline on day 8
Group 2 (n=6): Morphine for 7 days, followed by Morphine on day 8 (chronic treatment) 
Group 3 (n=6): Morphine for 7 days, followed by Saline on day 8 (acute withdrawal) 
Group 4 (n=6): Saline for 7 days, followed by 7 day withdrawal
Group 5 (n=6): Morphine for 7 days, followed by 7 day withdrawal (chronic withdrawal)
Two injections were given daily (5 pm and 9 am) in accordance with protocols 
investigating opiate-induced addictive processes in animal models of drug abuse 
(Spanagel, 1995; Muller and Unterwald, 2004). Mice in the escalating group received 
morphine at 2 x 20 ml/kg/inj on days 1 and 2, 2 x 40 mg/kg/inj on days 3 and 4, 2 x 80 
mg/kg/inj on days 5 and 6 , and 2 x 100 mg/kg/inj on day 7, followed by a single 
morphine injection (100 mg/kg) on day 8 (chronic treatment group). A separate group of
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animals was treated under the same protocol, with the exception of receiving an injection 
of saline instead of morphine on day 8 (acute withdrawal group). Two separate groups 
received ‘intermittent’ injections of morphine or saline for 7 days, and were subsequently 
allowed to withdraw from treatment for a period of 7 days (chronic withdrawal). The 
maximum daily morphine dose used in the study was 200 mg/kg, as illustrated in Table 
4.1.
Day 1 2 3 4 5 6 7 8
Dose per injection 
(mg/kg)
20 20 40 40 80 80 100 100
Daily dose 
(mg/kg) 40 40 80 80 160 160 200 100
Table 4.1 Daily morphine intake
The dose per injection and the maximum daily morphine dose, administered to C57BL/6 mice subcutaneously, using a 
chronic ‘intermittent’ escalating dose paradigm.
Animals in the chronic treatment and acute withdrawal groups were killed 2 h following 
the last injection of saline or morphine on day 8 . Mice in the chronic withdrawal groups 
were killed 7 days after the end of the ‘intermittent’ escalating dose morphine treatment. 
All mice were killed by cervical dislocation. Brains were immediately removed, snap 
frozen into isopentane at -25 °C and stored at -80 °C until further processed for 
quantitative autoradiography.
4.2.2 Quantitative autoradiography o f a4p2* and a?nicotinic cholinergic receptors 
Tissue sectioning was carried out at -21 °C using a Zeiss Microm HM505E cryostat. 20 
pm frozen coronal sections were cut at 300 pm intervals, from rostral to caudal levels. 
On the day of assay, slides for labeling a4p2* and a7 nAChRs were thawed to room
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temperature for 20  min, prior to incubation with [^^^I]epibatidine and 
bungarotoxin, respectively. Sections for analysis were derived from 6 brains from each 
of the five treatment groups (n=6  per group). Multiple, adjacent sections from all groups 
were processed together in a paired binding protocol. Radioligand bound sections were 
apposed to Kodak BioMax MR-1 film (Sigma-Aldrich, UK), along with appropriate 
microscale standards, to allow quantification. Detailed experimental protocols for 
autoradiographic procedures can be found in Section 3.2.6.
For nAChRs, radioligand bound sections were apposed to film for 24h. Structures of 
exceptionally high nAChR density, including the medial habenula, fasciculus retrofiexus, 
and the interpeduncular nucleus were apposed for a period of 6h, to avoid film saturation. 
All structures were identified by reference to the mouse brain atlas of Franklin and 
Paxinos, (2001), and analysed using an MCID image analyser (Image research, Linton, 
UK).
4.2.3 Statistical analysis
Two-way ANOVA for the factors treatment and region was used for the comparison of 
quantitative measures of a4(32* and a7 nicotinic receptors in brain regions of chronically 
treated and acutely withdrawn morphine and saline C57BL/6 mice. The effects of 
prolonged withdrawal from morphine treatment on nAChR density were analysed 
separately using two-way ANOVA (independent variables treatment and region).
Structures of the habenulo-interpeduncular pathway were quantified using a 6h exposure 
to film, because of the high densities of heteromeric nAChRs in this cholinergic system. 
Therefore, comparisons between structures of high nicotinic receptor density were
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performed using a separate two away ANOVA (independent factors treatment and 
region).
4.3 Results
4.3.1 Quantitative autoradiography o f heteromeric nAChRs following chronic 
morphine administration and withdrawal
The present study was conducted to determine whether morphine or withdrawal from 
morphine alters the receptor component of the nicotinic cholinergic system. Figure 4.1 
shows representative autoradiograms of total and cytisine-resistant [^^^I]epibatidine 
binding in coronal brain sections of morphine-treated, and of acutely and chronically 
morphine-withdrawn animals. The ‘intermittent’ administration of escalating doses of 
morphine, as well as the acute withdrawal from morphine treatment had no effect on the 
density of total, cytisine-sensitive, and cytisine-resistant [^^^I]epibatidine binding, 
compared to saline treatment. Similarly, no significant differences in heteromeric 
nAChR binding density were observed between groups that were chronically withdrawn 
from saline or morphine. The density of total, cytisine-sensitive, and cytisine-resistant 
[^^^I]epibatidine binding is detailed for all areas analysed in Tables 4.2, 4.3, and 4.4, 
respectively. Non specific [^^^I]epibatidine binding was indistinguishable from film 
background.
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T o ta l  p ^ ^ l] e p lb a t ld in e
Cytisine-resistant
fmoi/mg Chronic Saiine Chronic Morphine Acute Withdrawai p2S|]epibatidine NSB
T o ta l p 2 ® l]ep ib a tld in e
B
S a l in e  M o rp h in e
fm o l/m g  7 d a y  w ith d ra w a l  7  d a y  w ith d ra w a l
C y t is in e - r e s i s t a n t
p25i]epibatidine N SB
Figure 4.1 Representative autoradiogram s o f [*^T]epibatidine binding following A. chronic m orphine treatm ent 
and acute morphine withdrawal, and B. long term withdrawal from ‘interm ittent’ m orphine adm inistration
C57BL/6 mice were subcutaneously administered morphine using an ‘intermittent’ escalating dose paradigm. 
Following 8 days of morphine administration, and after the acute and prolonged withdrawal from morphine treatment, 
animals were killed by cervical dislocation, their brains were immediately removed, frozen into isopentane, and 
subsequently processed for quantitative autoradiography. The panels show coronal brain sections cut at the level of the 
caudate (bregma 0.74 mm) and thalamus (bregma -2.54 mm). To label a4|32* receptors, adjacent sections were 
incubated for 2 hrs with 100 pM of ['^ I^Jepibatidine alone or in the presence of 20 nM cytisine and 300 pM (-) nicotine 
hydrogen tartrate, to calculate non-specific binding (NSB). NSB was indistinguishable from film background. 
Sections were apposed to Kodak BioMax MR-1 film for a period of 24 hrs, except for areas of high nAChR density, 
such as the medial habenula, the fasciculus retrofiexus, and the imterpeduncular nucleus, which were laid to film for 6 
hrs to avoid film saturation. The colour bar indicates a pseudo-colour interpretation of black and white image density, 
calibrated in fmol/mg of tissue equivalent.
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T o ta l [ l ] e p ib a t id ln e  b in d in g  (fm o l/m g  t i s s u e  e q u iv a le n t)
Region
S a l in e M o rp h in e
M o rp h in e  1 D ay 
W ith d ra w a l
S a l in e  7  D ay 
W ith d ra w a l
M o rp h in e  7 D ay 
W ith d ra w a l
Medial h ab en u la 122.0 ± 24.6 111.8 ± 23.7 120.4 ± 26.4 130.2 ± 39.8 126.0 ± 35.7
F a sc icu lu s  re tro fiex u s 119.8 ± 28.5 88.9 ± 21.1 80.9 ± 22.8 146.8 ± 49.8 102.4 ± 29.9
In te rp ed n cu la r n u c le u s 129.6 ± 24.9 97.2 ± 18.7 119.2 ± 31.1 162.4 ± 54.8 139.9 ± 40.6
Frontal a s so c ia tio n  co rtex 6.6 ± 2.3 4.5 ± 1.2 5.9 ± 1.5 6.2 ± 1.7 6.6 ± 1 .3
Preiim bic  co rtex 5.6 ± 2.1 3.3 ± 1.0 5.1 ± 1.5 6.2 ± 2.0 5.2 ± 1.1
C ingu la te  co rtex 7.7 ± 2.6 6.7 ± 1.8 4.8 ± 1.4 7.7 ± 1.2 9.1 ± 1.8
N uc ieus a c c u m b e n s  
C ore 7.1 ± 1.9 7.2 ± 2.0 8.1 ± 1.6 7.4 ± 1.8 7.4 ± 1.4
Sheli 7.1 ± 1.8 7.6 ± 2.0 6.9 ± 1.2 7.8 ± 1.7 7.6 ± 1.4
C a u d a te  pu tam en 9.9 ± 2.5 9.8 ± 2.7 7.7 ± 1.5 10.3 ± 2.0 11.9 ± 2.3
Prim ary m o to r co rtex 6.0 ± 1.9 5.3 ± 1.2 5.2 ± 1.3 7.9 ± 2.0 8.1 ± 1.6
S e c o n d ary  m o to r co rtex 6.5 ± 2.3 5.3 ± 1.2 4.6 ± 1.2 7.9 ± 1.0 8.0 ± 1.6
H ip p o cam p u s 3.2 ± 1.4 2.6 ± 1.0 2.6 ± 0.9 3.0 ± 0.3 3.3 ± 1.4
A nteroven tra l th alam ic  
n u c ie u s 22.0 ± 5.5 24.6 ± 6.1 25.7 ± 5.6 23.6 ± 5.4 24.8 ± 5.3
P o s te r io r  th a lam ic  n u c le a r 
g ro u p 23.2 ± 7.1 23.5 ± 5.7 21.3
+ 4.3 29.5 ± 8.8 22.6 ± 6.3
L ateral p o s te rio r th a lam ic  
n u c ie u s 24.3 ± 7.1 25.0 ± 6.0 22.6 ± 4.8 29.5 ± 9.2 22.0 ± 5.9
Medial g en icu la te  n u c ie u s 19.4 ± 2.4 20.8 ± 4.4 18.4 ± 4.4 14.0 ± 3.7 17.4 ± 5.6
V entral latera l g en icu la te  
n u c le u s 22.5 ± 5.4 27.7 ± 6.7 24.1 ± 4.9 28.9 ± 6.9 27.8 ± 7.9
D orsal latera l g en icu la te  
n u c le u s 26.5 ± 7.2 33.7 ± 8.2 33.5 ± 7.2 36.7 ± 8.9 35.3 ± 9.5
Visual C ortex 5.6 ± 1.4 6.1 ± 1.4 5.7 ± 2.0 7.4 ± 2.2 7.0 ± 2.2
Superficial gray  layer o f th e  
su p e rio r  co iiicu iu s 24.1 ± 7.3 25.1 ± 6.0 18.4 ± 7.0 25.2 ± 5.9 23.5 ± 6.2
V entral teg m en ta l a rea 21.0 ± 5.9 18.0 ± 5.1 15.9 ± 3.1 18.7 ± 4.4 19.1 ± 3.5
S u b s ta n tia  nigra, p a rs  
co m p a c ta 21.1 ± 5.9 16.4 ± 4.5 16.5 ± 3.0 19.5 ± 5.0 14.4 ± 3.7
Table 4.2 Q uantitative autoradiography o f  total [^^®I]epibatidine binding, following chronic m orphine  
treatm ent and withdrawal
The effect of ‘intermittent’ escalating-dose morphine administration and withdrawal on the nicotinic cholinergic system 
of C57BL/6 mice was explored using quantitative autoradiography of nAChRs. Values represent the mean specific 
binding of total [^ ^ I^Jepibatidine ± SEM in brain regions of 6 animals per group. Two-way ANOVA showed no 
treatment [F(2,273)=0.3, P>0.05] or treatment x region interaction effects [F(36,273)=0.2, P>0.05] on total 
[^ ^ I^Jepibatidine binding after ‘intermittent’ morphine administration and following acute morphine withdrawal. Areas 
of the interpeduncular pathway were analysed separately by two-way ANOVA, which showed no effects of treatment 
[F(2,30)=0.8, P>0.05], and no treatment x region interaction effects [F(4,30)=0.1, P>0.05] on total ['^^I]epibatidine 
density. Similarly, long term withdrawal from morphine treatment did not alter total [^^ I^Jepibatidine binding density in 
brain areas that were analysed using either the 24 hr [F(l,187)=0.3, P>0.05] or the 6 hr film exposure [F(l,18)=0.5, 
P>0.05].
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C y t is in e - s e n s i t iv e  [ l ] e p lb a t id ln e  b in d in g  ( fm o l/m g  t i s s u e  e q u iv a le n t )
Region
S a l in e M o rp h in e
M o rp h in e  1 D ay  
W ith d ra w a l
S a l in e  7  D ay  
W ith d ra w a l
M o rp h in e  7  D ay  
W ith d ra w a l
M edial h a b en u la 10.7 ± 2.9 13.6 ± 2.2 9.3 ± 3.8 4.6 ± 1.2 13.3 ± 1.4
F a sc ic u lu s  re tro fiex u s 21.5 ± 5 .6 20.0 ± 5.2 9.6 ± 3.5 18.8 ± 5.8 17.8 ± 6.1
In te rp e d n cu la r  n u c ie u s 9.2 ± 1 .0 12.2 ± 3.5 1.9 ± 0.8 19.4 ± 1.5 20.0 ± 7.4
F ron ta l a s s o c ia t io n  co rte x 4.8  ± 1 .5 3.0 ± 1.0 5.1 ± 1.3 4.8 ± 0.9 5.3 ± 1.0
P re iim bic  c o rte x 4.0  ± 1 .3 2.7 ± 0.9 4.5 ± 1.3 5.1 ± 1.7 4.2  ± 0.8
C in g u la te  c o rte x 5.7 ± 2.6 5.2 ± 1.7 3.9 ± 0.9 6.4 ± 1.0 7.5 ± 1.7
N u c leu s a c c u m b e n s
C ore 3.9 ± 1.3 4.6 ± 1.3 4.7 ± 0.8 5.0 ± 1.1 4.9  ± 0.9
Shell 3 .7 ± 1 .4 4.9 ± 1.4 4.2 ± 0.8 5.3 ± 1.1 5.1 ± 1.1
C a u d a te  p u tam e n 6.1 ± 2.2 7.1 ± 2.0 5.1 ± 1.0 7.7 ± 1.3 9.0 ± 2.1
P rim ary  m o to r c o rte x 4.3 ± 1.8 4.1 ± 1.1 4.6 ± 0.9 6.8 ± 1.1 6.7 ± 1.6
S e c o n d a ry  m o to r c o rte x 5.0 ± 2.2 4.2 ± 1.1 4.1 ± 0.9 6.8 ± 0.9 6.7 ± 1.6
H ip p o cam p u s 1.7 ± 0 .7 1.9 ± 0.6 1.8 ± 0.5 2.1 ± 0.3 1.8 ± 0.6
A nte ro v en tra l th a lam ic  
n u c le u s 13.0 ± 3.7 14.5 ± 4.0 17.9 ± 4.3 15.0 ± 3.8 15.4 ± 3.3
P o s te r io r  th a la m ic  n u c le a r  
g ro u p 16.6 ± 5 .4 18.1 ± 4.1 16.6 ± 4.3 22.2 ± 7.3 17.4 ± 5.5
L ateral p o s te r io r  th a lam ic  
n u c ie u s 17.2 ± 5.1 18.2 ± 5.4 17.8 ± 4.7 21.6 ± 7.5 16.2 ± 4.7
M edial g e n ic u la te  n u c ie u s 15.9 ± 3 .3 16.8 ± 4.0 13.1 ± 5.1 9.0 ± 3.0 13.0 ± 4.0
V entral la te ra l g e n ic u la te  
n u c le u s 9.3 ± 2.5 14.0 ± 4.3 16.6 ± 4.9 17.0 ± 4.1 14.7 ± 4.3
D orsal latera l g e n ic u la te  
n u c le u s 15.1 ± 4 .2 19.7 ± 6.1 24.1 ± 6.8 25.5 ± 6.3 22.5 ± 6.7
V isual C ortex 4.6 ± 1.3 4.8 ± 1.4 4.7 ± 2.0 6.6 ± 2.2 6.3 ± 2.1
S up erfic ia l g ray  lay er o f th e  
su p e r io r  c o iiicu iu s 13.0 ± 2 .8 18.3 ± 5.7 10.5 ± 6.6 14.4 ± 4.8 15.7 ± 3.9
V entral teg m e n ta l a re a 15.1 ± 5 .7 12.7 ± 4.2 8.4 ± 2.5 10.0 ± 3.0 12.9 ± 2.9
S u b s ta n tia  n ig ra , p a rs  
c o m p a c ta 16.7 ± 6 .1 12.4 ± 3.6 11.4 ± 3.0 13.1 ± 3.9 10.6 ± 3.5
Table 4.3 Quantitative autoradiography o f  cytisine-sensitive epibatidine binding, follow ing chronic  
morphine treatm ent and withdrawal
Values represent the mean specific binding of cytisine-sensitive ['^^I]epibatidine ± SEM in brain regions of 6 animals per 
group. Two-way ANOVA showed no treatment [F(2,270)=0.1, P>0.05] or treatment x region interaction effects 
[F(36,270)=0.3, P>0.05] on cytisine-sensitive [^ ^ I^Jepibatidine binding. Areas of the interpeduncular pathway were 
analysed separately by two-way ANOVA, which showed no effects of treatment [F(2,30)=1.9, P>0.05], and no treatment x 
region interaction effects [F(4,30)-0.3, P>0.05] on cytisine-sensitive ['^ I^Jepibatidine density. Similarly, long term 
withdrawal from morphine treatment did not alter cytisine-sensitive ['^ I^Jepibatidine binding density in brain areas that were 
analysed using either the 24 hr [F(l,187)=0.1, P>0.05] or the 6 hr film exposure [F(l,18)=0.0, P>0.05].
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C y tis in e - r e s i s ta n t l]e p ib a tid in e  b in d in g  (fm o l/m g  t i s s u e  e q u iv a le n t)
R egion
S a lin e M o rp h in e
M o rp h in e  1 D ay 
W ith d ra w a i
S a lin e  7 D ay 
W ith d raw a l
M o rp h in e  7 D ay 
W ith d ra w a l
Medial h ab en u la 111.3 ± 22.8 98.2 ± 21.6 111.1 ± 23.4 125.5 ± 46.7 112.6 ± 24.6
F a sc icu lu s  re tro fiex u s 98.3 ± 22.9 69.0 ± 16.9 71.3 ± 20.8 128.0 ± 42.4 84.6 ± 23.8
In terp ed n cu la r n u c ie u s 120.4 ± 37.4 85.0 ± 17.8 117.3 ± 32.9 143.0 ± 40.9 119.9 ± 37.1
C ingulate  co rtex  
N ucieus a cc u m b e n s
2.0 ± 0.7 1.5 ± 0.6 0.9 ± 0.4 1.3 ± 0.5 1.6 ± 0.7
C ore 3.2 ± 1.6 2.6 ± 0.9 3.4 ± 1.4 2.4 ± 0.8 2.5 ± 0.8
Shell 3.4 ± 1.6 2.7 ± 0.8 2.7 ± 0.2 2.6 ± 0.7 2.5 ± 0.6
C au d ate  pu tam en 3.8 + 1.9 2.7 ± 0.8 2.6 ± 1.0 2.6 ± 0.8 2.9 ± 0.9
A nteroventral th alam ic  
n u c ieu s
9.0 ± 2.3 10.1 ± 2.9 7.9 ± 1.6 8.5 ± 2.3 9.4 ± 2.0
P o s te rio r  th a lam ic  n u c lea r 6.7 ± 2.1 5.4 ± 1.6 4.7 ± 1.6 7.3 ± 2.0 5.2 ± 1.9
Lateral p o ste rio r thalam ic  
n u c ieu s
7.1 ± 2.4 6.8 ± 1 .3 4.8 ± 1.6 7.9 ± 1.9 5.8 ± 2.0
Medial g en icu la te  n u c leu s 3.5 ± 0.9 4.0 ± 0.8 5.3 ± 1.2 5.0 ± 0.8 4.4  ± 0.9
Ventral lateral g en icu la te  
n u c ieu s
13.2 ± 4.0 13.7 ± 3.2 7.5 ± 2.7 11.9 ± 3.8 13.1 ± 4.1
D orsal lateral g en icu la te  
n u c leu s
11.4 ± 3 .2 14.0 ± 2.8 9.4 ± 2.2 11.2 ± 3.6 12.8 ± 3.7
Superficial gray  layer o f th e  
su p e rio r  co iiicu ius
11.1 ± 5.1 6.7 ± 1.5 7.9 ± 1.7 10.8 ± 4.4 7.7 ± 3.2
V entral teg m en ta l a rea 5.9 ± 1.4 5.2 ± 1.1 7.4 ± 0.8 8.6 ± 1.6 6.2 ± 1.4
S u b s ta n tia  nigra, p a rs  
co m p acta 4.4 ± 1.5
4.1 ± 1.2 5.1 ± 1.7 6.4 ± 1.2 3.8 ± 0.8
Table 4.4 Quantitative autoradiography o f  cytisine-resistant [^ “ l]epibatidine binding, following m orphine 
treatm ent and w ithdraw al
Values represent the mean specific binding of cytisine-resistant epibatidine ± SEM in brain regions of 6 animals 
per group. Two-way ANOVA showed no treatment [F(2,181)=0.8, P>0.05] or treatment x region interaction effects 
[F(25,181)=0.5, P>0.05] on cytisine-resistant [*^ I^]epibatidine binding. Areas of the interpeduncular pathway were 
analysed separately by two-way ANOVA, which showed no effects of treatment [F(2,30)=0.9, P>0.05], and no 
treatment x region interaction effects [F(4,30)=0.2, P>0.05] on cytisine-resistant [^ ^ I^Jepibatidine density. Similarly, 
long term withdrawal from morphine treatment did not alter cytisine-resistant ['^ I^Jepibatidine binding density in brain 
areas that were analysed using either the 24 hr [F(l,126)-0.4, P>0.05] or the 6 hr film exposure [F(l,18)=0.8, P>0.05].
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4.3.2 Quantitative autoradiography of a l  nAChRs following chronic morphine 
administration and withdrawal
[^^^I]a-bungarotoxin autoradiography was performed to examine the effects of morphine 
treatment and withdrawal on a7 nAChR density. Representative autoradiograms of a7 
nAChR binding sites in coronal brain sections from saline and morphine-treated and 
withdrawn animals are shown in Figure 4.2. Escalating doses of morphine administration 
had no effect on a7 nAChR binding, compared to saline treatment. Similarly, acute or 
chronic withdrawal from ‘intermittent’ morphine administration did not alter [^^^I]a- 
bungarotoxin binding density, compared to saline controls. The mean density of specific 
['^^I]a-bungarotoxin binding in brain regions of saline and nicotine treated mice is shown 
for all areas analysed in Table 4.5.
S a lin e  M o rp h in e
fm o l/m g  C h ro n ic  S a l in e  C h ro n ic  M o rp h in e  A c u te  W ith d ra w a l 7 d a y  w ith d ra w a l 7 d a y  w ith d ra w a l N SB
Figure 4.2 Representative autoradiogram s o f [ I]a-bungarotoxin binding following m orphine treatm ent and 
withdrawal
C57BL/6 mice were subcutaneously administered morphine using an ‘intermittent’ escalating dose paradigm. Following 8 days of 
morphine administration and after the acute and prolonged withdrawal from morphine treatment, animals were killed by cervical 
dislocation, and their brains were immediately removed, frozen into isopentane, and subsequently processed for quantitative 
autoradiography. The panels show coronal brain sections cut at the level of the caudate (bregma 0.74 mm) and hippocampus (bregma 
-1.70 mm). To label a l  nAChRs, adjacent sections were incubated for 3 hrs at room temperature with 3 nM ['^^I]a-bungarotoxin 
alone or in the presence of ImM of nicotine salt to calculate non-specific binding. Sections were apposed to Kodak BioMax MR-1 
film for a period of 7 days. The bar shows black and white image density calibrated in fmol/mg of tissue equivalent. Abbreviations: 
NSB: Non Specific Binding.
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[^^® l]a-bungarotoxin b in d in g  (fm ol/m g t i s s u e  e q u iv a le n t)
i\eg ion
Saline M orphine M orphine 1 Day W ithdrawal
Saline 7 Day 
W ithdrawal
M orphine 7 Day 
W ithdrawal
F ro n ta l a s s o c ia t io n  c o r te x 12.6 ± 4 .2 12.5 ± 2.2 12.0 ± 3 .0 10.3  ± 1.9 13.4 ± 3 .1
C in g u la te  c o r te x 12.0 ± 2 .4 11.3 ± 2 .2 9.9  ± 0.7 18.6 ± 3.6 15.3 ± 2 .5
C a u d a te  p u ta m e n 18.7 ± 6 .0 10.7 ± 3 .4 13.1 ± 2 .6 21 .7  ± 4 .1 23.1 ± 2.7
E n d o p irifo rm  n u c le u s ,  d o rsa l 25.9 ± 8 .6 19.1 ± 5.1 22 .3  ± 4.8 24 .5  ± 6.5 31.6  ± 4 .9
P rim ary  m o to r  c o r te x 17.8 ± 5 .2 12.1 ± 3.9 11.6 ± 1 .5 20 .8  ± 4 .8 18.1 ± 4 .5
C la u s tru m 25.8 ± 9 .0 17.7  ± 5.0 18.7 ± 3 .3 21 .3  ± 3 .9 26.8  ± 3 .0
P o s te r io r  th a la m ic  n u c le a r  
g ro u p
13.7 ± 4 .1 10.2 ± 2 .5 7.2 ± 1 .4 14.0 ± 3.9 15.0 ± 5 .2
H ip p o c a m p u s , CA1 17.4 ± 3 .2 13.8 ± 3.1 14.6 ± 4 .4 23 .6  ± 6.3 23 .4  ± 3.5
H ip p o c a m p u s , CA3 19.0 ± 4 .1 19.8 ± 3.7 21.6  ± 4 .8 24 .9  ± 7.6 22 .6  ± 7 .7
D e n ta te  g y ru s 14.5 ± 3 .0 14.3 ± 4.1 14.7 ± 3 .5 21 .6  ± 5 .2 17.3 ± 6 .9
B a so la te ra l a m y g d a lo id  
n u c le u s
13.2 ± 3 .8 14.3 ± 3.5 11.6 ± 1 .9 24.3  ± 3.4 18.8 ± 3 .9
P o s te ro m e d ia l  c o r tic a l 
a m y g d a lo id  n u c le u s 39.8 ± 9 .6
4 0 .3  ± 8.1 42 .2  ± 8.0 46 .2  ± 2.6 53.6  ± 14.4
M edial a m y g d a lo id  n u c le u s 38.6 ± 6 .3 27 .9  ± 4 .3 27.9 ± 3.4 46 .5  ± 10.0 3 1 .0  ± 5 .1
D o rso m e d ia l h y p o th a la m ic  
n u c le u s
28.8 ± 2 .5 25.4  ± 7.7 24.9 ± 5.9 24 .5  ± 5.1 31 .7  ± 9 .5
V e n tro m e d ia l h y p o th a la m ic  
n u c le u s
19.2 ± 2 .0 22.0  ± 6.4 24.1 ± 2.8 38 .3  ± 10 .2 34 .7  ± 7 .0
L atera l h y p o th a la m u s 16.3 ± 4 .3 13.0 ± 2.9 12.3 ± 4 .0 26.3  ± 2.2 22.6  ± 4 .6
Z o n a  in c e r ta 4 1 .6 ± 8 .7 39.9 ± 8.1 39.6  ± 3.1 39 .6  ± 4 .5 31 .5  ± 1 3 .3
S u p e rf ic ia l  g ra y  la y e r  o f  th e  
s u p e r io r  c o llic u lu s
43.0 ± 4 .5 42 .0  ± 12.7 33.9  ± 4 .0 52 .7  ± 19.2 61.5  ± 1 5 .3
V en tra l te g m e n ta l  a r e a 26.9 ± 2 .0 24.3  ± 4.9 26.3  ± 7.2 24.3  ± 5.9 25 .5  ± 7 .6
S u b s ta n t ia  n ig ra 8.5 ± 0 .7 9 .8  ± 3.8 7.7  ± 2.4 9.9  ± 3.8 11.1 ± 6 .5
Table 4.5 Q uantitative autoradiography o f  [^^®I]a-bungarotoxin binding, following m orphine treatm ent and 
withdrawal
The effect of ‘intermittent’ escalating-dose morphine administration and withdrawal on the nicotinic cholinergic system of 
C57BL/6 mice was explored using quantitative autoradiography of nAChRs. Values of a7 nAChR binding represent the 
mean specific binding of [*^^I]a-bungarotoxin ± SEM in brain regions of 6 animals per group. Two-way ANOVA showed 
no significant effect of treatment [F(2,251)=1.5, P>0.05], and no treatment x region interaction effects [F(38,251)=0.2, 
P>0.05] on o7 nAChR density, following chronic morphine administration and acute withdrawal. In addition, [’^^ I]a- 
bungarotoxin binding was not altered after long term withdrawal from escalating ‘intermittent’ morphine administration 
[F(l,152)=0.0, P>0.05].
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4.4 Discussion
Previously published reports suggest that nicotine and mophine influence each other’s 
effects in various experimental settings (see Section 1.3.2). The aim of the present study 
was to investigate whether the reported behavioural and neurochemical interactions 
between the two substances could be depicted at the nicotinic receptor binding level, 
following morphine treatment and withdrawal. The current results demonstrate no clear 
effects of escalating morphine administration, and of acute and prolonged withdrawal 
from ‘intermittent’ morphine treatment on [^^^Ijepibatidine and [^^^I]a-bungarotoxin 
binding sites. These negative results suggest that interactions between morphine and the 
nicotinic cholinergic sytem do not directly occur at the nAChR density level.
Among the nAChR subtypes that may mediate interactions between morphine and the 
nicotinic cholinergic system, a3p4 receptors have been demonstrated to influence 
morphine’s addictive properties at both the behavioural and neurochemical levels. Thus, 
administration of the synthetic aSp4 antagonist 18-methoxycoronaridine into the medial 
habenula (MHb) and the interpeduncular nucleus (IP) reduces morphine self­
administration (Click et al., 1996), alleviates symptoms of morphine withdrawal (Panchal 
et al., 2005), and blocks dopamine sensitization to repeated morphine treatment 
(Taraschenko et al., 2007a), strongly implying that a3p4 nAChRs in these brain regions 
are involved in morphine reinforcement and withdrawal. Cytisine-resistant 
[^^^I]epibatidine sites constitute the predominant nicotinic receptor binding population in 
the MHb and IP, and are believed to correspond to nAChRs with a pharmacology 
suggestive of aSp4 receptors (Zoli et al., 1998; Whiteaker et al., 2000b; Marks et al..
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2002). These nAChRs, however, are relatively resistant to agonist-induced upregulation 
both in vivo (Nguyen et al., 2003) and in vitro (Wang et al., 1998). Therefore, the 
inherent lack of sensitivity of aSp4 nAChRs to upregulation may account for the absence 
of morphine-induced alterations in [^^^IJepibatidine binding sites in the present study.
Contrary to the effects of chronic cocaine treatment on nAChR density, no change in 
[^^^I]epibatidine and [^^^I]a-bungarotoxin binding was observed following morphine 
administration and withdrawal, suggesting that cocaine-induced nicotinic receptor 
regulation does not generalize to opiates. Upregulation of binding to nAChRs is 
observed after exposure to several nicotinic agonists, including the structural analogues 
of acetylcholine (ACh), methylcarbamylcholine and N, N-dimethylcarbmylcholine 
(Warpman et al., 1998; Whiteaker et al., 1998). Differences in the regulation of ACh 
release between morphine and cocaine may therefore account for the effects of the two 
drugs on nAChR density. Administration of cocaine has been consistently shown to 
enhance acetylcholine release in various brain regions, including the hippocampus 
(Imperato et al., 1992), cerebral cortex (Day et al., 1997), nucleus accumbens (Crespo et 
al., 2006) and striatum (Zocchi and Pert, 1994). On the contrary, in vivo micodialysis of 
opiate-induced ACh release reveals that the levels of neurotransmitter increase, decrease, 
or remain unchanged in response to morphine, depending on its dose and dosing regimen, 
as well as on the brain area under investigation (Rada et al., 1991; Imperato et al., 1996; 
Rada et al., 1996; Taraschenko et al., 2007b). In the interpeduncular nucleus, the acute 
administration of morphine at 5 mg/kg increases ACh release, whereas 20 mg/kg of 
morphine exert the opposite effect, reducing extracellular ACh concentrations 
(Taraschenko et al., 2007b). MOP receptor-mediated activation of cholinergic
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intemeurons in the nucleus accumbens (NAc) has been shown to suppress cholinergic 
activity (Britt and McGehee, 2008), diminishing ACh release following escalating doses 
of moprhine for a period of 8 days (Rada et ah, 1996). Spontaneously or electrically 
evoked ACh release after high doses of morphine is also reduced in slices from the 
mammalian striatum (Arenas et ah, 1990), hippocampus (Jackisch et ah, 1986), thalamus 
(Beani et ah, 1982) and cerebral cortex (Lapchak et ah, 1989). Hence, a possible 
explanation for the distinct effects of cocaine and morphine on nAChR density lies in the 
fact that the two substances differentially regulate cholinergic neuron activity. It is worth 
mentioning that nicotine-induced changes in MOP receptor density have similarly been 
shown to depend on the paradigm of drug administration used. Thus, chronic nicotine 
increases (Wewers et ah, 1999; Walters et ah, 2005), decreases (Galeote et ah, 2006; 
Marco et ah, 2007), or induces no change (Vihavainen et ah, 2008a) in MOP receptor 
binding, depending on the dose and length of its administration.
Several reports have demonstrated that naloxone-precipitated withdrawal from chronic 
morphine increases brain ACh levels in various regions, including the nucleus accumbens 
and areas of the cortex (Bhargava and Way, 1975; Antonelli et ah, 1986; Rada et ah, 
1996). In the present study, however, neither the acute, nor the prolonged withdrawal 
from ‘intermittent’ morphine treatment altered [^^^IJepibatidine and [^^^I]a-bungarotoxin 
binding sites in the brains of morphine withdrawn animals. To the extent that enhanced 
concentrations of extracellular ACh would lead to increased nAChR density, the current 
data suggest that ACh release during morphine abstinence depends on whether 
withdrawal occurs spontaneously or is induced by opioid-antagonists. Indeed, contrary to 
the acute increases in neurotransmitter release following naloxone-precipitated
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withdrawal, basal levels of extracellular ACh in the rat nucleus accumbens have been 
shown to increase fifteen days after the termination of escalating morphine treatment, 
normalizing on day thirtyfive of abstinence (Fiserova et al., 1999). Although 
concentrations of ACh were not measured in the current study, it could be that changes in 
nAChR density during morphine abstinence may take longer to develop, reflecting the 
long term adaptive changes that characterize cholinergic responses to spontaneous 
morphine withdrawal.
The lack of morphine-induced effects on nAChR density does not preclude that 
alterations in nicotinic receptor function occur following morphine treatment and 
withdrawal. Using the acetylcholine binding protein as a model o f nicotinic receptor 
binding domains, for instance. X-ray crystallography demonstrates that morphine binds to 
non-a nicotinic subunit interfaces with pM affinity, at sites that are similar to those of 
modulating benzodiazepines on GABAa receptors (Hansen and Taylor, 2007; Taly et al., 
2009). In addition, in cell lines that express a3p4 nAChRs, morphine has been shown to 
inhibit nicotine-induced ^^Rb  ^efflux by directly binding to the central lumen of the ion 
channel, indicating that the opiate is a non-competitive antagonist at this nicotinic 
receptor subtype (Jozwiak et al., 2006). Together, these data suggest that morphine has 
the potential to interact and alter heteromeric nAChR function by acting both as as 
channel blocker, and as a negative allosteric modulator. Conceivably, if a morphine- 
induced reduction in the function of nAChRs has occurred in the present study, it would 
not be detectable by quantitative autoradiography.
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Several alternative explanations can be offered for the absence of changes in nAChR 
binding in the current study. First, the effects of morphine treatment and withdrawal on 
nAChR binding may only have occurred in certain neuronal populations. Morphine’s 
effects on dopaminergic regulation are exerted via MOP receptor hyperpolarization of 
GABAergic neurons (Johnson and North, 1992), and the alteration in the GABAergic 
neuronal input to mesolimbic dopaminergic neurons has been suggested to mediate the 
interactions between morphine and nicotine (Vihavainen et al., 2008b). Therefore, 
morphine administration may have selectively altered nAChR density on GABAergic 
cells. Second, morphine appears to selectively alter distribution of dentritic, and not 
somatic MOP receptors (Haberstock-Debic et al., 2003). By way of analogy, similar 
changes in nAChRs may have occurred only across certain neuronal subcompartments. 
Third, signaling cascades downstream of nicotinic receptors, rather than changes in 
nAChR abundance and function may mediate the nicotinic modulation of morphine- 
induced effects. Evidence suggests that adaptations in the cAMP signaling transduction 
pathway critically mediate the rewarding properties of many drugs of abuse. In particular, 
chronic morphine increases levels of the cAMP response element-binding protein 
(CREB), whereas morphine withdrawal symptoms are reduced in CREB“^  mutant mice 
(Widnell et al., 1994; Maldonado et al., 1996). Similarly, nicotine-induced conditioned 
place preference requires CREB phosphorylation, and so does the expression of the 
nicotinic withdrawal symptom (Brunzell et al., 2003; Brunzell et al., 2009). Importantly, 
a link between nicotine, MOP receptor activation, and CREB phosphorylation has been 
established (Walters et al., 2005). These findings support the concept that indirect 
actions at the anatomical and/or molecular levels are involved in the interactions between 
morphine and nicotine.
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As nicotine exerts its effects by binding in the CNS to neuronal nAChRs, an obvious 
hypothesis for the mechanism of interactions between nicotine and morphine is that 
administration of the opioid alters DAergic neurotransmission via nicotinic cholinergic 
receptors. To test this, a protocol that mimics the pattern of opiate abuse in human 
addicts was employed, and escalating ‘intermittent’ morphine was administered at doses 
that have been shown to produce sensitisation and dependence (reviewed in Spanagel, 
1995). Notwithstanding that morphine-induced changes in ACh release depend on the 
dosing regimen employed, and that changes in receptor abundance do not always 
translate to nAChR function, the present report suggests that alterations in nAChR 
density do not contribute to morphine-nicotine interactions.
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5 CHANGES IN THE NICOTINIC CHOLINERGIC AND DOPAMINERGIC 
SYSTEMS OF MICE DEFICIENT IN THE Aja GENE, EXPLORED BY 
QUANTITATIVE AUTORADIOGRAPHY
5.1 Introduction
The purine neuromodulator adenosine exerts its effects through four classes of G-protein 
coupled receptors, namely A%, A2A, Ais, and A3 adenosine receptors (see Section 1.3.3.1). 
Among them, A2A receptors have attracted much interest as potential modulators of the 
effects of abused substances, because of their restricted localization in brain pathways 
that are involved in drug addiction, and due to the altered behavioural phenotype that A2A 
receptor knockout (KO) mice exhibit in response to drugs of abuse (reviewed in Ferre et 
al., 2007). Indeed, adenosine A2A receptors are abundantly expressed in structures of the 
mesolimbic dopaminergic system, where they have been shown to mediate the properties 
of several addictive substances, including opioids (Bailey et al., 2004b), cannabinoids 
(Soria et al., 2004), psychostimulants (Soria et al., 2006), and nicotine (Castane et al., 
2006). Thus, A2A receptor KO mice exhibit enhanced naloxone-precipitated morphine 
withdrawal (Bailey et al., 2004b), diminished delta9-tetrahydrocannabinol (THC)- 
induced place conditioning (Soria et al., 2004), and reduced rate of cocaine self- 
administraiton (Soria et al., 2006). The participation of adenosine A2A receptors in 
nicotine addiction, in particular, is revealed by the fact that caffeine, a non selective 
antagonist at Ai and A2A receptors, is commonly consumed in combination with nicotine 
by tobacco smokers. Evidence suggests that caffeine intake leads to increased cigarette 
smoking (Brown and Benowitz, 1989), and that smokers tend to consume more caffeine 
compared to the general population (reviewed in Swanson et al., 1994). Moreover, 
preclinical studies show that adding caffeine into the drinking water of rats potentiates
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nicotine self-administration, whereas its exclusion brings nicotine intake back to baseline 
levels (Shoaib et ah, 1999). A specific role for adenosine A2A receptors to enhance the 
reinforcing properties of nicotine has been futher revealed in mice with a genetic ablation 
of the A2A receptor gene. Using the conditioned place preference (CPP) paradigm, it has 
been shown that nicotine-induced CPP is attenuated in A2A receptor KO animals, which 
do not exhibit an increase in their extracellular levels of accumbal dopamine following 
the acute administration of nicotine (Castane et al., 2006). Hence, a growing body of 
evidence demonstrates the occurence of interactions between adenosine A2A receptors 
and the nicotinic cholinergic system, and suggests that the adenosinergic modulation of 
nicotine-induced effects takes place within the mesolimbic DAergic system.
The generation of the A2A KO mouse provides a powerful genetic tool to analyse the 
involvement of A2A receptors in nicotine addicition in vivo. It may be a prima facie case, 
however, that the reported nicotine-induced phenotypes are precipitated in animals with 
permanent and global inactivation of the A2A gene, as a result of compensatory 
developmental changes in the nicotinic cholinergic and dopaminergic systems. Therefore, 
to investigate whether alterations in nicotinic and dopaminergic receptor binding occur in 
the absence of A2A receptors, quantitative autoradiographic analysis of heteromeric and 
homomeric nAChRs, and of dopaminergic D1 and D2 receptors and transporters, has 
been performed in brain sections from drug naïve, wild type (WT) and homozygous (-/-) 
A2A receptor KO GDI mice. In addition, to further investigate the involvement of A2A 
receptors in modulating nicotine-induced neuroadaptation, the regulation of the nicotinic 
and dopaminergic systems has been assessed in WT and A2A receptor KO mice, 
following chronic nicotine treatment.
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5.2 Materials and methods
5.2.1 Generation o f  the A 2A KO mouse and experimental conditions 
CDl adenosine Aia receptor KO mice, originally generated by Ledent et al., (1997), were 
obtained from the breeding colony of the University of Surrey, as previously described 
(Prentice et al., 2002). In brief, mutant mice were bred from heterozygote breeding pairs, 
which originated from the individual crossing of a number of heterozygote males from 
the existing colony, each with a wildtype female of the CDl strain, which was obtained 
from an external supplier (Charles River, Margate, Kent). The male and female 
heterozygotes from the litters of the newly created breeding pairs were paired and these 
formed the main breeding colonies, which were maintained for approximately a year 
before new breeding pairs were created. All mice were genotyped at weaning using a 
polymerase chain reaction (PCR) based method. Tail tip samples were collected at three 
weeks of age, from which DNA was extracted using the DNeasy tissue kit, according to 
the manufacturer’s protocol (Qiagen, Hilden, Germany).
8-12 week old male CDl mice (n=5-7) were used for in vivo and autoradiography 
experiments. The animals were single-housed in a temperature controlled environment, 
under a 12 h light/dark cycle. Food and water were available ad libitum. All studies 
were conducted in accordance with protocols approved by the Home Office, UK.
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5.2.2 Minipump preparation and implantation
Prior to surgical implantation, osmotic minipumps (ALZET®2002 model, Charles River, 
UK) were filled with either nicotine hydrogen salt in 0.9% sterile saline, or vehicle (0.9% 
sterile saline). Nicotine hydrogen salt (Sigma-Aldrich, UK) was delivered to CDl mice 
at a dose of 7.8 mg/kg/day (free-base weight), at a rate of 0.5pl/hour, for 14 days. The 
procedure followed for the implantation of the miniosmotic pumps has been described in 
Section 3.2.1.2.
Fourteen days after the minipumps had been implanted, mice were rapidly killed by 
cervical dislocation and the intact brains immediately removed and rapidly frozen in 
isopentane at -20 °C. Brains were stored at -80 °C for a maximum period of 1 month 
before sectioning.
5.2.3 Quantitative receptor autoradiography
Quantitative autoradiography was performed in order to measure density of a4|32* and a7 
nAChRs, dopaminergic D1 and D2 receptors, and of the dopamine transporter (DAT), in 
drug naïve and nicotine-treated WT and adenosine Aia receptor KO mice. In addition, 
binding to adenosine A2A receptors was performed in nicotine-treated WT and A2A KO 
animals, in order to confirm genotype. For receptor binding experiments, sections were 
thawed and processed according to established protocols (Javitch et al., 1984; Orr- 
Urtreger et al., 1997; Whiteaker et al., 2000b; Marks et al., 2002; Bailey et al., 2004a; 
Lena et al., 2004), with minor modifications. Sections for analysis were derived from 
five to seven brains from each group (n=5-7). Multiple, adjacent sections were processed 
together in a paired binding protocol. Radioligand bound sections were apposed to 
Kodak BioMax MR-1 film (Sigma-Aldrich, UK), along with appropriate microscale
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standards to allow quantification. All structures were identified by reference to the 
mouse brain atlas of Franklin and Paxinos, (2001), and analysed using an MCID image 
analyser (Image research, Linton, UK).
To confirm the genotype of nicotine-treated animals, sections for A2A receptor binding 
were pre-incubated for 30 minutes in 170 mM Tris-HCl, containing ImM EDTA (pH 7.4, 
room temperature). For the determination of total receptor binding, sections were 
incubated at room temperature with 10 nM of [^H]CGS21680 (PerkinElmer; specific 
activity 30 Ci/mmol) for 2 hours, in incubation buffer containing 170 mM Tris-HCl, 10 
nM MgCh, and 2 U/ml adenosine deaminase (pH 7.4 at 25 °C). Incubations were 
terminated by 3 x 5 minute washes into ice cold 50 mM Tris buffer (ph 7.4), and a rapid 
rinse in ice cold water. Radioligand bound sections were apposed to film for a period of 
3 weeks.
For nAChRs, radioligand bound sections were apposed to film for 24h. Structures of 
exceptionally high nAChR density, including the medial habenula, fasciculus retrofiexus, 
and the interpeduncular nucleus were apposed for a period of 6h, to avoid film saturation. 
Detailed experimental protocols for autoradiographic procedures can be found in Section 
3.2.6.
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5.2.4 Determination o f nicotine and cotinine levels
Chronic nicotine-treated WT and adenosine A2A receptor KO mice were killed by 
cervical dislocation at the end of the experiment and core blood from each animal was 
collected in ice cold tubes. Plasma was obtained by centrifugation for 20 min. at 2500 
rpm in a refrigerated centrifuge, and transported in dry ice to ABS Laboratories Ltd, 
Welwyn Garden city, UK, for analysis of nicotine and cotinine levels by gas liquid 
chromatography (Feyerabend and Russell, 1990).
5.2.5 Statistical analysis
Two-way ANOVA for the factors genotype and region was used for the comparison of 
quantitative measures of a4p2* and a7 nicotinic receptors, dopaminergic D1 and D2 
receptors, and of dopamine transporters in brain regions of drug naïve CDl mice. For 
nAChR binding, structures of the habenulo-interpeduncular pathway were quantified 
using a 6 h exposure to film, because of the high densities of heteromeric nAChRs in this 
cholinergic system. Therefore, comparisons between structures of high nicotinic receptor 
density were performed using a separate two away ANOVA (independent factors 
genotype and region). Three-way ANOVA for the factors treatment, genotype, and 
region, was used to compare differences in receptor binding between nicotine-treated WT 
and adenosine A2A receptor KO animals.
Where ANOVA yielded significant treatment effects, and depending on the n number of 
the treatment groups, Duncan’s multiple ranges or Fisher’s LSD post hoc analysis was 
used to investigate differences in radioligand binding between groups in individual 
regions.
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5.3 Results
5.3.1 Naïve study
5.3.1.1 Nicotinic receptor autoradiography in naïve WT and adenosine A2A receptor KO 
mice
To investigate whether deletion of the genes encoding for the adenosine A2A receptor 
leads to any alterations in nicotinic receptor density, quantitative autoradiography of 
a4p2* and a7 nAChRs was carried out in brain sections from drug naïve wild type (WT) 
and A2A receptor knockout (KO) CDl mice. The pattern of distribution of all nicotinic 
receptor subtypes studied in homozygous adenosine A2A receptor KO mice was identical 
to wild type. For heteromeric nicotinic receptors, no change in total, cytisine-sensitive, 
and cytisine-resistant [^^^I]epibatidine binding was observed between naïve WT and A2A 
receptor KO mice, in any of the brain regions examined (Fig. 5.1 & 5.2 & 5.3). The 
majority of CDl mouse brain [^^^Ijepibatidine binding sites were of the cytisine-sensitive, 
a4p2* nAChR subtype. High levels of cytisine-resistant [^^^Ijepibatidine binding were 
observed in the medial habenula, fasciculus retrofiexus, and interpeduncular nucleus. 
Non specific binding (NSB) was indistinguishable from film background.
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Figure 5.1 Q uantitative autoradiography o f  heterom erie nA ChR binding in naïve W T  and adenosine A ja  
receptor KO mice
To investigate whether deletion o f  the genes encoding for the adenosine AgA receptor leads to any alterations in nicotinic 
receptor density, quantitative autoradiography o f  heteromeric nAChRs was carried out in brain sections from drug naïve 
wild type (WT) and AzA receptor knockout (KO) CDl mice. Values represent the mean specific binding o f  total 
[ IJepibatidine ± SEM in brain regions o f  6 animals per group. Two-way ANOVA showed no significant genotype 
[F(l,167)=0.0, P>0.05] or genotype x region interaction effect [F(16,167)=0.4, P>0.05] on heteromeric nAChR density. 
Areas o f  the interpeduncular pathway were analysed separately by two-way ANOVA, which showed no effects o f  
genotype [F(l,27)=0.3, P>0.05], and no genotype x region interaction effects [F(2,27)=0.5, P>0.05] on total 
[ IJepibatidine binding. Abbreviations: FrA: Frontal Association Cortex, MCx: Motor Cortex; Cg: Cingulate Cortex; 
CPu; Caudate Putamen; AcbC: Nucleus Accumbens, Core; AcbSh: Nucleus Accumbens, Shell; Tu: Olfactory Tubercle; 
AV: Anteroventral Thalamic Nucleus; LPMR: Lateral Posterior Thalamic Nucleus; Po: Posterior Thalamic Nuclear Group; 
DLG: Dorsal Lateral Geniculate Nucleus; VLG: Ventral Lateral Geniculate Nucleus; SuG: Superficial Gray Layer o f  the 
Superior Colliculus; SNc: Substantia Nigra, pars Compacta;VTA: Ventral Tegmental Area; MG: Medial Geniculate 
Nucleus; CAl: Hippocampus, C Al; MHb: Medial Habenula; ff: Fasciculus Retrofiexus; IP: Interpeduncular Nucleus.
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Figure 5.2 Q uantitative autoradiography o f  cytisine-sensitive nA ChR binding in naïve W T  and adenosine A ja 
receptor KO mice
Values o f a4p2* nAChR binding represent the mean specific binding o f cytisine-sensitive ['^^I]epibatidine ± SEM in brain regions o f 
6 animals per group. Two-way ANOVA showed no significant genotype [F(l,167)=0.0, P>0.05] or genotype x region interaction 
effects [F(16,167)=0.5, P>0.05] on o4p2* nAChR density. Areas o f the interpeduncular pathway were analysed separately by two- 
way ANOVA, which showed no effects o f genotype [F(l,26)=0.0, P>0.05], and no genotype x region interaction effects [F(2,26)=2.1, 
P>0.05] on cytisine-sensitive [^^^I]epibatidine binding. Abbreviations: FrA: Frontal Association Cortex, MCx: Motor Cortex; Cg: 
Cingulate Cortex; CPu: Caudate Putamen; AcbC: Nucleus Accumbens, Core; AcbSh: Nucleus Accumbens, Shell; Tu: Olfactory 
Tubercle; AV: Anteroventral Thalamic Nucleus; LPMR: Lateral Posterior Thalamic Nucleus; Po: Posterior Thalamic Nuclear Group; 
DLG: Dorsal Lateral Geniculate Nucleus; VLG: Ventral Lateral Geniculate Nucleus; SuG: Superficial Gray Layer o f the Superior 
Colliculus; SNc: Substantia Nigra, pars Compacta;VTA: Ventral Tegmental Area; MG: Medial Geniculate Nucleus; C A l: 
Hippocampus, CA l; MHb: Medial Habenula; ff: Fasciculus Retrofiexus; IP: Interpeduncular Nucleus.
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Figure 5.3 Q uantitative autoradiography o f  cytisine-resistant nA ChR binding in naïve W T  and adenosine A%A 
receptor KG mice
Values represent the mean spécifié binding o f cytisine-resistant [^^^I]epibatidine ± SEM in brain regions o f 6 animals per group. Two-way 
ANOVA showed no significant genotype [F(l,88)=0.9, P>0.05] or genotype x region interaction effects [F(8,88)=0.8, P>0.05]. Areas o f the 
interpeduncular pathway were analysed separately by two-way ANOVA, which showed no effects o f genotype [F(l,28)=0.1, P>0.05], and no 
genotype x region interaction effects [F(2,28)=1.5, P>0.05] on cytisine-resistant [’^^I]epibatidine binding density. Abbreviations; CPu 
Caudate Putamen; AcbC: Nucleus Accumbens, Core; AcbSh: Nucleus Accumbens, Shell; DLG: Dorsal Lateral Geniculate Nucleus; VLG 
Ventral Lateral Geniculate Nucleus; SuG: Superficial Gray Layer o f the Superior Colliculus; SNc: Substantia Nigra, pars Compacta; VTA 
Ventral Tegmental Area; MG: Medial Geniculate Nucleus MHb: Medial Habenula; ff: Fasciculus Retrofiexus; IP: Interpeduncular Nucleus.
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Quantitative autoradiography of a? nAChRs revealed no significant differences in 
bungarotoxin density between genotypes (Fig. 5.4). Representative autoradiograms of 
nAChR binding are shown in coronal brain sections of WT and KO animals in Figure 5.5 
A&B, for heteromeric and homomeric nicotinic receptors, respectively.
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Figure 5.4 Quantitative autoradiography of a7 uAChR binding in naïve WT and adenosine Aja receptor KG mice
To investigate whether deletion of the genes encoding for the adenosine A2A receptor leads to any alterations in nicotinic receptor 
density, quantitative autoradiography of homomeric nAChRs was carried out in brain sections from drug naïve wild type (WT) and 
A2A receptor knockout (KG) CDl mice. Values represent the mean specific binding of ['^^I]a-bungarotoxin ± SEM in brain regions of 
6 animals per group. Two-way ANOVA showed no significant genotype [F(l,170)=0.1, P>0.05] and no genotype x region interaction 
effects [F(19,170)=0.3, P>0.05] on a7 nAChR density. Abbreviations; FrA: Frontal Association Cortex; Cg: Cingulate Cortex; CPu: 
Caudate Putamen; DEn: Dorsal Endopiriform Nucleus; Ml: Primary Motor Cortex; Cl: Claustrum; Po: Posterior Thalamic Nuclear 
Group; CAl: Hippocampus, CAl; CA3: Hippocampus, CA3; DG: Dentate Gyrus; BLA: Basolateral Amygdaloid Nucleus; PLCo: 
Posteromedial Cortical Amygdaloid Nucleus; MAN: Medial Amygdaloid Nucleus; DM: Dorsomedial Hypothalamic Nucleus; VM 
Ventromedial Hypothalamic Nucleus; LH: Lateral Hypothalamus; Zl: Zona Incerta; SuG: Superficial Gray Layer of the Superior 
Colliculus; VTA: Ventral Tegmental Area; SN: Substantia Nigra.
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Figure 5.5 Representative autoradiograms of [‘^^IJepibatidine (A) and [‘^®I]a-bungarotoxin (B) binding in naïve 
wild type and adenosine A%A receptor KO mice
A. The panels show coronal brain sections cut at the level of the caudate putamen (Bregma 0.74mm) and o f the hippocampus 
(Bregma -1.70mm). To label a4p2* receptors, adjacent sections were incubated for 2 hrs with 100 pM o f ['^^IJepibatidine alone or 
in the presence of 20 nM cytisine. Sections were apposed to Kodak BioMax M R-1 film for a period o f 24 hrs, except for areas of 
high nAChR density, which were laid to film for 6 hrs, to avoid film saturation. The colour bar indicates a pseudo-colour 
interpretation o f black and white image density, calibrated in fmol/mg o f tissue equivalent. B. To label a7 nAChRs, adjacent 
sections were incubated for 3 hrs at room temperature with 3 nM ['^^IJa-bungarotoxin alone or in the presence of ImM o f nicotine 
salt to calculate non specific binding. Sections were apposed to Kodak BioMax MR-1 film for a period of 7 days. The calibration 
bar shows black and white image density calibrated in fmol/mg of tissue equivalent. Representative sections are shown at the level 
o f the hippocampus (Bregm a-1.70). Abbreviations: WT: Wild type; KO: Knockout; NSB: Non Specific Binding.
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5.3.1.2 Dopaminergic receptor and transporter autoradiography in naïve WT and 
adenosine A2A receptor KO mice
To investigate whether deletion of the adenosine A2A receptor gene leads to 
compensatory changes in the expression of dopaminergic D1 and D2 receptors, and of the 
dopamine transporters, quantitative autoradiography was perfomed in brain sections from 
naïve WT and KO CDl mice. D2 receptor binding was enhanced in adenosine A2A 
receptor knockout mice compared to WT animals, across all regions examined (Fig. 5.6). 
However, the level of upregulation was small and post hoc comparison revealed no 
individual region-significant differences between WT and KG mice.
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Figure 5.6 Q uantitative autoradiography o f  D2 receptor binding in naïve W T  and adenosine A 2A receptor K O  m ice
To investigate whether deletion of the genes encoding for the adenosine A2A receptor leads to any compensatory changes in the 
expression of dopaminergic D2 receptor density, quantitative autoradiography was carried out in brain sections from drug naïve wild 
type (WT) and A2A receptor knockout (KO) CDl mice. Values represent the mean specific binding of fHJraclopride ± SEM in brain 
regions of 6 animals per group. Two-way ANOVA showed a significant genotype effect on D2 receptor density [F(l,66)=4.7, P<0.05], 
with no genotype x region interaction effects [F(6,66)=0.2, P>0.05]. LSD post hoc analysis confirmed that the level of D2 
upregulation was small, with no differences in receptor density being observed between groups in individual regions. Abbreviations; 
AcbC: Nucleus Accumbens, Core; AcbSh: Nucleus Accumbens, Shell; CPuR: Caudate Putamen, Rostral part; CPuC: Caudate 
Putamen, Caudal part; Tu: Olfactoiy Tubercle; SNe: Substantia Nigra, pars compacta; VTA: Ventral Tegmental Area.
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No differences in the expression of D1 receptors and dopamine transporters were
observed between groups (Fig. 5.7 A&B).
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Figure 5.7 Quantitative autoradiography of D1 receptors (A) and dopamine transporters (B) in naïve WT and 
adenosine Aja receptor KO mice
To investigate whether deletion of the genes encoding for the adenosine A2A receptor leads to any compensatory changes in the 
expression of dopaminergic D1 receptor and dopamine transporter density, quantitative autoradiography was carried out in brain 
sections from drug naïve wild type (WT) and adenosine A2A receptor knockout (KG) CDl mice. Sections were labelled with 
4nM [^H]SCH23390 and 4nM [^HJmazindol, for D1 receptors and DAT, respectively. No genotype effect on D1 receptor 
density [F(l,87)=2.6, P>0.05] and on DAT binding [F(l,38)=2.3, P>0.05] was observed between groups. Abbreviations: AebC: 
Nucleus Accumbens, Core; AcbSh: Nucleus Accumbens, Shell; Tu: Olfactory Tubercle; CPuR: Caudate Putamen, Rostral part; 
CPuC: Caudate Putamen, Caudal part; SN: Substantia Nigra; SNe: Substantia Nigra, pars Compacta; VTA: Ventral Tegmental 
Area; Cl: Claustrum; DEn: Dorsal Endopiriform Nucleus; KG: knockout.
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5.3.2 Nicotine treatment
5.3.2.1 Confirmation o f genotype
Binding of [^H]CGS21680 to adenosine Asa receptors showed a complete absence of A 
binding sites in the brains of homozygous mice, confirming the genotype of the animals 
used in this study (Fig. 5.8).
W T  A2a KO
2A
miceFigure 5.8 Adenosine Az* receptor expression in naïve CDl wildtype and adenosine A^^  receptor KO
To confirm the genotype o f the animals used in the present experiments, sections were labeled with lOnM 
[ HJCGS21680 for a period of 2 hrs. From top to bottom, the horizontal panels show Ag* receptor binding at the level 
o f the caudate putamen (bregma 0.98mm) and of the ventral tegmental area (bregma -3.40mm).
5.3.2.2 Levels o f  plasma nicotine and cotinine following chronic nicotine administration 
Plasma nicotine and cotinine levels were determined after 14 days of treatment with 
nicotine at a dose of 7.8 mg/kg/day, in WT and adenosine A2A receptor KO mice. In 
nicotine-treated groups, the mean plasma levels of nicotine (34.9±3.7 ng/ml) and cotinine 
(72.0±5.7 ng/ml) were similar between genotypes (Fig. 5.9).
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Figure 5.9 M ean plasm a nicotine and cotinine levels follow ing chronic nicotine adm inistration
Nicotine was delivered to CDl mice at a dose of 7.8 mg/kg/day, at a rate of O.Spldiour, for a period of 14 days, using 
miniosmotic pumps. The mean plasma levels of nicotine and cotinine were in the range of 16-56 ng/ml, and 44-104 
ng/ml, respectively. Data are expressed as mean nicotine and cotinine levels ± SEM, in plasma from 5-7 animals per 
group. Two-way ANOVA was conducted for the factors genotype and treatment, showing no significant genotype 
effects on the levels of plasma nicotine [F(l,20)=3.0, P>0.05] or cotinine [F(l,20)=0.9, P>0.05] between WT and 
adenosine AzA receptor KO mice. An unpaired t-tcst was used to confirm results between nicotine-treated WT and Aja
receptor KO animals obtained by two-way ANOVA [WT vs. KO: nicotine levels, t(l,10)=1.8, P>0.05; cotinine levels,
t(l,10)=0.9,P>0.05].
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J.3.2.3 Nicotinic receptor autoradiography in WT and adenosine A2A receptor KO mice, 
following chronic nicotine treatment
The density of total, cytisine-sensitive, and cytisine-resistant [^^^Ijepibatidine binding is 
detailed for all brain regions analysed in Tables 5.1, 5.2, and 5.3. Administration of 
nicotine for 14 days resulted in a significant increase of total and cytisine-sensitive 
[^^^I]epibatidine binding sites in nicotine-treated WT and adenosine A2A receptor KO 
mice, compared to saline controls (Tables 5.1 & 5.2). The degree of upregulation was 
identical between genotypes, and was primarily observed in cortical areas of nicotine- 
treated wildtype and knockout animals. Duncan’s post hoc analysis was performed in 
order to investigate differences in radioligand binding between groups in individual brain 
regions. Higher levels of total and cytisine-sensitive [^^^IJepibatidine binding were 
observed in the frontal association cortex, primary motor cortex, visual cortex, and 
auditory cortex of nicotine-treated mice, compared to saline controls. No changes in 
cytisine-resistant [^^^IJepibatidine binding were observed among groups (Table 5.3).
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R e a io n
T o ta l [^^® l]epibatid ine b in d in g  
( fm o l/m g  t i s s u e  e q u iv a le n t )
%  c h a n g e  In b in d in g
WT Saline  ’WT N icotine KO S aline KO N icotine
WT N icotine vs. 
WT S aline
KO N icotine v s. 
KO Saline
Frontal a sso c ia tio n  co rtex 10.1 ± 0 .8 17.8 ±1.3* 12.0 ±1 .0 15.2 ±1.6*' 76.2 26.7
Preiim bic co rtex 9.2 ± 0.6 14.6 ± 0 .9 1 1 .2±1 .1 13.8 ± 2 .3 58.7 23.2
C ingulate co rtex 12.5 ±1.1 16.3 ± 1 .6 13.4 ±1.1 16.1 ± 2 .2 30.4 20.1
Prim ary m o to r co rtex 11.2 ± 0 .8 15.6 ±1.7* 11.3 ±0 .9 15.1 ±2.1" 39.3 33.6
S eco n d ary  m o to r co rtex 10.9 ± 0.7 15.5 ±1.3* 11.3 ±0 .8 14.9 ± 2.3" 42.2 31.9
Visual co rtex 12.3 ± 0 .6 17.5 ± 0.8 12.3 ± 1 .2 17.7 ± 1 .6 42.3 43.9
Prim ary so m a to sen so ry  
co rtex
11.2 ± 0 .6 14.3 ± 1 .4 10.5 ±0 .8 13.9 ± 1 .8 27.7 32.4
Subiculum 17.1 ± 1 .3 17.2 ± 1 .6 17.3 ±1 .4 18.4 ± 1 .4 0.6 6.4
Auditory co rtex 10.1 ± 0 .8 14.5 ±1.1* 10.2 ±0 .6 14.8 ±1.0" 43.6 45.1
H ippocam pus 3.7 ± 0.4 6.4 ± 1 .6 3.9 ±0 .2 6.3 ± 0.7 73.0 61.5
H ypothalam us 
N ucleus acc u m b e n s
11.9 ±1.1 14.9 ±1.1 11.8 ±0.8 15.2 ± 1 .3 25.2 28.8
C ore 13.5 ± 0 .5 13.7 ± 2.0 13.7 ±0.9 14.8 ± 2.0 1.5 8.0
Shell 13.2 ± 0 .7 15.0 ± 1 .7 13.8 ±0.9 15.7 ± 2 .2 13.6 13.8
C audate  pu tam en 15.9 ± 0 .9 17.6 ± 2 .0 16.0 ±1 .0 17.4 ± 2 .3 10.7 8.7
O lfactory tu b erc le 13.1 ± 0 .8 15.6 ± 1 .5 14.1 ±0 .4 15.4 ±2.1 19.1 9.2
A nteroventral thalam ic 
nu c leu s
34.6 ± 2.7 36.1 ± 3.2 36.1 ±2 .9 32.4 ± 3.0 4.3 -10.2
Lateral p o s te rio r thalam ic  
nu c leu s
30.1 ± 2.7 28.4 ± 3.1 31.9 ±2 .5 28.4 ± 2.4 -5.6 -11.0
P o s te rio r thalam ic  n u c lear 
group
28.1 ± 2.3 28.3 ± 2.4 26.2 ±2 .8 26.3 ± 2.1 0.7 0.4
Dorsal lateral g en icu la te  
nu c leu s
38.5 ± 3.7 36.6 ± 2.5 38.3 ± 3 .5 37.4 ± 2.5 ■4.9 -2.3
V entral lateral g en icu la te  
nu c leu s
38.9 ± 3.1 36.5 ± 2.5 37.6 ± 3 .5 35.1 ± 1 .7 -6.2 -6.6
Medial g en icu la te  n u c leu s 25.2 ± 2.5 26.4 ± 1 .3 27.4 ± 1 .2 28.5 ± 2.2 4.8 4.0
Superficial gray layer of th e  
su p e rio r co lllcu lus
34.8 ± 3.1 35.0 ± 2.8 40.1 ±2.1 37.3 ± 2.6 0.6 -7.0
V entral tegm en ta l a rea 28.2 ± 2.6 27.7 ± 1 .2 27.7 ±1 .0 27.7 ± 2.1 -1.8 0.0
S u b s ta n tia  nigra, p a rs  
co m p acta
27.8 ± 2.2 27.1 ± 1 .3 26.2 ±2.1 27.7 ± 2.4 -2.5 5.7
Table 5.1 Q uantitative autoradiography o f total [‘“ ijepibatid ine binding in W T  and adenosine A ;* receptor KO  
mice, following chronic nicotine adm inistration
Nicotine was delivered to GDI mice at a dose of 7.8 mg/kg/day for a period of 14 days. On day 14 animals were killed by 
cervical dislocation, and their brains were immediately removed and frozen into isopentane for subsequent processing using 
quantitative receptor autoradiography. Values of specific [*^ I^]epibatidine binding represent mean ± SEM fmol/mg of tissue 
equivalent in brain regions of 5-7 animals per group. Three-way ANOVA was performed for the factors treatment, genotype, and 
region. Analysis showed significant main effects of treatment [F(1,480)=17.4, P<0.0001] and region [F(23,480)—104.3, 
P<0.0001], and significant treatment x region interaction effects [F(23,480)=1.6, P<0.05]. Genotype had no effect on total 
[*^ I^]epibatidine density [F(l,480)=0.2, P>0.05]. Within-region differences were examined using Duncan’s post hoc test. 
*P<0.05 vs. WT saline, ^P<0.05 vs. KO saline.
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R e g io n
C y tis in e -s e n s i t iv e  [^^^l]ep lbatid lne b in d in g  
(fm o l/m g  t i s s u e  e q u iv a le n t)
% c h a n g e  In b in d in g
F ro n ta l a s s o c ia t io n  c o r te x  
P re llm b ic  c o r te x  
C in g u la te  c o r te x  
P r im a ry  m o to r  c o r te x  
S e c o n d a r y  m o to r  c o r te x  
V isu a l c o r te x  
P rim a ry  s o m a to s e n s o r y  
c o r te x  
S u b ic u lu m  
A u d ito ry  c o r te x  
H ip p o c a m p u s  
H y p o th a la m u s  
N u c le u s  a c c u m b e n s  
C o re  
S h e ll 
C a u d a te  p u ta m e n  
O lfa c to ry  tu b e rc le  
A n te ro v e n tra l  th a la m ic  
n u c le u s
L a te ra l p o s te r io r  th a la m ic  
n u c le u s
P o s te r io r  th a la m ic  n u c le a r  
g ro u p
D o rsa l la te ra l  g e n ic u la te  
n u c le u s
V e n tra l la te ra l  g e n ic u la te  
n u c le u s
M edial g e n ic u la te  n u c le u s  
S u p e rf ic ia l  g ra y  la y e r  o f  th e  
s u p e r io r  c o ll lc u lu s  
V e n tra l te g m e n ta l  a r e a  
S u b s ta n t ia  n ig ra , p a r s  
c o m p a c ta ________
WT S aline WT Nicotine KO S aline KO Nicotine WT Nicotine 
vs. WT S aline
KO Nicotine 
vs. KO Saline
9 .6  ± 0.8 16.8  ± 1 .2 * 1 1 .4  ± 0 .9 14 .2  ± 1 .3 * 7 5 .2 25 .2
8 .8  ± 0.5 13.8  ± 0 .9 1 0 .7  ± 1 .0 13 .0  ± 2 .3 57 .0 21.8
11 .7  ± 1 .1 1 5 .2  ± 1 .6 12 .8  ± 1 .1 15 .0  ± 2 .2 29 .3 17.2
10 .6  ± 0 .8 1 4 .6  ± 1 .6 * 10 .8  ± 0 .9 14.1 ± 1 .9 * 37 .7 30 .7
1 0 .3  ± 0 .7 14 .5  ± 1 .2 * 10.9  ± 0 .8 1 4 .0  ± 2 .1 * 4 0 .5 28 .5
1 1 .6  ± 0 .5 1 6 .4  ± 0 .8 11 .7  ± 1 .2 16.5  ± 1 .5 4 1 .2 4 0 .9
1 0 .4  ± 0 .6 12 .8  ± 1 .3 9 .7  ± 0 .8 12 .5  ± 1 .8 23 .3 2 9 .5
15.1 ± 1 .3 15 .2  ± 1 .5 15 .3  ± 1 .5 16.1 ± 1 .4 0.5 5.2
9 .3  ± 0.8 13.2  ± 1 .1 * 9 .3  ± 0 .7 1 3 .4  ± 1 .0 * 4 2 .0 4 4 .3
3 .4  ± 0.3 5 .7  ± 0.5 3 .6  ± 0 .2 5 .7  ± 0.7 6 5 .4 6 0 .3
1 0 .6  ± 1 .1 13 .0  ± 1 .2 10 .4  ± 0 .7 13 .3  ± 1 .2 2 2 .8 28 .2
10 .6  ± 0 .5 11.5  ± 1 .8 11 .2  ± 0 .9 12.3  ± 1 .9 8 .7 10 .2
10 .5  ± 0 .6 12.8  ± 1 .6 1 1 .3  ± 0 .9 13.3  ± 2 .2 2 1 .8 17 .4
1 3 .4  ± 0 .9 15.3  ± 1 .9 1 3 .6  ± 1 .1 15.0  ± 2 .2 14 .2 11.0
11 .7  ± 0 .7 13.7  ± 1 .6 12.1 ± 0 .4 13.7  ± 2 .0 17 .3 13.6
29 .9  ± 2.6 31 .3  ± 3 .0 31.1 ± 3 .0 27 .6  ± 3.0 4 .7 -11 .4
26 .2  ± 2.9 2 4 .2  ± 3.3 28.1 ± 2 .6 23 .8  ± 2.2 -7.6 -15.1
25 .2  ± 2.3 2 5 .0  ± 2.5 2 3 .6  ± 2.7 23.1 ± 2.0 -0.8 -2.2
25 .6  ± 3.4 2 4 .4  ± 3.1 2 5 .4  ± 3.2 2 5 .5  ± 2.6 -4.8 0.2
22 .0  ± 2.3 2 2 .7  ± 3 .6 22 .5  ± 2.7 2 2 .2  ± 1 .9 2 .9 -1.5
2 2 .5  ± 2.5 23.1 ± 1 .3 25 .0  ± 1 .2 2 4 .9  ± 2.2 2 .4 -0.5
17 .5  ± 1 .6 1 8 .4  ± 2 .5 24 .5  ± 2.0 2 1 .8  ± 0 .9 5 .0 -11.1
2 2 .5  ± 2.5 21 .6  ± 1 .2 20 .8  ± 1 .6 2 1 .2  ± 1 .8 -3.9 2.0
23.1 ± 2.5 22 .3  ± 1 .2 22 .9  ± 1 .8 2 2 .6  ± 2 .4 -3.6 -1.2
Table 5.2 Q uantitative autoradiography o f cytisine-sensitive [*“ l]epibatid ine binding in W T  and adenosine A za 
receptor KG  mice, following chronic nicotine adm inistration
Values of cytisine-sensitive ['^ I^Jepibatidine binding represent mean ± SEM fmol/mg of tissue equivalent in brain regions of 5-7 
animals per group, and were derived by subtraction of cytisine-resistant from total [*^ I^]epibatidine binding. Three-way ANOVA 
was performed for the factors treatment, genotype, and region. Analysis showed significant main effects of treatment 
[F(1,480)=15.6, P<0.0001] and region [F(23,480)=27.8, P<0.0001], with no significant genotype effect on cytisine-sensitive 
[*^ I^]epibatidine density [F(l,480)=0.6, P>0.05]. No significant treatment x region [F(23,480)=1.3, P>0.05], treatment x genotype 
[F(l,480)=1.0, P>0.05], and region x genotype interaction effects [F(23,480)=0.5, P>0.05] were observed. Within-region 
differences were examined using Duncan’s post hoc test. *P<0.05 vs. WT saline, "P<0.05 vs. KG saline.
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R sg io n
C y tis in e -re s is ta n t [^^®l]eplbatidine b in d in g  
(fmol/mg tis su e  equivalent)
% c h a n g e  In b ind ing
WT S a lin e WT N icotine KO S a lin e KG N icotine WT N ico tine  
v s. WT S a lin e
KO N icotine 
v s . KO S a lin e
S u b icu lu m  
N u c leu s  a c c u m b e n s
2.0 ± 0.2 2.0 ± 0.2 2.0 ± 0.2 2.3 ± 0.1 0.9 14.9
C ore 2.9 ± 0.1 2.2 ± 0.4 2.5 ±0 .1 2.5 ± 0.1 -24.8 -1.7
Shell 2.7 ± 0.2 2.2 ± 0.3 2.5 ±0 .1 2.4 ± 0.1 -17.7 -2.6
C a u d a te  p u tam en 2.5 ± 0.1 2.3 ± 0.2 2.4 ± 0.1 2.4 ± 0.1 -8.0 -3.6
O lfacto ry  tu b e rc le 1.4 ± 0.4 1.9 ± 0 .2 2.0 ± 0.2 1.7 ± 0 .2 33.9 -17.2
A n te ro v en tra l th a lam ic  n u c le u s 4.7 ± 0.2 4.8  ± 0.5 5.0 ±0 .1 4.8 ± 0.3 2.3 -2.7
L ateral p o s te r io r  th a la m ic  n u c le u s 3.9 ± 0.2 4.2  ± 0.2 3.8 ± 0.2 4.6 ± 0.2 7.5 19.2
P o s te r io r  th a la m ic  n u c le a r  g ro u p 2.9 ± 0.3 3.3 ± 0.2 2.6 ± 0 .3 3.2 ± 0.2 13.7 23.8
D orsal la te ra l g e n ic u la te  n u c le u s 12.9 ± 0 .5 12.2 ± 1.1 12.9 ± 1 .0 11.9 ± 0 .9 -5.3 -7.6
V entral la te ra l g e n ic u la te  n u c le u s 16.9 ± 1 .2 13.8 ± 1.4 15.1 ± 1 .7 12.9 ± 1 .4 -18.0 -14.3
M edial g e n ic u la te  n u c le u s 2.7 ± 0.1 3.3 ± 0.1 2.4  ± 0.2 3.6 ± 0.3 24.5 52.1
S up erfic ia l g ray  layer o f th e  
su p e r io r  co lllcu lu s 17.3 ± 2.3 16.6 ± 2 .8 15.6 ± 1 .6 15.5 ± 2 .4 -3.9 -0.5
V entral teg m e n ta l a re a 5.7 ± 0.6 6.1 ± 0.5 6.9 ± 1 .7 6.5 ± 0.6 6.4 -6.1
S u b s ta n tia  n ig ra , p a rs  c o m p a c ta 4.7  ± 0.6 4.8  ± 0.4 3.3 ± 0.5 5.1 ± 0.5 2.6 54.1
Table 5.3 Q uantitative autoradiography o f  cytisine-resistant [^^®I]epibatidine binding in W T  and adenosine A za 
receptor K G mice, following chronic nicotine adm inistration
Values of cytisine-resistant ['^ I^Jepibatidine binding represent mean ± SEM fmol/mg of tissue equivalent in brain regions of 5-7 
animals per group. Three-way ANOVA was performed for the factors treatment, genotype, and region. Analysis showed no 
significant main effects of treatment [F(l,280)=0.2, P>0.05] and genotype [F(l,280)=0.6, P>0.05] on cytisine-resistant [^^ I^Jepibatidine 
density. No significant treatment x region [F(13,280)=l.l, P>0.05], treatment x genotype [F(l,280)=0.3, P>0.05], and region x 
genotype interaction effects [F(13,280)=0.4, P>0.05] were observed.
Representative autoradiograms of total and cytisine resistant ['^^Ijepibatidine binding in 
brain sections of chronically treated WT and adenosine A2A receptor KO animals are 
shown in Figure 5.10.
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Figure 5.10 Representative autoradiogram s o f [‘^^IJepibatldine binding in nicotine-treated wild type and adenosine  
A za receptor KO mice
Computer enhanced colour autoradiograms, showing the labelling of heteromeric nicotinic receptors with ['^^I]epibatidine, following 
treatment of WT and adenosine Aza receptor KO mice with saline (left column) or nicotine (7.8 mg/kg/day; right column) for a period 
of 14 days. Horizontal panels show adjacent, coronal brain sections cut at the level of (top to bottom): the caudate putamen (Bregma 
0.74mm), the hippocampus (Bregma -1.70mm), and the ventral tegmental area (Bregma -3.16mm). Sections were apposed to Kodak 
BioMax MR-1 film for 24 hours. Cytisine-sensitive receptor density was calculated following subtraction o f  specific cytisine-resistant 
['""Ijepibatidine binding Ifom total ['^Ijepibatidine binding. All structures were identified by reference to the mouse brain atlas o f  
Franklin and Paxinos, (2001). Abbreviations: WT: Wild type; KO: Knockout; NSB: Non Specific Binding.
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Representative autoradiograms of a7 nAChR binding in brai..i sections from WT and 
adenosine Aia receptor KO mice are shown in Figure 5.11. Chronic nicotine 
administration resulted in an overall increase of a7 receptor binding across all regions, 
compared to saline treatment. Individual post hoc comparisons, however, revealed no 
individual region-significant increase in [^^^I]a-bungarotoxin binding among groups. 
Although the mean density of a7 nAChR was identical between genotypes, the pattern of 
upregulation differed significantly between nicotine-treated WT and adenosine A2A 
receptor KO animals (genotype x treatment interaction effect: P<0.01, 3-way ANOVA). 
Indeed, ['^^I]a-bungarotoxin binding sites were predominantly upregulated across brain 
regions of nicotine-treated WT mice, rather than KO animals. The mean density of 
specific ['^^I]a-bungarotoxin binding in brain regions of saline and nicotine treated mice 
is shown for all areas analysed in Table 5.4.
fm o l/m g  W T  Saline W T N icotine
* -* 5 %■ . " . f  -
fm o l/m g  ^ 2^^ KO Saline ^ 2a  N icotine
NSB
NSB
Figure 5.11 Representative autoradiogram s o f [*^T]bungarotoxin binding in nicotine-treated wild type and
adenosine A ja receptor KO mice
To label a7 nAChRs, adjacent brain sections from nicotine-treated mice were incubated for 3 hrs at room temperature with 3 nM 
['^^I]a-bungarotoxin alone or in the presence of ImM of nicotine salt to calculate non specific binding. Sections were apposed to 
Kodak BioMax MR-1 film for a period of 7 days. The bar shows black and white image density calibrated in fmol/mg of tissue 
equivalent. Abbreviations: WT: Wild type; KO: Knockout; NSB: Non Specific Binding.
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f  ^ ® l]a-bungaro tox in  b in d in g  (fm ol/m g  t i s s u e  e q u iv a le n t) %  c h a n g e  in  b in d in g
R e g io n
W T S a l in e W T N ic o tin e KO S a l in e KO N ic o tin e W T N ic o tin e  
v s .  W T S a l in e
KO N ic o tin e  
v s .  KO S a l in e
F ro n ta l  a s s o c i a t i o n  c o r te x 1 2 .5  ± 2 .7 1 8 .7  ± 3 .9 1 7 .8  ± 3 .3 1 7 .0  ± 3 .6 5 0 .3 -4 .4
C in g u la te  c o r te x 9 .5  ±  2 .8 1 5 .3  ± 3 .1 1 2 .5  ± 0 .8 1 0 .8  ± 4 .3 6 1 .0 -1 3 .8
C a u d a te  p u ta m e n 1 6 .6  ± 3 .8 1 8 .9  ± 5 .0 1 4 .7  ± 0 .8 1 2 .8  ± 2 .8 1 3 .3 -1 3 .3
E n d o p ir ifo rm  n u c le u s ,  d o r s a l 2 1 .5  ± 3 .7 2 7 .7  ± 6 .5 21.1  ± 0 .7 2 1 .8  ± 3 .5 2 8 .6 3 .3
P r im a ry  m o to r  c o r te x 1 5 .2  ± 3 .8 2 0 .4  ± 5 .7 1 5 .4  ± 1 .8 1 6 .7  ± 3 .8 34.1 8 .5
C ia u s tru m 2 1 .9  ± 3 .7 2 9 .5  ±  7 .3 22.1 ± 1 .6 1 8 .7  ± 3 .3 3 4 .4 -1 5 .6
P o s te r io r  th a la m ic  n u c le a r  
g r o u p 7 .6  ±  2 .2 1 3 .5  ± 2 .9 8 .8  ± 1 .9 9 .9  ± 2 .3 7 6 .7 12 .0
H ip p o c a m p u s ,  CA1 1 6 .5  ± 4 .0 2 3 .3  ± 4 .4 1 8 .4  ± 4 .6 2 1 .5  ± 4 .0 41.1 1 7 .0
H ip p o c a m p u s ,  CA3 2 0 .6  ± 3 .5 2 8 .6  ±  5 .5 2 3 .6  ± 4 .5 2 6 .9  ±  4 .5 3 8 .6 14.1
D e n ta te  g y r u s 1 2 .6  ±  2 .8 1 9 .0  ± 3 .2 1 4 .3  ± 3 .1 1 7 .0  ± 2 .9 5 0 .4 1 8 .4
B a s o la te ra l  a m y g d a lo id  
n u c le u s 1 4 .5  ± 2 .9 1 7 .3  ± 3 .1 1 6 .8  ± 2 .1 1 9 .9  ± 3 .5 1 9 .3 1 8 .3
P o s te r o m e d ia l  c o r t ic a l  
a m y g d a lo id  n u c le u s 1 5 .8  ± 2.1 2 3 .3  ±  4 .5 1 9 .6  ± 3 .5 1 7 .4  ± 2 .3 4 7 .5 -11.1
M edial a m y g d a lo id  n u c le u s 46 .1  ± 8 .0 4 8 .2  ± 6 .8 4 3 .2  ± 2 .4 4 7 .6  ± 6 .6 4 .6 1 0 .4
D o rs o m e d ia l  h y p o th a la m ic  
n u c le u s 1 7 .3  ±  2 .7 2 0 .4  ±  2.1 2 3 .2  ±  3.1 2 3 .5  ± 4 .5 18.1 1 .0
V e n tro m e d ia l  h y p o th a la m ic  
n u c le u s 1 9 .4  ±  2.1 2 4 .4  ±  4 .7 2 6 .5  ±  6 .8 2 5 .6  ± 2 .8 2 5 .6 -3 .4
L a te ra l  h y p o th a la m u s 8 .7  ±  1 .4 11.1 ±  1 .2 1 1 .4  ± 1 .4 1 2 .0  ± 1.6 2 6 .9 5 .3
Z o n a  in c e r ta 5 2 .0  ± 5 .5 6 1 .6  ± 8 .7 5 0 .5  ±  3 .5 5 3 .4  ± 6 .4 1 8 .4 5 .8
S u p e r f ic ia l  g ra y  la y e r  o f  th e  
s u p e r i o r  c o i l ic u lu s 5 4 .0  ± 2 .6 5 4 .8  ± 5 .8 5 7 .5  ± 1 1 .1 58.1 ± 10 .5 1 .5 1 .0
V e n tra l t e g m e n ta l  a r e a 2 6 .6  ±  2.1 3 0 .5  ± 5 .0 2 5 .8  ± 5 .1 2 9 .4  ± 2 .7 1 4 .3 1 3 .7
S u b s ta n t i a  n ig ra 7 .0  ± 1 .0 8.1 ± 1 .0 5 .7  ± 1 .0 8 .6  ± 1.6 1 6 .3 5 1 .2
Table 5.4 Q uantitative autoradiography o f  a7 nAChR binding in nicotine-treated W T  and adenosine A za receptor 
KO mice
Nicotine (7.8 mg/kg/day) was delivered to WT and Aza receptor KO GDI mice for a period of 14 days. The values of a l  nAChR 
binding represent the mean specific binding of [ I]a-bungarotoxin ± SEM in brain regions of 5-7 animals per group. Three-way 
ANOVA showed significant main effects of treatment [F(l,380)=9.3, P<0.01], region [F(19,380)=39.3, P<0.0001], and significant 
genotype x treatment interaction effects [F(l,380)=4.3, P<0.01]. No significant genotype effect [F(l,380)=0.1, P>0.05], and no 
genotype x region [F( 19,380)—0.3, P>0.05] or treatment x region [F(19,380)=0.1, P>0.05] interaction effects were observed on a7 
nAChR density.
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53.2.4 Dopaminergic receptor and transporter autoradiography in WT and adenosine 
A ia receptor KO mice, following chronic nicotine treatment
The impact of deletion of the adenosine A2A receptor gene on nicotine-induced 
dopaminergic binding was investigated in WT and adenosine A2A receptor KO animals 
by means of quantitative autoradiography of D1 and D2 receptors, and of the dopamine 
transporter (DAT). Three-way ANOVA revealed that chronic administration of nicotine 
increased D1 receptor density, compared to saline treatment (Fig. 5.12). [^F1]SCH23390 
binding was significantly enhanced in the nucleus accumbens core of nicotine-treated 
GDI mice, compared to controls. Following fourteen days of nicotine administration, D2 
receptor binding was significantly decreased in nicotine-treated animals, compared to 
saline controls. [^FI]raclopride binding was significantly downregulated in the rostral and 
caudal caudate putamen of nicotine-treated mice, compared to saline-treated animals (Fig. 
5.13). Importantly, the effect of nicotine on D1 and D2 receptor binding was similarly 
observed in both WT and adenosine A2A receptor KO mice. No treatment or genotype 
effects on dopamine transporter density were observed among groups (Fig. 5.14).
163
□  WT Saline 
■  WT N icotine 
S  KO Saline 
inn KO N icotine
oj 400 
I 375
« 300
O) 275-
I 250
R 175
Ü 125-
Figure 5.12 Quantitative autoradiography of dopaminergic D1 receptor binding in nicotine-treated WT and 
adenosine Aza receptor KO mice
The impact of deletion of the adenosine Aza receptor gene on D1 receptor binding was investigated using WT and adenosine Aza 
receptor KO animals, which had been treated with nicotine (7.8 mg/kg/day) for a period of 14 days. Values represent the mean 
spedfic binding ofFH]SClT23390 i  SEIW in bmin regions of 5-7 animals per group. Three-way ANC)V/L showed wgnifkant 
treatment effects on D1 receptor density [F(l,179)=4.0, P<0.05]. No main effect of genotype [F(l,179)=1.0, P>0.05], and no 
genotype x region [F(8,179)=0.3, P>0.05], treatment x genotype [F(l,179)=0.6, P>0.05], and treatment x region [F(8,179)=0.7, 
P>0.05] interaction effects on D1 receptor binding were observed. Duncan’s hoc analysis revealed that D1 receptor density 
was significantly increased in the nucleus accumbens core of nicotine-treated animals, compared to saline controls. 
Abbreviations: AcbC: Nucleus Accumbens, Core; AcbSh: Nucleus Accumbens, Shell; Tu: Olfactory Tubercle; CPuR: Caudate 
Putamen, Rostral part; CPuC: Caudate Putamen, Caudal part; SN: Substantia Nigra; VTA: Ventral Tegmental Area; Cl: 
Ciaustrum; DEn: Dorsal Endopiriform Nucleus.
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Figure 5.13 Q uantitative autoradiography o f dopam inergie D2 reeeptor binding in nicotine-treated W T  and  
adenosine A za receptor K O mice
Nicotine-induced changes in D2 receptor binding were examined in WT and adenosine Aza receptor KO GDI mice that had been 
treated with 7.8 mg/kg/day of nicotine for a period of 14 days. Values represent the mean specific binding of [^H]raclopride ± 
SEM in brain regions of 5-7 animals per group. Three-way ANOVA showed significant treatment effects on D2 receptor density 
[F(l,138)-11.8, P<0.01]. No main effect of genotype [F(l,138)=2.5, P>0.05], and no genotype x region [F(6,138)=0.3, P>0.05], 
treatment x genotype [F(l,138)=0.0, P>0.05], and treatment x region [F(6,138)=1.7, P>0.05] interaction effects on D2 receptor 
binding were observed. Duncan’s post hoc analysis confirmed that D2 receptor density was significantly decreased in the 
caudate putamen of nicotine-treated animals, compared to saline controls. Abbreviations: AcbC: Nucleus Accumbens, Core; 
AcbSh: Nucleus Accumbens, Shell; Tu: Olfactoiy Tubercle; CPuR: Caudate Putamen, Rostral part; CPuC: Caudate Putamen, 
Caudal part; SNc: Substantia Nigra, pars compacta; VTA: Ventral Tegmental Area.
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Figure 5.14 Quantitative autoradiography of dopaminergie transporter binding in nicotine-treated WT and 
adenosine Aza receptor KO mice
Nicotine (7.8 mgAg/day) was delivered to WT and A ,, receptor KO CDl mice for a period o f 14 days. Values of dopamine 
transporter binding represent the mean speeific binding of [’H]mazindoi ± SEM in brain regions o f 5-7 animals per group. 
Three-way ANOVA showed no significant main effects of treatment [F(l,139)=3.0, P>0.05] and genotype [F(l,139)=0.4, 
P>0.05], and no genotype x region [F(6,139)=0.0. P>0.05], treatment x genotype [F(l,139)=0.7. P>0.05]. and treatment x region 
[F(6,139)=0.2, P>0.05] interaction effects on dopamine transporter density. Abbreviations: Tu: Olfactoiy Tubercle; AcbC: 
Nucleus Accumbens, Core; AcbSh: Nucleus Accumbens, Shell; SNc: Substantia Nigra, pars compacta; VTA: Ventral Tegmental 
Area; CPuR: Caudate Putamen, Rostral part; CPuC: Caudate Putamen, Caudal part.
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5.4 Discussion
The development of adenosine A2A receptor KO mice has generated a wealth of 
information on the incidence of interactions between A2A receptors and the nicotinic 
cholinergic and dopaminergic systems, both at the behavioural (Castane et ah, 2006) and 
molecular levels (Svenningsson et ah, 2000). To further characterize nicotinic and 
dopaminergic regulation in mice with ablation of adenosine A2A receptors, quantitative 
autoradiography of a4p2* and a? nAChRs, dopaminergic D1 and D2 receptors, and of 
the dopamine transporters was performed in brain sections of drug naïve and nicotine- 
treated wild type (WT) and homozygous A2A receptor knockout (KO) animals.
In the current set of experiments, no changes in the distribution or density of a4p2* and 
a7 nAChRs were observed between drug naïve WT and KO animals, suggesting that 
deletion of the adenosine A2A receptor gene does not alter the constitutional expression of 
nicotinic cholinergic receptors. This lack of interdependence between nAChRs and A2A 
receptors builds on previous autoradiographic studies, which have examined the 
modification of several neurotransmitter systems in response to A2A gene deletion, 
drawing similar conclusions. Indeed, A2A receptor KO mice exhibit no compensatory 
alterations in the distribution and expression of MOP, KOP, DOP, and ORL-1 opioid 
receptors (Bailey et ah, 2002). Similarly, both the expression and the functional activity 
of cannabinoid CB-1 receptors remain unchanged in the adenosine A2A KO mouse (Soria 
et ah, 2004). Moreover, [^H]CGP-39653 (Dassesse et ah, 2001) and [^H]MK-801 (Chen 
et ah, 1999) autoradiography reveals no change in glutamatergic NMDA receptor binding 
between wild type and mutant mice, while no quantitative difference in striatal and 
cortical density of AMP A receptors has been detected between WT and A2A receptor KO 
animals (Snell et ah, 2000). In line with the above reports, it is shown here that the lack
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of adenosine A2A receptors does not impact on the distribution or binding characteristics 
of two major neuronal nAChR subtypes, the heteromeric a4g2* and the homomeric a7 
nicotinic receptors.
Within the mesolimbic dopaminergic pathway, a wide body of literature describes 
reciprocal antagonistic interactions between adenosine A2A and dopaminergic D2 
receptors (reviewed in Fuxe et al., 2007). In various cell lines, activation of A2A 
receptors has been shown to induce a reduction in D2 receptor affinity, Gi protein 
coupling, and signal transduction (Ferre et al., 1991; Dasgupta et al., 1996; Salim et al., 
2000; Hillion et al., 2002). Moreover, co-immunoprecipitation and resonance energy 
transfer studies show that A2a/D2  receptor heteromeric comlplexes are constitutively 
expressed in striatal cells (Hillion et al., 2002; Canals et al., 2003). The modest increase 
in D2 receptor density that was observed across all brain structures in drug naïve mutant 
mice may therefore reflect a global compensatory mechanism of the dopaminergic system 
in response to ablation of adenosine A2A receptors. Indeed, small increases in D2 
receptor mRNA expression have been consistently reported upon disruption of the A2A 
receptor gene (Dassesse et al., 2001; Short et al., 2006b). In keeping with these studies, 
which show that slightly increased D2 receptor mRNA does not translate to additional D2 
binding sites in individual areas of the A2A receptor KO brain, the quantification of 
[^HJraclopride binding revealed no region-specific differences in D2 receptor density 
between mutant and wild type animals. Nevetheless, the behavioural consequences o f a 
modest overall D2 receptor upregulation may be significant, as evidenced by the 
diminished haloperidol-induced catalepsy observed in A2A receptor KO mice (Chen et al., 
2001b).
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Previous reports on the regulation of D1 receptors in adenosine A2A receptor KO mice 
have produced contradictory results. In agreement with the current data, D1 receptor 
density is unaltered in A2A receptor KO animals developed on a C57BL/6 background 
(Chen et al., 2000; Chen et al., 2001b). On the other hand, evidence exists for increased 
DI receptor expression in mutant mice with mixed C57BL/6-CD1 genetic background 
(Short et al., 2006a), as well as in A2A receptor KO animals bred for fourteen generations 
on a CD I background (Dassesse et al., 2001). Similarly, the observed lack of alteration 
in DAT density between wild type and adenosine A2A receptor KO mice is consistent 
with studies on inbred (Chen et al., 1999; Chen et al., 2001a), but not mixed background 
strains (Short et al., 2006b). Therefore, the absence of a uniform genetic preparation 
between this and the aforementioned studies compromises the direct comparison and 
interpretation of results. In view of the significant impact that genes from parental strains 
have on the mutant phenotype (Crawley et al., 1997), it is highly probable that regulation 
of dopaminergic D l receptors and transporters depends on the mouse line being assessed.
Behavioural responses induced by nicotine have been shown to differ between wild type 
and adenosine A2A receptor KO mice, providing direct evidence for the involvement of 
A2A receptors in nicotine addiction (Castane et al., 2006). To further elucidate the 
neurochemical basis of this interaction, wild type and A2A receptor mutant mice were 
chronically treated with nicotine, and changes in the nicotinic cholinergic and 
dopaminergic systems were subsequently assessed by means of quantitative receptor 
autoradiography. The blood plasma concentrations of nicotine observed after fourteen 
days of subcutaneous treatment at 7.8 mg/kg/day (base-weight) are comparable with the 
nicotine levels achieved in C57BL/6 mice following chronic nicotine infusion at similar 
doses (Marks et al., 2004). At this nicotine concentration, enhanced a4p2* nAChR
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density was observed across brain areas that are particularly susceptible to upregulation, 
including regions of the cerebral cortex. Moreover, an increase of 72% and 25% was 
observed in the hippocampus and hypothalamus of nicotine-treated mice, respectively. 
On the contrary, cytisine-sensitive [^^^I]epibatidine binding sites in thalamic structures 
were resistant to nicotine-induced upregulation. These region-specific alterations in 
a4p2* nAChR density are in agreement with several reports, which have established that 
upregulation of high affinity binding sites in the mouse differs in individual brain areas, 
as a function of treatment dose (Pauly et al., 1991; Marks et al., 2004). Importantly for 
the present experiment, the observed changes in cytisine-sensitive [^^^I]epibatidine 
binding sites occurred with similar intensity and regardless of genotype, suggesting that 
direct interactions between A2A receptors and the nicotinic cholinergic system do not 
occur at the a4p2* nAChR level. Although this does not preclude functional alterations 
in a4p2* nAChR regulation, [^^^I]a-bungarotoxin autoradiography suggests that a7 
nAChRs mediate the reported nicotine-induced behavioural differences between WT and 
A2A mutant mice. In line with evidence that demonstrate upregulation of the low affinity 
nicotinic receptor in response to behaviourally relevant nicotine doses (Pauly et al., 1991; 
Rasmussen and Perry, 2006), chronic administration of the drug increased a l  nAChR 
density across all regions analysed, compared to saline treatment. However, enhanced 
nicotine-induced [^^^I]a-bungarotoxin binding sites were predominantly observed in brain 
regions of WT mice, rather than adenosine A2A receptor KO mutants, suggesting that a l  
nAChRs comprise the neurochemical substrate for interactions between nicotine and A2A 
receptors.
The enhancement of striatal DA release after acute nicotine administration is abolished in 
A2A receptor KO mice, indicating that the receptors mediate nicotine’s reinforcing
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properties by modulating mesolimbic DAergic neurotransmission (Castane et a l, 2006). 
Nevertheless, adenosine A2A receptors are not expressed on dopamine nerve terminals 
(Hettinger et al., 2001; Rosin et al., 2003). Therefore, hypodopaminergic responses in 
nicotine-treated A2A receptor mutants are probably secondary to nicotine’s effects on 
other neurotransmitter systems. The lack of nicotine-induced a l  nAChR upregulation in 
A2A receptor KO mice, implicates glutamatergic signalling in the mechanism of 
interactions between adenosine A2A receptors and nicotine. Indeed, by acting on a l  
nAChRs that are located presynaptically on glutamatergic nerve terminals, nicotinic 
agonists have been shown to modulate glutamate release in various brain regions, 
including the stiatum (Kaiser and Wonnacott, 2000), ventral tegmental area (Mansvelder 
and McGehee, 2000), hippocampus (Gray et al., 1996), amygdala (Girod et al., 2000), 
olfactory bulb (Alkondon et al., 1996), lateral geniculate nucleus (Guo et al., 1998), and 
synapses of the interpeduncular pathway (McGehee et al., 1995). In addition, nicotine 
induces adaptive changes in glutamatergic regulation postsynaptically, in brain areas that 
express high levels of [^^^I]a-bungarotoxin binding sites. Thus, nicotine administration 
upregulates metabotropic I glutamate receptors in the amygdala and VTA (Kane et al.,
2005), and increases NMDA receptor density and subunit expression in the hippocampus 
and prefrontal cortex, respectively (Levin et al., 2005; Wang et al., 2007). Accordingly, 
antagonism of mGluR5 receptors (Paterson et al., 2003) or a l  nAChRs (Markou and 
Paterson, 2001) reduces nicotine self-administration, and NMDA receptor blockade 
attenuates nicotine-induced a l  nAChR upregulation (Levin et al., 2005), suggesting that 
a l  nAChR can modulate glutamatergic signaling both at pre- and postsynaptic levels. 
The finding that increased a l  nAChR density was robustly observed in nicotine-treated 
WT mice may thus reflect impaired glutamatergic neurotransmission in the absence of 
the A2A gene. Functional synergistic interactions that favour glutamate signalling occur
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between A2A/mGluR5 receptors both pre- and postsynaptically (Ferre et a l, 2002; 
Rodrigues et al., 2005), as well as between A2a/NMDA receptors postsynaptically in the 
striatum (Quarta et al., 2004b). Furthermore, activation of presynaptic A2A receptors on 
glutamatergic terminals has been shown to potentiate glutamate release (Ciruela et al., 
2006). Therefore, the constitutional deletion of A2A receptors presumably removes 
adenosine’s pre- and postsynaptic facilitatory action on glutamate neurotransmission, 
further suggesting that the lack of upregulation in a-bungarotoxin binding sites in 
nicotine-treated A2A receptor mutants reflects decreased nicotine-induced glutamatergic 
neurotransmission.
In support of a substantial role for a l  nAChRs in mediating nicotine-adenosine A2A 
interactions primarily via glutamatergic, rather than dopaminergic mechanisms, similar 
changes in D l and D2 receptor density were observed between WT and adenosine A2A 
receptor KO mice following fourteen days of nicotine treatment. Chronic continuous 
nicotine administration has been shown to decrease D2 receptor binding in the rat basal 
ganglia (Janson et al., 1992), as well as D2 receptor availability in the dorsal striatum of 
human smokers (Fehr et al., 2008). In keeping with these reports, nicotine treatment in 
the current study resulted in a decrease of D2 receptor binding in the caudate putamen of 
CD I mice, irrespective of genotype. In addition, there were no genotype effects on 
dopamine transporter density, while nicotine-induced D l receptor upregulation was 
equally observed in the nucleus accumbens (NAc) core of WT and A2A receptor mutants. 
These results tie in with evidence for increased D l receptor mRNA expression in the 
NAc of nicotine-treated rats (Bahk et al., 2002), and with data from systemically or 
intracerebrally delivered nicotine, which show that acute and long-term changes in the 
mesolimbic dopaminergic pathway of nicotine-treated animals do not involve the
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dopamine transporter (Ferrari et al., 2002). Importantly, the lack of differential nicotine- 
induced dopaminergic regulation between WT and adenosine A2A receptor KO mice 
supports the hypothesis that a l  nAChR-mediated signalling is the predominant 
mechanism by which A2A receptors modulate the effects of chronic nicotine 
administration.
Of note, autoradiographic studies on the regulation of dopaminergic D l and D2 receptors 
following nicotine treatment have produced contradictory results. In contrast to this and 
the aforementioned studies, no change in DI and D2 receptor binding has been observed 
after seven weeks of oral nicotine administration in mice (Pietila et al., 1996), or 
following 21 days of continuous nicotine delivery via osmotic minipumps in the rat 
(Kirch et al., 1992). Moreover, dopamine receptor autoradiography in the human post­
mortem brain reveals no differences in D l or D2 binding density between smokers and 
the general population (Court et al., 1998). Hence, nicotine-induced dopamine receptor 
regulation seems to depend on the treatment paradigm used, as well as on the duration 
and dose of nicotine administration. Nevertheless, the present findings have been 
obtained at a behaviourally-relevant nicotine dose (Davis et al., 2005; Castane et al.,
2006), which resulted in nicotine plasma concentration that are compatible with those 
observed in human smokers (Russell et al., 1980). Notwithstanding that dopaminergic 
binding levels do not always translate to receptor function (Bailey et al., 2008), the 
current study suggests that the modulatory effects of adenosine A2A receptors on nicotine- 
induced neuroadaptation are exerted via actions on the a l  nAChR.
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6 QUANTITATIVE AUTORADIOGRAPHY OF HETEROMERIC NICOTINIC 
AND DOPAMINERGIC RECEPTORS, AND OF THE DOPAMINE 
TRANSPORTER IN C57BL/6 MICE, FOLLOWING CONTINGENT AND 
NON-CONTINGENT NICOTINE ADMINISTRATION
6.1 Introduction
Nicotine exerts its reinforcing effects by binding in the brain to its corresponding 
pharmacological targets, the neuronal nicotinic receptors (nAChRs). These are a 
heterogeneous family of pentameric structures, formed by the assembly of five a  and p 
subunits. To date twelve different subunits have been identified (a2-al0, p2-p4), whose 
combinations give rise to nAChRs with unique pharmacological properties and distinct 
topographical distribution (reviewed in Gotti and Clementi, 2004). This prominent 
heterogeneity accounts for many of nicotine’s acute reinforcing effects (Pidoplichko et al., 
1997). However, it cannot explain the transition from the activation of nicotinic receptors to 
addictive behaviour, which is a complicated and multistage process, involving the acquisition, 
maintenance, extinction, and reinstatement of drug-taking. The observation that nicotine 
administration leads to increased brain nAChR density in both cigarette smokers (Perry et al., 
1999) and animal models of nicotine consumption (Marks et al., 1983) is considered to be 
central to the course of development of nicotine addiction, and constitutes the hallmark of 
chronic nicotine exposure. Of the multiple nicotinic subtypes that exist in the mammalian 
brain, a4p2* receptors are abundantly expressed throughout the central nervous system, and 
they readily upregulate following exposure to nicotine (Nguyen et al., 2003; Marks et al., 
2004). As shown in a conditioned place preference paradigm, a mutation that renders a4 
subunits hypersensitive to agonists creates mice that are more susceptible to nicotine 
reinforcement than wild type animals (Tapper et al., 2004). Moreover, deletion of the p2
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subunit gene attenuates nicotine self-administration (Picciotto et al., 1998) and its re­
expression in the VTA of p2 subunit knockout animals re-establishes the behaviour (Maskos 
et al., 2005). Altogether, these data demonstrate an important role for a4p2* nAChRs in 
nicotine addiction.
Among the paradigms employed to model different aspects of drug reinforcement, self­
administration has been favoured as the most direct way of investigating the behavioural and 
neurobiological processes that lead to addiction. Its face validity is supported by increasing 
evidence, which suggests that drugs of abuse exert different effects, depending on whether 
their administration is forced by the experimenter or is under the control of the experimental 
animal (reviewed in Jacobs et al., 2003). The yoked-control paradigm has been particularly 
designed to examine differences produced by the active or passive drug administration. In 
this model, self-administering animals have control over the rate and amount of drug intake 
that a yoked littermate passively receives in an identical environment. Thus, potential 
differences in the consequences of active versus passive administration can be attributed to 
having control over the pattern of drug exposure. To determine the extent to which nicotine- 
induced neuroadaptation is the consequence of the drug’s direct pharmacological action or 
the result of the contingency between a subject’s response and the delivery of a reinforcer, a 
yoked-control paradigm of chronic nicotine administration in mice has been employed, using 
nose-poking as the operating response. The latter is considered to more naturally mimic 
smoking behaviour in mice, requiring less motor and motivational output than lever pressing 
responding (Pons et al., 2008). The consequences of active versus passive nicotine exposure 
on the nicotinic cholinergic and dopaminergic systems of C57BL/6 mice have been examined 
by means of quantitative autoradiography of cytisine-sensitive heteromeric nicotinic 
receptors, Dl and D2 dopaminergic receptors, and dopamine transporters.
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6.2 Materials and methods
The self administration experiments were carried out at the University of Pompeu Fabra, 
Barcelona, Spain, and the brains from the animals were provided for quantitative 
autoradiography. In order to fully interpret the autoradiography results, the methods and 
results for the self-administration protocol are presented in full.
6.2.1 Self administration paradigm
6.2.1.1 Animals
All animal procedures were conducted in accordance with the guidelines of the European 
Communities Directive 86/609/EEC regulating animal research, and were approved by 
the local ethical committee of the University of Pompeu Fabra, Barcelona, Spain (CEEA- 
IMAS-UPF). C57BL/6 male mice (Charles River Ltd., France), weighing 24-26 g at the 
beginning of the study were used. Animals were housed individually in controlled 
laboratory conditions under a reversed 13h/l Ih dark/light cycle (lights off at 7.30h, lights 
on at 20.30h), with the temperature maintained at 21 ± 1 °C, and humidity at 55 ± 10%. 
Mice were tested during the dark phase of the dark/light cycle. Food and water were 
available ad libitum, except during the experimental sessions.
6.2.1.2 Surgery and self-administration procedure
Mice were anaesthetised with a mixture of ketamine (100 mg/kg; Imalgène 1000; Rhône 
Mérieux, Lyon, France) and xylazine (20 mg/kg; Sigma, Madrid, Spain), and then 
implanted with indwelling i.v. catheters as previously described (Soria et al., 2005). 
Following surgery, all incisions were sutured and coated with antibiotic ointment 
(Bactroban, GlaxoSmithKline, Spain), and animals were allowed to recover for 3 days. 
Mice were subsequently randomly assigned to contingent or yoked groups (n=l 1). Drug
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self-administration experiments were conducted in mouse operant chambers (Model 
ENV-307A-CT, Medical Associates, Georgia, VT, USA), housed in sound- and light- 
attenuated boxes that were equipped with fans to provide ventilation and white noise. 
The house light was on at the beginning of the session for 3 sec and off during the 
remaining time. The chambers were equipped with two holes, of which one was selected 
as the active and the other as the inactive hole. Responding in both holes was recorded 
for all groups, throughout the experiments. The contingent group was trained to self- 
administer nicotine (0.03 mg/kg/infusion delivered in a volume of 23.5 pi over 2s; Sigma, 
Madrid, Spain) in single daily 1-h sessions for a period of 12 days. Each session started 
with a priming injection of nicotine or saline (depending on the group). Acquisition of 
nicotine self-administration was conducted under a fixed ratio 1 (FR-1) schedule of 
reinforcement; one poke in the active nose hole resulted in one nicotine infusion, while 
nose poking in the inactive hole had no programmed consequences. A 10 sec time-out 
period was established following each nicotine infusion. During this period, responses on 
the active and inactive holes were recorded but had no programmed consequences. The 
session was terminated after 50 infusions had been delivered, or after one hour, 
whichever occurred first. Each contingent mouse was connected to two animals, one in 
the yoked nicotine and one in the yoked saline groups. Yoked mice passively received 
the same number of drug infusions as compared with their self-administration partners, at 
identical times during each session. Their nose-poking activity on the active and inactive 
holes had no consequences. A stimulus light located above the active hole was paired 
with the delivery of nicotine or saline, according to the response o f the contingent mouse. 
The patency of intravenous catheters was evaluated periodically, and whenever drug self­
administration behaviour appeared to deviate dramatically from that observed previously, 
by the infusion of 0.1 ml of thiobarbital (5 mg/ml) through the catheter. If prominent
178
signs of anaesthesia were not apparent within 3 sec of the infusion, the mouse and its 
corresponding littermates were removed from the experiment. The criteria for the 
acquisition of self-administration behavior have been described previously (Orejarena et 
al., 2009; Trigo et al., 2009), and were achieved when all o f the following conditions had 
been met: a stable responding, with less than 20% deviation from the mean of the total 
number o f reinforces earned in three consecutive sessions (80% of stability), at least 65% 
of responding on the active hole, and a minimum of 4 nicotine infusions earned per 
experimental session. After each session, animals were returned to their home cages. At 
the end of the study mice were killed by cervical dislocation, their brains were rapidly 
removed and frozen for storage at -80 °C, and subsequently sent to the University of 
Surrey, UK, for quantitative autoradiography studies.
6.2.2 Quantitative receptor autoradiography
Quantitative autoradiography was performed in order to measure nAChRs with a4p2* 
subtype properties, dopaminergic Dl and D2 receptors, and the dopamine transporters (DAT), 
according to the procedures described in Section 3.2.6. On the day of each experiment, 
sections were thawed and processed according to established protocols, with minor 
modifications (Javitch et al., 1984; Marks et al., 2002; Lena et al., 2004). Sections for 
analysis of nAChR bindings were derived from 11 brains from each of the three treatment 
groups. Dopaminergic receptor and transporter binding was performed in 3 self- 
administering mice that achieved acquisition criteria, 3 that did not, and their corresponding 
littermates (n=6 per group). Multiple, adjacent sections from all groups were processed in a 
paired binding protocol. Radioligand bound sections were apposed to Kodak BioMax MR-1 
film (Sigma-Aldrich, UK), along with appropriate microscale standards, to allow 
quantification. For nAChRs, radioligand bound sections were apposed to film for 24h. All
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structures were identified by reference to the mouse brain atlas of Franklin and Paxinos, 
(2001), and analysed using an MCID image analyser (Image research, Linton, UK).
6.2.3 Statistical analysis
Behavioural results were analysed using a mixed-design multivariate analysis of variance 
(MANOVA), with group (contingent, non-contingent, and saline-treated) as the between- 
subjects variable. Daily sessions and hole (active vs. inactive) represented the within- 
subjects variable. Overall interactions were further analysed using the Newman-Keuls post 
hoc test, when the initial P value was smaller than 0.05. All the results are expressed as 
mean ± standard error of the mean (SEM).
For quantitative autoradiography, the mean±SEM of radioligand binding was calculated in 
each region for all three treatment groups, as previously described (Kitchen et al., 1997). 
Two-way ANOVA for the factors treatment and region was carried out in order to compare 
quantitative measurements of autoradiographic binding in brain areas of contingent, non­
contingent, and saline-treated animals. Moreover, quantitative differences in nicotinic and 
dopaminergic binding sites between self-administering mice that achieved acquisition criteria 
and those that did not were analysed using a separate two-way ANOVA. LSD post hoc 
analysis was applied, when appropriate, to investigate differences in radioligand binding 
between groups in individual regions. All data were analysed using the Statistica software 
(StatSoft Inc., France).
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6.3 Results
6.3.1 Nicotine self-administration
Figure 6.1 shows the mean number of nose-pokes in the active and inactive holes, carried 
out by nicotine contingent, non-contingent and saline-treated animals under an FR-1 
schedule of reinforcement, for each of the Ihr daily self-administration sessions.
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F ig u re  6.1 A cquisition  an d  m ain ten an ce  o f  n icotine se lf-ad m in is tra tio n  by  C57B L/6 m ice
Acquisition of nicotine self-administration was conducted under a fixed ratio 1 (FR-1) schedule of reinforcement; one poke in the 
active nose hole resulted in one nicotine infusion (0.03 mg/kg/infusion), while nose poking in the inactive hole had no 
programmed consequences. Data are expressed as mean ± SEM of the number of nose pokes in the active and the inactive holes 
during the 1-hour sessions performed over 12 days (n = 11). Stable drug-taking behaviour was observed in animals receiving 
response-dependent nicotine following day 7, and it was maintained for the duration of this study. The mean cumulative nicotine 
intake throughout the training sessions was at 0.25±0.04 mg/kg/hr. These data were collected by M.F. Barbano and L. Galeote at 
the University of Pompeu Fabra, Barcelona, Spain.
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At the nicotine dose of 0.03 mg/kg/inflision, contingent mice started to discriminate 
between the active and inactive holes from the first training session. The percentage of 
animals that proceeded to complete all o f the criteria for stable nicotine self­
administration was 54.5% (six out of eleven), and the mean time of acquisition was 
8.83±1.19 days. On the contrary, nicotine- and saline- yoked mice did not discriminate 
between holes in any of the experimental sessions. On days 1 and 2, the number of nose 
pokes was enhanced in all groups, compared to days 3-12. The mean nicotine intake 
decreased from 0.38±0.01 mg/kg/hr on days 1 and 2, to 0.22±0.01 mg/kg/hr for days 3-12. 
Contingent mice showed a mean cumulative nicotine intake of 0.25±0.04 mg/kg/hr 
throughout the training sessions. In the case of the animals that achieved acquisition 
criteria, the mean intake of nicotine during the last three days of self-administration was 
0.35±0.09 mg/kg/hr. The overall ANOVA revealed a statistically significant effect of the 
factors group [F(2,31)=10.4, P<0.001], time [F(ll,341)=11.3, P<0.001], and nose-poke 
[F(l,31)=35.7, P<0.001], as well as significant group x nose-poke interaction effects 
[F(2,31)=l 1.9, P<0.001]. Newman-Keulspost hoc analysis confirmed that the responses 
on the active nose-poke were significantly higher only in the contingent group and not in 
the yoked groups.
6.3.2 Quantitative receptor autoradiography
6.3.2.1 Effects of response contingency on nAChR density
Quantitative autoradiography was conducted for a4p2* nAChRs, using 100 pM of 
[*^^I]epibatidine alone or in the presence of cytisine (20 nM). The majority o f mouse 
brain [^^^Ijepibatidine binding sites were of the cytisine-sensitive, a4g2* subtype. Non­
specific [^^^Ijepibatidine binding was indistinguishable from film background (Fig. 6.2).
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Figure 6.2 Com puter-enhanced colour autoradiogram s o f  total, cytisine-resistant, and non-specific  
l‘^^I|epibatidine binding in coronal sections from saline-treated C57BL/6 mouse brain.
Adjacent sections were incubated for 2 hrs with 100 pM o f ['^^Ijepibatidine alone (first row) or in the presence of 
20 nM cytisine (second row), and 300 pM (-) nicotine hydrogen tartrate (third row). Non-specific binding was 
indistinguishable from film background. The majority of ['^^Ijepibatidine binding sites were of the cytisine-sensitive, 
a4p2* subtype. High levels of cytisine-resistant [ '“^Ijepibatidine binding were observed in the medial habenula, 
fasciculus retroflexus, and interpeduncular nucleus. Sections were apposed to Kodak BioMax MR-1 film for a period 
of 24 hours. The colour bar indicates a pseudo-colour interpretation of black and white image density, calibrated in 
fmol/mg of tissue equivalent.
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The density o f total, cytisine-sensitive, and cytisine-resistant [^^^I]epibatidine binding in 
brain regions of saline, contingent, and non-contingent mice is detailed in Tables 6.1, 6.2, 
and 6.3, respectively. For total [^^^I]epibatidine binding, significantly higher levels of 
heteromeric nAChR density were observed in the superficial gray layers of the superior 
colliculus (SuG), the dorsal (DLG) and ventral (VLG) lateral geniculate nucleus, and the 
lateral posterior thalamic nucleus (LPMR) of contingent mice, compared to saline 
controls. In non-contingent nicotine animals, higher levels of heteromeric receptor 
binding were observed in the VLG compared to saline-treated mice. Contingent nicotine 
increased total [^^^IJepibatidine binding in the ventral tegmental area and the SuG of self- 
administering mice, compared to non-contingent animals. Two-way ANOVA (treatment 
and region) showed significant main effects of treatment [F(2,462)=13.3, P<0.001] and 
region [F( 17,462)= 183.0, P<0.001], with no significant treatment x region interaction 
effects [F(34,462)=1.0, P>0.05].
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R egion
f  ^ ®l]epibatidine sp e c if ic  b ind ing  
(fm ol/m g tis su e )
% c h a n g e  in b in d in g
S a lin e C o n tin g en t Non C o n tin g en t sa lin e  v s. sa lin e  v s. 
c o n tin g e n t n o n  c o n tin g e n tDopaminergic regions
C a u d a te  P u tam en 1 2 .9  ± 0 .7 1 3 .6  ± 0 .6 1 3 .0  + 0 .4 5 .2 1.0
N ucleus a c c u m b e n s , co re 9 .2  ±  0 .6 10.2 ± 0 .6 9 .3  + 0 .4 10.2 0 .5
N ucleus a c c u m b e n s , sh e ll 9 .8  ± 0 .6 1 0 .0  ± 0 .5 9 .6 +  0 .5 2 .9 -1 .5
S u b s ta n tia  n igra, p a rs  co m p a c ta 2 2 .7  ± 0 .8 2 2 .7  ± 1 .3 21.6 + 1 .2 0.0 -5 .0
V entral teg m en ta l a rea 2 3 .3  ± 1 .3 2 6 .6  ± 1 .5 2 2 .4  + 1.3*' 1 4 .3 -3 .9
Optic tract regions
Visual co rtex 9 .8  ± 0 .4 9 .9  ± 0 .5 9 .2 +  0 .6 1.6 -5 .6
Superficial gray  layer o f th e  
su p e r io r  co llicu lu s
3 2 .4  ± 1 .8 3 7 .5  ±2.4** 3 2 .4  + 2.2** 1 5 .7 -0.1
D orsal lateral g e n ic u la te  n u c le u s 3 2 .7  ± 0 .9 3 9 .2  ± 2.2*** 3 6 .1 + 1 .9 1 9 .9 1 0 .4
V entral lateral g e n ic u la te  n u c le u s 2 9 .6  ± 0 .9 3 5 .7  ±1.9*** 3 4 .2  + 2.3** 2 0 .5 1 5 .4
Other regions
A ccesso ry  o lfactory  bu lb 2 3 .7  ± 1 .1 2 5 .2  ± 1 .4 2 7 .4  + 3 .5 6 .4 1 5 .8
In su la r co rtex 9 .6  ± 0 .3 1 0 .4  ± 0 .5 9 .8 +  0 .4 8 .4 2.2
C in g u la te  co rtex 10.2 ± 0 .6 1 0 .3  ± 0 .6 9 .8  + 0 .4 1 .9 -3 .7
O lfactory tu b e rc le 10.1 ± 0 .9 11.6 ± 0 .8 1 1 .3  + 0 .8 1 4 .6 1 1 .9
Lateral p o s te r io r  th a lam ic  n u c le u s 2 3 .4  ±  0 .9 2 7 .2  ± 1 .4 * 2 4 .7  + 1.0 1 6 .5 5 .6
P o s te r io r  th a lam ic  n u c le a r  g ro u p 21.0 ± 1 .0 2 4 .3  ± 1 .8 2 3 .5  + 1 .6 1 5 .7 11.8
Medial g en ic u la te  n u c le u s 2 2 .9  ± 1 .0 2 4 .6  ± 1 .3 2 3 .0  + 1 .3 7 .6 0.6
In term ed ia te  g ray  layer o f  th e  
su p e r io r  co llicu lu s
1 8 .0  ± 1 .0 1 8 .5  ± 1 .0 16.1 + 1.1 2 .4 -1 0 .5
A nteroven tra l th a lam ic  n u c le u s 3 4 .8  ± 0 .8 36.1 ± 1 .8 3 3 .9  + 2.1 3 .6 -2 .8
Mean 9 .3 2 .3
Table 6.1 Q uantitative autoradiography o f  total p^^Ijepibatidine binding in nicotine contingent, non contingent, 
and saline treated animals
Nicotine was administered to C57BL/6 mice using a yoked-control paradigm of self-administration for a period of 12 
days. At the end of treatment animals were killed by cervieal dislocation and their brains were removed and processed 
for quantitative autoradiography of heteromeric nAChRs. Values of total [*^ I^]epibatidine binding represent mean ± 
SEM in brain regions of 11 animals per group. *P<0.05, **P<0.01, ***P<0.001 vs. saline controls, ^P<0.05, ^P<0.01 
vs. contingent values, LSD post hoc.
Significantly higher levels of a4p2* nAChRs were observed in the dorsal lateral 
geniculate nucleus (DLG) and the VTA of self-administering mice, compared to non­
contingent animals and to saline controls. Contingent nicotine also increased cytisine- 
sensitive [^^^IJepibatidine binding in the superficial gray layers of the superior colliculus
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(SuG) and certain thalamic nuclei, such as the ventral lateral geniculate nucleus (VLG), 
the posterior thalamic nuclear group (Po), and the lateral posterior thalamic nucleus 
(LPMR), compared to saline treatment. In non-contingent animals, higher levels of 
a4p2* receptor binding were observed in the VLG and SuG compared to saline controls. 
For nAChRs with a4p2* nAChR properties, two-way ANOVA showed significant main 
effects of treatment [F(2,463)=20.4, P<0.001] and region [F(17,463)=48.3, P<0.001], 
with no treatment x region interaction effects [F(34,463)=1.2, P>0.05]. LSD post hoc 
analysis confirmed significant, region specific differences in cytisine-sensitive 
[^^^I]epibatidine binding between self-administering and nicotine-yoked mice in the VLG 
and the VTA.
No differences in cytisine-sensitive [^^^I]epibatidine binding sites were detected between 
contingent mice that achieved acquisition criteria, and animals that did not stably respond 
for nicotine [F(l,140)=1.8, P>0.05].
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R eg io n
[^^^l]epibatidine sp e c if ic  b in d in g  
(fm ol/m g t is s u e )
% c h a n g e  in b in d in g
sa l in e  v s . 
c o n tin g e n t
sa l in e  v s. 
n o n  c o n tin g e n tS a lin e C o n tin g e n t Non C o n tin g e n t
Dopaminergic regions
C a u d a te  P u ta m e n 1 0 .7 1 0 .6 1 1 .4 ± 0 .5 1 0 .8  ± 0 .4 6.6 0 .9
N u c leu s  a c c u m b e n s ,  c o re 7 .3 1 0 .6 8 .0  ± 0 .4 7 .3  ± 0 .3 9 .9 1.1
N u c leu s  a c c u m b e n s ,  sh e ll 7 .6 1 0 .6 7 .9  ± 0 .4 7 .5  ± 0 .3 3 .9 -1 .3
S u b s ta n tia  n ig ra , p a rs  c o m p a c ta 1 7 .2 1 1 .3 1 8 .7  ± 1 .0 1 7 .9  ± 1 .2 8 .7 4.1
V entral te g m e n ta l a re a 1 6 .4 1 1 .2 2 0 .4  ± 1 .0 * 1 7 .0  ± 1 .0 * 2 4 .3 3 .4
Optic tract regions
V isual c o r te x 9 .2 1 0 .4 9 .3  ± 0 .4 8.8 ± 0 .6 1 .5 -3 .9
S u p e rfic ia l g ra y  lay e r o f  th e  
s u p e r io r  c o llic u lu s
1 3 .4 1 1 .2 1 8 .2 ± 2 .1 * 1 7 .2  ± 2 .3 * 3 6 .2 2 8 .7
D orsal la te ra l g e n ic u la te  n u c le u s 2 0 .6 1 0 .9 2 7 .8  ± 2.4*** 2 3 .4  ± 1 .5 * 3 5 .0 1 3 .6
V entral la te ra l g e n ic u la te  n u c le u s 1 7 .3 1 0 .7 2 4 .6  ±1.8*** 2 1 .5  ± 1 .5 * 4 2 .2 2 4 .3
Other regions
A c c e s s o ry  o la fc to ry  b u lb 6 .5 1 0 .8 9 .3  ± 2 .0 9 .2  ± 1 .0 4 3 .1 4 1 .5
In su la r  c o rte x 8 .8 1 0 .3 9 .4  ± 0 .5 9.1 ± 0 .4 6.8 3 .4
C in g u la te  c o r te x 9 .5 1 0 .5 9 .7  ± 0 .5 9.1 ± 0 .4 2.6 -3 .4
O lfac to ry  tu b e rc le 8 .9 1 1 .0 9 .8  ± 0 .7 9 .9  ± 0 .8 1 0 .5 11.6
L ateral p o s te r io r  th a la m ic  n u c le u s 1 8 .8 1 0 .9 22.6 ± 1 .1 * 20.6 ± 1 .1 1 9 .8 9 .6
P o s te r io r  th a la m ic  n u c le a r  g ro u p 1 8 .3 1 0 .9 2 1 .4  ± 1 .8 * 2 0 .7  ± 1 .6 1 7 .2 1 3 .2
M edial g e n ic u la te  n u c le u s 1 9 .7 1 1 .1 2 1 .4  ± 1 .0 2 0 .3  ± 1 .3 8 .7 2.8
In te rm ed ia te  g ra y  lay er o f  th e  
s u p e r io r  c o llic u lu s
1 2 .7 1 1 .0 1 5 .8  ± 0 .8 1 3 .8  ± 1 .2 2 4 .2 8 .9
A n te ro v en tra l th a la m ic  n u c le u s 3 0 .4 1 0 .8 3 1 .2  ± 1 .6 29 .1  ± 2 .1 2 .5 -4 .4
M ean 1 6 .9 8.6
Table 6.2 Q uantitative autoradiography o f  cytisine-sensitive [^^®I]epibatidine binding in nicotine contingent, non 
contingent, and saline treated animals
Values of cytisine-sensitive [*^ I^]epibatidine binding represent mean ± SEM in brain regions of 11 animals per group, 
and were quantified after the subtraction of cytisine-resistant from total ['^ I^Jepibatidine binding. *P<0.05, 
***P<0.001 vs. saline controls, ^P<0.05 vs. contingent values, LSD post hoc.
Cytisine-resistant binding was significantly lower in the SuG, the intermediate gray layer 
of the superior colliculus (InG), and the substantia nigra pars compacta (SNs) o f nicotine 
yoked animals, compared to saline controls. A lower level of cytisine-resistant binding 
was also observed in the InG of se lf  administering animals, compared to controls. Two 
way ANOVA confirmed significant main effects of treatment [F(2,463)=3.0, P<0.05] and
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region [(F17,463)=216.8, P<0.001], and significant treatment x region interaction effects 
[F (34,463)=!.5, P<0.05] on cytisine-resistant receptor density. No differences were 
detected between nicotine-contingent and yoked mice, in any of the brain regions 
analysed [F(l,140)=2.0, P>0.05].
f^^l]epibatidine spec ific  binding 
(fmol/mg tissu e )
% ch an g e  in binding
Region
Saline C ontingent Non C ontingent
sa iine  v s. sa line  vs. 
co n tin g en t non con tingen t
Dopaminergic regions
C audate Putam en 2.1 ± 0 .2 2.2 ± 0 .2 2.2 1 0 .2 0 .5 2.8
N ucleus accum bens, core 2 .0  ± 0.3 2.2 ± 0 .2 2.0 1 0 .2 11.1 -1.5
N ucleus accum bens, shell 2.2 ±  0 .2 2.1 ± 0 .2 2.0 1 0 .2 -0.9 -5.6
S u b stan tia  nigra, pa rs  com pacta 5 .5  ± 0.9 4 .0  ± 0 .7 3 .7 1 0 .5 * -26.2 -32.1
Ventral tegm ental area 6.8 ± 0 .3 6 .2  ± 0 .5 5 .3 1 0 .5 -9.7 -22.6Optic tract regions
Visual cortex 0.6 ± 0.1 0 .7  ±0 .1 0 .4 1 0 .1 4 .8 -29.0
Superficial gray layer o f th e  su p erio r 
colliculus 19.1 ± 1.0 19.3 ± 1 .5 15.111.2*** 1.2 -20.6
Dorsal lateral gen icu late  nucleus 12.2 ± 0 .5 1 1 .4 ± 0 .9 1 2 .7 1 1 .0 -5.8 4 .3
Ventral lateral gen icu late  nucleus 12.4  ± 0 .6 11.1 ±1 .1 1 2 .7 1 1 .4 -10.4 2.6
Other regions
A ccessory  olfactory bulb 17.2  ± 1 .0 15.9 ± 1 .2 1 8 .2 1 3 .3 -7.6 6 .4
Insular cortex 0.8 ± 0.1 0 .9  ±0 .1 0 .7 1 0 .1 14.6 -17.1
C ingulate cortex 0 .7  ± 0.1 0.6 ±0 .1 0 .6 1 0 .1 -8.7 -13.0
Olfactory tubercle 1.2 ± 0 .2 1.8 ± 0 .2 1 .4 1 0 .2 4 6 .7 13.3
Lateral p o ste rio r thalam ic n ucleus 4 .6  ± 0.3 4 .7  ± 0 .4 4 .1 1 0 .3 2.9 -11.0
Posterio r thalam ic nuc lear group 2.8 ±  0 .2 2 .9  ± 0 .2 2 .8 1 0 .3 5.5 1.8
Medial gen icu late  n ucleus 3 .2  ± 0.3 3 .2  ± 0 .3 2 .8 1 0 .5 0.9 -13.1
Interm ediate gray layer of th e  su p erio r 
colliculus 5 .3  ± 1 .1 2 .7  ±0.3** 2.310.5*** -49.5 -56.9
Anteroventral thalam ic nucleus 4 .4  ±  0.6 4 .9  ± 0 .5 4 .8 1 0 .4 11.6 8.6
M ean -1.1 -10.1
Table 6.3 Q uantitative autoradiography o f cytisine-resistant [*^®I]epibatidine binding in nicotine contingent, non 
contingent, and saline treated anim als
Values o f  cytisine-resistant ['^^IJepibatidine binding represent mean ±  SEM in brain regions o f  11 animals per group. 
*P<0.05, **P<0.01, ***P<0.001 vs. saline controls, LSD post hoc.
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Figure 6.3 shows representative autoradiograms of [’^ ^Ijepidatidine binding sites in 
coronal brain sections from saline and nicotine treated mice, cut at the level of the 
thalamus and of the ventral tegmental area.
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Figure 6.3 Representative autoradiogram s o f heteromeric nAChR binding in coronal brain sections from  
nicotine contingent, non contingent, and saline treated animals
The effects of response-contingency on nicotinic receptor binding populations are shown at the levels of thalamus 
(bregma -2.06 mm), and the VTA (bregma -3.16), following nicotine self-administration. a4p2* receptor expression 
was calculated after subtraction of specific cytisine-resistant ['^ I^Jepibatidine binding from total ['^ "’IJepibatidine 
binding. Response-dependent nicotine increased a4p2* receptor binding in the dorsal geniculate nucleus and the 
ventral tegmental area of self-administering mice, compared to yoked animals. The colour bar indicates a pseudo­
colour interpretation of black and white image density, calibrated in fmol/mg of tissue equivalent.
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6.3.2.2 Effects o f  response contingency on dopaminergic D1 and D2 receptors, and on 
dopamine transporter density
Full quantification of dopaminergic D1 and D2 receptor binding, and of the dopamine 
transporters (DAT) was carried out on brain sections from all treatment groups, using 
£^H]SCH23390, [^H]raclopride, and [^H]mazindol, respectively. For D2 receptor binding, 
two-way ANOVA revealed significant main effects of treatment [F(2,95)=6.1, P<0.01] 
and region [F(6,95)=74.4, P<0.001], with no significant treatment x region interaction 
effect [F(12,95)=0.3, P>0.05] (Fig. 6.4). There was an overall increase in D2 receptor 
binding across all regions, in both nicotine contingent and non-contingent mice, 
compared to saline controls. However, post hoc comparison revealed no individual 
region significant increase among groups. The small level of increase in D2 receptor 
density was observed in self-administering animals, as well as in contingent mice that did 
not fulfil acquisition criteria [(Fl,24)=0.0, P>0.05].
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Figure 6.4 Q uantitative autoradiography o f D2 receptor binding in nicotine contingent, non contingent, and  
saline treated animals
Nicotine was administered to C57BL/6 mice using a yoked-control paradigm of self-administration for a period of 12 
days. At the end of treatment animals were killed by cervical dislocation and their brains were removed and processed for 
quantitative autoradiography of Dopaminergic D2 receptors. Values represent the mean specific binding of 
[^Hjraclopride ± SEM in brain regions of 6 animals per group. Abbreviations: AcbC: Nucleus Accumbens, Core; AcbSh: 
Nucleus Accumbens, Shell; CPuR: Caudate Putamen, Rostral part; CPuC: Caudate Putamen, Caudal part; SNc: 
Substantia Nigra, pars compacta; VTA: Ventral Tegmental Area; Tu: Olfactory Tubercle.
Neither response-dependent, nor passively received nicotine had any significant effects 
on dopamine D1 receptor [(F2,133)=2.6, P>0.05] and dopamine transporter binding 
[(F2,105)=2.0, P>0.05], compared to saline treatment (Fig. 6.5). Moreover, no changes 
in D1 receptor density [(Fl,36)=0.2, P>0.05] and DAT binding [(FI,28)= 1.1, P>0.05] 
were detected in brain sections from animals that stably responded for nicotine, compared 
to mice that did not achieve acquisition criteria. Representative autoradiograms of 
dopaminergic receptor and transporter bindings in brain sections of nicotine contingent, 
yoked, and saline-treated animals are shown in Figure 6.6.
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Figure 6.5 Q uantitative autoradiography o f D1 reeeptors (A) and dopam ine transporters (B) in nicotine 
contingent, non contingent, and saline treated animals
The effects of response-contingency on dopaminergic D1 receptors and transporters are shown following nicotine self­
administration for 12 days. No treatment effect on D1 receptor density and on DAT binding was observed among groups. 
Abbreviations: AcbC: Nucleus Accumbens, Core; AcbSh: Nucleus Accumbens, Shell; Amy: Amygdala; Tu: Olfactory Tubercle; 
CPu: Caudate Putamen; CPuR: Caudate Putamen, Rostral part; CPuC: Caudate Putamen, Caudal part; SN: Substantia Nigra; SNc: 
Substantia Nigra, pars Compacta; VTA: Ventral Tegmental Area; Cl: Claustrum; DEn: Dorsal Endopiriform Nucleus.
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Figure 6.6 Com puter-enhanced colour autoradiogram s o f dopam ine D2 (A) and D1 receptors (B), and o f  DA 
transporters (C), in coronal brain sections from  nicotine contingent, non contingent, and saline treated 
animals
Sections were labelled with 4nM [^HJraclopride, [^H]SCH23390, and [^H]mazindol, for D2 and DI receptors, and for 
DAT, respectively. The horizontal panels show adjacent sections cut at the level of the caudate putamen (bregma 
0.98mm), and of the ventral tegmental area (bregma -3.40mm). Sections were apposed to Kodak BioMax MR-1 film 
for a period of 5-6 weeks. Specific binding was calculated after subtraction of non-specific binding images from total 
binding images. No change in D 1 and DAT binding was observed among groups. The colour bars indicate a pseudo­
colour interpretation of black and white image density, calibrated in fmol/mg of tissue equivalent.
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6.4 Discussion
Previous studies have shown that nicotine, at a concentration range between 0.01-0.05 
mg/kg/infusion, supports self-administration in diverse species, including humans 
(Henningfield et al., 1983), non-human primates (Goldberg et al., 1981) and rodents 
(Martellotta et al., 1995; Donny et al., 1998). In agreement with this literature, it is 
shown here that freely moving C57BL/6 mice will chronically self-administer an optimal 
dose of response-dependent nicotine, using nose-poking as the operating procedure. The 
yoked-control model of self-administration allows discriminating the neurobiological 
response that occurs as a result o f the direct pharmacological effects of a drug, from 
neuroplasticity that is due to the contingency between a behavioural reaction and drug 
delivery. By applying this operant paradigm in mice, it is revealed that differential 
neuroadaptation takes place in the nicotinic cholinergic system, depending on whether 
nicotine is administered actively or passively. Indeed, cytisine-sensitive [^^^I]epibatidine 
binding differed between self-administering and nicotine-yoked animals in the ventral 
tegmental area (VTA) and the dorsal lateral geniculate nucleus (DLG), suggesting that 
these brain regions are critically involved in the processes relating to nicotine self­
administration.
The increased rate of self-administration observed on days 1 and 2 may be partly 
attributed to the novelty of the experimental procedure. Similar patterns of increased 
intake during the initial phase of drug exposure have also been observed elsewhere 
(Mendizabal et al., 2006). As early as on day 1, however, contingent mice were 
discriminating between the active and inactive holes, suggesting that the enhanced initial 
consumption may partly constitute a specific, nicotine-maintained effect on behaviour. 
In line with this, a pattern of escalated drug intake that levels off in subsequent sessions
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has also been observed in rats that chronically self-administer nicotine (O'Dell et al.,
2007). Out of a wide range of doses, acute self-administration of nicotine in mice occurs 
around a narrow window of approximately 0.03 mg/kg/infusion, indicating that rodents 
will tightly regulate their amount of nicotine intake (Paterson et al., 2003; Pons et al.,
2008). Indeed, titration seems to be an important feature of nicotine self-administration 
across species, as both adult (Benowitz and Jacob, 1985) and adolescent (Kassel et al., 
2007) smokers carefiilly control their nicotine levels in order to experience the 
reinforcing effects of the drug. The observed enhanced initial rate of nicotine 
consumption may thus reflect a learning response at a given level of titration, which 
rapidly occurred within the first two experimental sessions.
Following day 7, reliable drug-taking behaviour was observed in animals receiving 
response-dependent nicotine, which was maintained for the duration of the experiment. 
Response-contingent animals adjusted their behaviour to obtain a mean drug intake of 
0.25 mg/kg/session, which approximates the range of nicotine chronically self­
administered by rats (Donny et al., 1995; Kenny and Markou, 2006). As demonstrated by 
cytisine-sensitive [^^^Ijepibatidine autoradiography, exposure to this dose of nicotine lead 
to region-specific increases of a4p2* nAChR density in the brains of self-administering 
animals. The upregulation displayed marked regional variability, with several areas of 
the brain participating and showing different sensitivity to upregulation. In this respect, 
these findings are consistent with previous observations that experimenter-administered 
nicotine (Marks et al., 1983; Schwartz and Kellar, 1983; Nguyen et al., 2003), as well as 
nicotine self-administration by rats (Parker et al., 2004), produces regional-specific 
increases in the density of nicotinic receptors. A plethora of experimental work has 
established nAChR upregulation as the hallmark of chronic nicotine treatment. Using
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intravenous nicotine infusion, it has been consistently demonstrated that nicotine-induced 
receptor upregulation is a dose and time dependent phenomenon, with the half maximal 
dose required to induce 50% of region-specific nAChR upregulation in mice being 
approximately 0.5 mg/kg/hr (Marks et al., 1991; Pauly et al., 1991; Marks et al., 2004). 
In the present study, the mean daily amount of se lf  administered nicotine was at 0.25 
mg/kg/hr. Therefore, it is not surprising that this dose failed to produce pronounced 
nAChR upregulation in animals passively receiving nicotine. Equal doses of self­
administered nicotine, however, produced the typical pattern of dose-dependent, region- 
specific nAChR upregulation across several brain regions. Therefore, this study 
underlies the significance of contingency in nicotine-induced neuroadaptation, since 
a4p2* nAChR upregulation was observed with smaller, albeit behaviourally relevant 
doses of nicotine. The finding that cytisine-sensitive [^^^I]epibatidine binding sites were 
increased in response-dependent mice that were stably se lf  administering nicotine, as 
well as in animals that did not achieve acquisition criteria, further supports that it is the 
contingent relationship between a behavioural response and drug delivery that crucially 
mediates nicotine-induced neuroplasticity.
Among the regions that responded differently to active and passive nicotine 
administration, the VTA is the biological substrate most likely to be involved in the 
initiation and maintenance of drug-taking behaviour. The VTA is source of the 
dopaminergic projection to the nucleus accumbens (NAc), and it has been implicated in 
mediating the reinforcing properties of many drugs of abuse, including nicotine (Di 
Chiara, 2000). Rats will self-administer nicotine directly into the VTA through 
intracranial injections, a behaviour that is attenuated by co-infusion of the p2-subunit 
antagonist DhOE, indicating that nicotine’s rewarding effects are exerted through
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nAChRs in this brain region (Corrigall et al., 1994). Moreover, evidence from studies on 
gain-of-function a4 nAChR subunit knock-in animals (Tapper et al., 2004), as well as 
data from p2 subunit knock-out mice (Picciotto et al., 1998), further reveals the critical 
role of VTA a4p2* receptors in mediating nicotine reinforcement. Therefore, the present 
data are not only in keeping with several other lines of evidence, but further suggest that 
a4p2* nAChRs in the VTA are particularly sensitive to small doses of nicotine, when the 
drug is self-administered rather than passively received.
A large body of literature suggests that nicotine reinforcement is not only the result of the 
drug’s primary rewarding effects, but also stems from nicotine’s ability to establish 
concurrent stimuli as conditioned reinforcers (reviewed in Chaudhri et al., 2006). In rat 
studies, environmental stimuli promote the rapid acquisition of drug-seeking behaviour 
(Caggiula et al., 2002), and the maintenance of nicotine self-administration during saline 
substitution (Donny et al., 1999). Although the dissociation of nicotine’s primary 
reinforcing, from its reinforcement-enhancing effects was not an aim of this study, the 
autoradiography data are suggestive of a role for the visually paired stimulus in the 
acquisition of nicotine self-administration. Increased cytisine-sensitive [^^^Ijepibatidine 
binding was observed in self-administering mice compared to nicotine yoked animals in 
the DLG, a brain region that is dedicated to the processing of visual information. In cells 
of the DLG, P2 subunits have been associated with fast latencies of visual responding, 
and high visually evoked firing rates (Grubb and Thompson, 2004). Moreover, mouse 
DLG neurons are capable of switching from tonic to burst firing, in order to facilitate 
signal detection (Grubb and Thompson, 2005). The enhanced density of a4p2* nAChRs 
in these brain areas may therefore underlie intense visual information processing, which 
might contribute to the acquisition of self-administration.
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Neuronal nAChRs constitute a heterogeneous family of receptors, which, depending on 
their subunit composition, exhibit distinct physiological and pharmacological properties 
(reviewed in Dani and Bertrand, 2007). From the present results, the possibility that 
contingent nicotine preferentially increases cytisine-sensitive [^^^IJepibatidine binding, 
while its passive administration regulates other nicotinic subtypes in a similar manner 
cannot be excluded. Cytisine-resistant nAChRs correspond to structurally diverse 
receptor subtypes, which require expression of a3, a4, a6, a2, p2, and p4 subunits (Gotti 
et al., 2005; Marks et al., 2006). Although cytisine-resistant nAChR density did not 
differ between animals receiving nicotine in a response-dependent or passive manner, 
subtle alterations in subunit-specific responses to contingent or passive nicotine remain to 
be examined. a6 subunits, for instance, have been shown to be crucially involved in 
acute nicotine self-administration (Pons et al., 2008). However, autoradiographic studies 
on the effects of chronic nicotine administration on a6* nAChRs have not yet produced 
conclusive results (Nguyen et al., 2003; Parker et al., 2004; Mugnaini et al., 2006). In 
addition, a3p4 nAChRs are relatively resistant to up-regulation, both in vivo and in vitro 
(Wang et al., 1998; Davila-Garcia et al., 2003; Nguyen et al., 2003). Moreover, evidence 
argues against the role of a7 nAChRs in nicotine reinforcement (Walters et al., 2006; 
Pons et al., 2008). Therefore, it seems probable that the effects of operant contingency 
are primarily depicted as changes in cytisine-sensitive nAChR density in self- 
administering mice.
Whatever produces neurobiological differences between response-dependent and 
passively received nicotine, it does not seem to involve dopaminergic DI and D2 
receptors or the dopamine transporters. In the current study, drug administration did not
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alter DI receptor or DAT density, and it equally upregulated D2 receptors in contingent 
and non-contingent animals. As shown by in vivo microdialysis, extracellular dopamine 
levels do not differ between rats self-administering nicotine and nicotine-yoked animals, 
further suggesting that dopaminergic responses to chronic nicotine administration are 
independent of response contingency (Rahman et al., 2004). D2 receptors have been 
implicated in nicotine dependence in both human (McEvoy et al., 1995) and animal 
experiments (Ikemoto et al., 2006). Radioligand studies, however, have produced 
conflicting results as to the effect of chronic nicotine on D2 receptor density. When 
delivered through osmotic minipumps, nicotine has been shown to decrease (Janson et al., 
1992) or produce no differences (Kirch et al., 1992) in D2 receptor density. Therefore, 
D2 receptor regulation seems to depend on the paradigm of nicotine administration 
employed, as well as on the drug dose and the duration of treatment.
In conclusion, these results demonstrate the influence of response-dependency on the 
neurobiological output of nicotine. The acquisition of self-administration specifically 
involved a4p2* nAChRs of the visual and reward circuitry, whereas the administration of 
equal doses of nicotine in a passive manner produced little change in the density of 
cytisine-sensitive receptors. These data add to the increasing evidence that experimenter 
and self-administered drugs of abuse produce different effects (Hemby et al., 1997; 
Kuzmin and Johansson, 1999; Donny et al., 2000; Lecca et al., 2007), and suggest that 
nicotine-induced neuroadaptation crucially depends on the contingent relationship 
between a subject’s response and the delivery of the reinforcer.
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CHAPTER
SEVEN
2 0 0
7 CONCLUSIONS AND FUTURE WORK
In the present thesis, in vivo and in vitro experiments have been carried out to further 
characterize the mechanism of nicotine’s abuse related potential, and the interactions that 
take place between nicotinic cholinergic with dopaminergic, opioidergic, and 
adenosinergic systems. A large body of published research indicates that nicotine is a 
weak primary reinforcer, and that the predominance of nicotine addiction stems from the 
drug’s reward conveying properties upon nicotine-associated stimuli (reviewed in 
Caggiula et al., 2009). As nicotine exerts its effects through neuronal nAChRs, it was 
hypothesized that changes in the number of heteromeric and/or homomeric binding sites 
occur following the administration of drugs of abuse, which could be indicative of the 
interactions that render nicotine so widely abused.
7.1 Neuronal nicotinic receptor subtypes differentially influence cocaine-induced 
behaviour, and are differentially regulated by chronic cocaine treatment and 
withdrawal
By employing a ‘binge’ cocaine administration protocol, it is shown here for the first 
time that the two most abundantly expressed nAChR subtypes, namely a4p2* and a7, 
mediate distinct behavioural effects of chronic cocaine administration. a4p2* nAChRs 
enhance the stimulating properties of the drug, whereas a7 nAChRs protect against the 
incidence of an intense cocaine-induced grooming phenotype, which is reminiscent of 
animal models of stress-induced or compulsive disorders. Moreover, cytisine-sensitive 
[^^^I]epibatidine binding is region-specifically increased in the VTA and SNc of cocaine- 
treated animals, whereas withdrawal from chronic cocaine results in a decrease of a7 
nAChR density in the VTA of abstinent mice, compared to controls. As there is currently
2 0 1
no pharmacotherapy for the treatment of cocaine addiction, this set of experiments 
provides evidence that manipulation of the nicotinic cholinergic system has the potential 
to influence treatment strategies for cocaine dependence.
The aforementioned nAChR-mediated effects on cocaine-induced behaviour and 
neurochemistry have been interpreted on the basis that chronic cocaine, similarly to 
nicotine, cell-specifically upregulates nAChRs on GABAergic terminals in the VTA, and 
on DAergic neurons in the SNc (Nashmi et al., 2007). Figure 7.1 shows a schematic 
representation of the nAChR populations that were affected by chronic cocaine treatment 
and withdrawal in the current experiment, along with their cholinergic innervation.
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Figure 7.1 Proposed mechanism for the 
modulation of the effects of cocaine via 
nAChRs in the VTA and SNc.
‘Binge’ administration of cocaine increases 
ACh release from the pedunculopontine 
tegmental nucleus (PPTg), filled circle, and 
laterodorsal tegmental nucleus (LDTg), 
open circle, which innervate the substantia 
nigra pars compacta (SNc) and ventral 
tegmental area (VTA), respectively. The 
increased cholinergic input in these brain 
areas can affect the release of practically 
every other neurotransmitter, via distinct 
subtypes of presynaptic nAChRs. In the 
present experiments, it is postulated that 
a4p2* nAChRs are functionally upregulated 
by ACh on DAergic neurons in the SNc and 
on GABAergic neurons in the VTA. The 
inhibition of p2* nAChR subunits by DhpE 
leads to the emergence of a protracted 
locomotor activity response in place of 
stereotypy in cocaine+DhBE treated mice. 
a7 nAChRs are resistant to upregulation, but 
their region-specific downregulation in the 
VTA following prolonged withdrawal from 
cocaine may constitute a compensatory 
response to the increased a4p2* nAChR 
density, which was observed in the same 
brain region following chronic ‘binge’ 
administration of cocaine. Modified from 
Maskos, 2008.
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Altough the current data strongly imply that the upregulation of a4p2* nAChRs in the 
SNc and the VTA is a neurobiological commonality that is shared by chronic nicotine 
and cocaine, the exact subunit composition of the nAChR subtypes that mediate the 
prolonged cocaine+DhBE induced locomotor activity, or the intense grooming phenotype 
following cocaine and MLA administration, cannot be determined from the present study. 
A confounding factor in the analyses of nAChR involvement in the behavioural effects of 
cocaine is the lack of pharmacological tools that selectively block individual nAChR 
subtypes. MLA, for instance, which was used to block a7 receptors, has been shown to 
have an affinity for nAChRs containing the a4/p2 (Buisson et al., 1996), a3/a6 (Mogg et 
al., 2002), and a3/p4 (Free et al., 2003) subunits. Therefore, the wide variety of nicotinic 
subtypes expressed in the CNS, coupled with the lack of subtype-selective ligands, 
renders the attribution of specific cocaine-induced behavioural phenotypes to specific 
nAChRs on individual neuronal populations extremely optimistic. To more accurately 
investigate the exact location and contribution of nAChRs to cocaine-induced behaviour, 
nAChR antagonists can be administered to the postulated brain regions of cocaine-treated 
mice intracerebrally, rather than systemically. This would allow a variety of selective 
nAChR antagonists to be tested for their effects on ‘binge’ cocaine-induced behaviour, 
without the confounding factors of blood brain barrier penetration or peripheral toxicity. 
In addition, several nAChR subunit gene knockout mice are currently available (see 
Section 1.1.4.2), which can be used to reproduce the phenotypes that were observed in 
the present study. The application of transgenic animal models would confirm that lower 
a7 nAChR availability predisposes to cocaine-induced behavioural abnormalities, 
whereas the availability of P2* subunits determines cocaine-induced stimulation.
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7.2 The density of distinct neuronal nicotinic receptor subtypes is not altered by 
escalating doses of morphine, and following the acute and long-term withdrawal 
from ‘intermittent’ morphine administration
The results from these studies reveal that morphine, contrary to cocaine, does not directly 
interact with nAChRs at the receptor density level. Several explanations have been 
offered for the lack of morphine-induced changes in nAChR binding sites, including the 
fact that there are multiple levels of synergy between the effects of opiates and nicotine, 
which range from the behavioural to the molecular levels (see Section 4.4). It should be 
noted that escalating doses of morphine were used in this study, compared to the steady 
dosing protocol that was employed in the cocaine experiments. As dosing regimens have 
been shown to influence the effects of cocaine and morphine (Schlussman et al., 2005; 
Dighe et al., 2009), it could be that changes in nAChR density are predominantly seen 
under treatment with steady dose protocols. While this remains to be investigated, the 
present results suggest that cocaine-induced effects on the regulation of nAChR binding 
sites do not generalize to opiates. Future experiments using pshychostimulants and 
opiates other than cocaine and morphine (amphetamines, heroin etc), will confirm that 
the two classes of drugs exert different effects on nAChR density, following their 
repeated administration.
7.3 The effects of adenosine A2A receptors on nicotine-induced neuroadaptation are 
exerted via interactions with the a7 nAChR
The concurrent consumption of nicotine with caffeine, a non-selective adenosine Ai and 
A2A receptor antagonist, prompted an investigation into the mechanism of interactions 
between nicotine and A2A receptors. This was performed using naïve and nicotine-treated
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adenosine A2A receptor knockout mice, as highly selective tools for the analysis of the 
contribution of individual receptors to physiological function. The results of the present 
study show that in the absence of adenosine A2A receptors nicotine fails to upregulate a7 
nAChR density, suggesting that the effects of the neuromodulator on nicotine-induced 
neuroadaptation are exerted via this nicotinic receptor subtype.
As there is a general consensus that the effects of nicotine on dopaminergic 
neurotransmission are partly exterted via a7 nAChRs located on glutamatergic nerve 
terminals (reviewed in Wonnacott, 1997), the current data suggest that nicotine-adenosine 
A2A receptor interactions primarily involve glutamatergic, rather than dopaminergic 
mechanisms. Indeed, no differences in DI and D2 dopaminergic receptor and transporter 
binding were observed between nicotine-treated wild type and mutant mice. However, 
this finding needs to be interpreted with caution. For instance, the small upregulation in 
the constitutive expression of D2 receptors that was detected in naïve A2A knockout mice 
(Figure 5.6) was not reproduced in saline-treated animals (Figure 5.13). Power analysis, 
performed after the completion of these experiments, showed that the study might indeed 
have missed a small effect of adenosine A2A receptor gene deletion on D2 receptors. 
Calculations based on the mean difference of D2 receptor density between the naïve WT 
and KO groups revealed that the nicotine treatment experiment had a power o f 60% to 
detect a statistically significant difference of 15.0 fmol/mg tissue equivalent between D2 
receptors in saline-treated WT and adenosine A2A receptor KO mice. Therefore, the 
possiblility of a Type II error in this study cannot be excluded, and increased n numbers 
are required to unambiguously investigate the regulation of D2 receptors after deletion of 
the adenosine A2A receptor gene. Alternatively, the discrepancy between the D2 receptor 
binding results from the naïve and nicotine-treatment studies may reflect increased inter-
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individual variability in the regulation of D2 receptors in mice of the outbred CDl strain, 
or could even be the result of surgical anaesthesia on the DAergic system.
7.4 The acquisition of nicotine self-administration induces region specific increases 
in the density of a4p2* nAChRs, which are not observed following passive 
administration of nicotine
Neuronal nAChR upregulation is the hallmark of chronic nicotine exposure. 
Neuroplasticity to abused drugs, however, depends on whether their administration is 
forced by the experimenter or is under the control of the experimental animal (reviewed 
in Jacobs et al., 2003). In this set of experiments, nicotine self-administration specifically 
upregulated a4(32* nAChRs of the visual and reward circuitry, whereas the 
administration of equal doses of the drug in a passive manner produced little change in 
the density of cytisine-sensitive [^^^I]epibatidine binding sites. Hence, these results add 
to a large body of literature, documenting that contingent and non-contingent drug 
administration produces different neurochemical effects, and extends the published 
research on this topic to include nicotine.
Nevertheless, it is difficult to draw any further conclusions from the data, as a number of 
fundamental questions arise from this study. First, is there a difference in the sensitivity 
(i.e. function) of the upregulated receptors between the contingent and non-contingent 
conditions? Second, would passively delivered nicotine also upregulate nAChRs 
following longer drug exposure? If so, what is the interpretation of the results in relation 
to the establishment and maintenance of nicotine self-administration? Whatever the case 
may be, the current results suggest that nicotine-induced neuroadaptation crucially
206
depends on the contingent relationship between a subject’s response and the delivery of 
the reinforcer, rather than on the amount of nicotine intake.
7.5 Quantitative autoradiography measurements
Quantitative autoradiography of nAChRs was conducted across all chapters of the present 
thesis. For heteromeric nAChRs, the quantification of total, cytisine-resistant, and 
cytisine-sensitive [^^^Ijepibatidine binding in brain sections from naïve or saline-treated 
controls was reproducible across chapters. [^^^Ijepibatidine binding showed extremely 
high selectivity for nAChRs; non-specific binding in the presence of excess nicotine as a 
‘cold’ displacement ligand was literally indistinguishable from autoradiographic film 
background. Extremelly high levels of total [^^^Ijepibatidine binding were observed in 
the medial habenula, fasciculus retroflexus, and the interpeduncular nucleus, followed by 
high to moderate levels of binding in the superficial gray layer of the superior colliculus, 
certain thalamic nuclei, the ventral tegmental area, and the substantia nigra. Low levels 
of binding were detected in the striatum, and in areas of the cortex. High levels of 
cytisine-resistant [^^^Ijepibatidine binding were observed in the medial habenula, 
fasciculus retroflexus, and interpeduncular nucleus, indicating that the nAChRs expressed 
in these brain regions are not of the cytisine-sensitive, a4|32* nAChR subtype. In general, 
these results are in good agreement with several rodent studies, which have used 
comparable amounts of [^^^Ijepibatidine for the visualisation of nAChRs (Nguyen et ah, 
2003; Whiteaker et al., 2002).
For the a? nAChR, [^^^I]a-bungarotoxin binding was higher in the superficial gray layer 
of the superior colliculus and the zona incerta, followed by lower levels of binding in 
nuclei of the amygdale, hypothalamus, hippocampus, and certain cortical brain regions.
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This pattern of distribution is consistent with the literature (Rasmussen and Perry, 2006; 
Sparks and Pauly, 1999). It should be noted that variation in the amount of specific a7 
nAChR binding was noted between chapter 3 and chapters thereafter, which the author 
attributes to the use of radioligands from different suppliers (GE Healthcare vs. Perkin 
Elmer), producing [^^^I]a-bungarotoxin at different specific activities (GE Healthcare, 
specific activity 250 Ci/mmol; PerkinElmer, specific activity 159 Ci/mmol), using 
different means of production (mono- vs. di- iodinated products). This change was 
necessary, however, as GE Healthcare announced the closure of its radiochemical 
product line in December 2008. Although the change of supplier does not affect the 
distribution pattern of a7 nAChRs, it underlines the importance of conducting 
quantitative autoradiography using paired binding protocols, in which all sections are 
processed together in an identical manner, in a carefully controlled environment.
7.6 Concluding remarks
The present work has generated further evidence for the presence of interactions that 
might underlie why nicotine is one of the most widely abused substances in the world. 
With the exception of morphine, all other types of interactions that were examined could 
be depicted at the nicotinic receptor level, as changes in the density of distinct nAChR 
subtypes. Importantly, this set of studies has prompted new questions concerning the 
nature and mechanism of interactions between the nicotinic cholinergic with 
dopaminergic, opioidergic, and adenosinergic systems, which remain to be answered.
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